書籍詳細

Part 1 / 病態生理編

P.30 掲載の参考文献

• 1) 小原克彦:アンジオテンシンIIとその関連ペプチドの生理作用. 日和田邦男, 猿田享男, 荻原俊男編, アンジオテンシンII受容体拮抗薬, 医薬ジャーナル社, 大阪, 1996, pp. 23-38

• 2) Dzau VJ, Batt DW, Pratt RE:Molecular biology of the renin-angiotensin system. Am J Physiol 255:F563-F573, 1988

• 3) Doolittle RF:Angiotensinogen is related to the antitrypsin-antithrombin-ovalbumin family. Science 222:417-419, 1983

• 4) Kageyama R, Ohkubo H, Nakanishi S:Primary structure of human preangiotensinogen deduced from the cloned cDNA sequence. Biochemistry 23:3603-3609, 1984
  pubmed

• 5) Clause E, Gaillard I, Wei L et al:Regulation of anglotensinogen gene. Am J Hypertens 2:403-410

• 6) Skidgel R, Erdos EG:アンジオテンシン変換酵素の生化学と分子生物学. 荻原俊男, 猿田享男, 日和田邦男編, ACE阻害薬のすべて (改訂版) , 先端医学社, 東京, 1994, pp.294-307

• 7) Corvol P, Michaud A, Soubrier F et al:Recent advances in knowledge of the stucture and function of the angiotensin I converting enzyme. J Hypertens 13 (suppl 3):S3-S10, 1995

• 8) Soubrier F, Alhenc-Gelas F, Hubert C et al:Two putative active centers in humanangiotensin I-converting enzyme revealed bymolecular cloning. Proc Natl Acad Sci USA 85:9386-9390, 1988

• 9) Wei L, Alhenc-Gelas F, Corvol P et al:The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem 266:9002-9008, 1991
  pubmed

• 10) Hubert C, Houot AM, Corvol P et al:Structure of the angiotensin I-conveting enzyme gene. Two alternate promoters corresponded to evolutionary steps of a duplicate gene. J Biol Chem 266:15377-15383, 1991

• 11) Kumar RS, Thekkumkara TJ, Sen GC:The mRNA encoding the two angiotensin-converting isozymes are transcribed from the same gene by atissue-specific choice of alternative transcription initiation sites. J Biol Chem 266:3854-3862, 1991

• 12) Rigat B, Hubert C, Alhenc-Gelas F et al:An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346, 1990
  pubmed

• 13) Danser AH, Schalekampf MA, Bax WA et al:Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 92:1387-1388, 1995

• 14) 高柳涼一:アンジオテンシンII受容体の分子生物学. 血圧 3:677-683, 1996
  Medical*Online

• 15) Koike G, Horiuch M, Yamada T et al:Human type 2 angiotensin II receptor gene:cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung. Biochem Biophys Res Commun 203:1842-1850, 1994

• 16) Chassgne C, Beatty BG, Meloche S:Assignment of the human angiotensin II type 2 receptor gene (AGTR2) to chromosome Xq22-q23by fluorescence in situ hybridization. Genomics 25:601-603, 1995

• 17) Marrero MB, Schieffer B, Paxton WG et al:Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 375:247-250, 1995
  pubmed

• 18) Bonnardeaux A, Davies E, Jeunemaitre X et al:Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24:63-69, 1994
  pubmed

• 19) Tiret L, Bonnardeaux A, Poirier O et al:Synergistic effects of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphism on risk of myocardial infarction. Lancet 344:910-913, 1994
  pubmed

• 20) Csikos T, Chung O, Unger Th:Receptors and their classification:focus on angiotensin II and the AT2 receptor. J Hum Hypertens 12:311-318, 1998

• 21) Yamada T, Horiuchi M, Dzau VJ:Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 93:156-160, 1996
  pubmed

• 22) Scheuer DA, Perrone MH:Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol 33:R917-R923, 1993

• 23) Hein L, Barsh GS, Pratt RE et al:Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature 377:744-747, 1995
  pubmed

• 24) Ichiki T, Labosky PA, Shiota C et al:Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377:748-750, 1995
  pubmed

• 25) Esler M, Zweifler A, Randall O et al:The determinants of plasma renin activity in essential hypertension. Ann Intern Med 88:746-752, 1978
  pubmed

• 26) Sealey JE, Blumenfeld JD, Bell GL et al:On the renal basis for essential hypertension:nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive basoconstriction-volume relationship. J Hypertens 6:763-777, 1988

• 27) Alderman MH, Madhavan S, Ooi WL et al:Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324:1098-1104, 1991
  pubmed

P.38 掲載の参考文献

• 1) 檜垣實男, 荻原俊男:レニン・アンジオテンシン-アルドステロン系の調節. 最新内科学大系 15:副腎疾患, 水・電解質異常, 猿田享男, 長瀧重信, 松倉茂編, 中山書店, 東京, 1993, pp.267-275

• 2) 檜垣實男, 荻原俊男:レニン. 総合臨床増刊号 40:119-123, 1991

• 3) 檜垣實男, 荻原俊男:腎血管性高血圧症の成因と内科的治療. 腎移植・血管外科 6:85-89, 1994

• 4) Lifton RP, Dluhy RG, Powers M et al:Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 2:66-74, 1992
  pubmed

• 5) 勝谷友宏, 檜垣實男, 荻原俊男:高血圧遺伝子の最新知見. Hypertension Frontier 1:33-50, 1998

P.45 掲載の参考文献

• 1) 長谷部直幸, 菊池健次郎:慢性心不全の治療-利尿薬の用い方と使用上の留意点-Mebio 12:92-99, 1995

• 2) The CONSENSUS Trial Study Group:Effects of enalapril on mortality in severe congestive heart failure:Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429-1435, 1987

• 3) The SOLVD Investigators:Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302, 1991
  pubmed

• 4) Van Gilst WH, Scholtens E, de Graeff PA et al:Differential influence of angiotensin convertingenzyme inhibitors on the coronery circulation. Circulation 77 (suppl I):124-129, 1988

• 5) Linz W, Martorara PA, Scholkens BA:Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol 15 (suppl 6):S99-S109, 1990

• 6) Urata H, Kinoshita A, Porez DM et al:Cloning of the gene and cDNA for human heart chymase. J Biol Chem 266:17173-17179, 1991

• 7) Swedberg K, Eneroth P, Kjekshus J et al:Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82:1730-1736, 1990

• 8) Francis GS, Cohn JN, Johanson G et al:Plasma norepinephrine, plasma renin activity, and cogestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation 87 (suppl VI):VI 40-VI 48, 1993

• 9) Schunkert H, Ingelfinger JR, Hirsch AT et al:Evidence for tissue specific activation of renal angiotensinogen mRNA expression in chronic stable heart failure. J Clin Invest 90:1523-1529, 1992
  pubmed

• 10) Marrero MB, Schieffer B, Paxton WG et al:Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 375:247-250, 1995
  pubmed

• 11) Marrero MB, Schieffer B, Li B et al:Role of Janus Kinase/signaltransduction and activation of transcription and mitogen-activated protein kinase cascades in angiotensin II and platelet derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem 272:24684-24690, 1997

• 12) Anderson KM, Murahashi T, Dostal DE et al:Morphological and biochemical analysis of angiotensin II internalization in cultured rat aortic smooth muscle cells. Am J Physiol 264:C179-C188, 1993
  pubmed

• 13) Inagami T, Kitami Y:Angiotensin II receptor:molecular cloning, functions and regulation. Hypertens Res 17:87-97, 1994

• 14) Asano K, Dutcher DL, Port JD et al:Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation 95:1193-1200, 1997
  pubmed

• 15) Haywood GA, Gullestad L, Katsuya T et al:AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation 95:1201-1206, 1997
  pubmed

• 16) Lee YA, Liang CS, Lee MA et al:Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo:A comprehensive study of all its components in the dog. Pro Natl Acad Sci USA, 93, 11035-11040, 1996
  pubmed

• 17) Luchner A, Stevens TL, Borgeson DD et al:Angiotensin II in the evolution of experimental heart failure. Hypertension 28; 472-477, 1996
  pubmed

• 18) Dell' italia L, Meng QC, Balcells E et al:Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. Am J Physiol 269:H2065-H2073, 1995
  pubmed

• 19) Studer R, Reinecke H, Muller B et al:Increased angiotensi-I converting enzyme gene expression in the failing human heart. J Clin Invest 94:301-310, 1994

• 20) Moravec CS, Schluchter MD, Paradnadi L et al:Inotropic effects of angiotensin II on human cardiac muscle in vitro. Circulation 82:1973-1984, 1990

• 21) Che-Ping Cheng, Makoto Suzuki, Nobuyuki Ohte et al:Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure. Circ Res 78:880-892, 1996

• 22) Nickenig G, Laufs U, Schnabel P et al:Down-regulation of aortic and cardiac ATI receptor gene expression in transgenic (mRen-2) 27 rats. Br J Pharmacol 121:134-140, 1997

• 23) Weber KT:Extracellular matrix remodeling in heart faolure. A role for de novo angiotensin II generation. Circulation 96:4065-4082, 1997

• 24) Weber KT:Cardiac Interstitium. In:heart failure, ed by Poole-Wilson PA Colucci WS, Massie BM, et al Coats NS, Churchill Livingstone. NY, pp.13-31, 1997

• 25) Pueyo ME, Amal JF, Rami J et al:Angiotensin II stimulates the production of NO and peroxyni-trite in endothelial cells. Am J Physiol 274:C214-C220, 1998

• 26) Gohlke P, Pee C, Unger T:AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31:349-355, 1998

• 27) Siragy HM, Carey RM:The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in consciious rats. J Clin Invest 100:264-269, 1997
  pubmed

• 28) Dubey RK, Jackson EK, Luscher TF:Nitric Oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. J Clin Invest 96:141-149, 1995
  pubmed

• 29) Hou J, Kato H, Cohen RA et al:Angiotensin II-induced cardiac fibrosis in the rat is increased by chronic inhibition of nitric oxide synthase. J Clin Invest 96:2469-2477, 1995
  pubmed

• 30) Ichiki T, Usui M, Kato M et al:Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypeitension 31:342-348, 1998
  pubmed

• 31) Raya TE, Fonken SJ, Lee RW et al:Hemodynamic effects of direct angiotensin II blockade compared to coverting enzyme inhibition in rat model for heart failure. Am J Hypertens 4:334S-340S, 1991

• 32) Smits JFM, Krimpen CV, Schoemaker RG et al:Angiotensin II receptor blockade after myocardial infarction in rats:Effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol 20:772-778, 1992

• 33) Nishikimi T, Yamagishi H, Takeuchi K et al:An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. Cardiovasc Res 29, 856-861, 1995
  pubmed

• 34) Quing G, Garcia R:Chronic captopril and losartan (DuP 753) administration in rats with high-output heart failure. Am J Physiol 263:H833-H840, 1992

• 35) Fitzpatrick MA, Rademaker MT, Charles CJ et al:Angiotensin II receptor antagonism in ovine heart failure:acute hemodynamic, hormonal, and renal effects. Am J Physiol 263:H250-256, 1992
  pubmed

• 36) Spinale FG, Mukherjee R, Iannini Jp et al:Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. II. Effects on myocyte contractile processes. Circulation 96:2397-2406, 1997
  pubmed

P.52 掲載の参考文献

• 1) 柴垣有吾, 藤田敏郎:Bartter症候群 / Gitelman症候群. 領域別症候群シリーズ (16pt1):595, 1997

• 2) 河野剛:Bartter症候群. 日本臨床 41:882, 1983
  Medical*Online

• 3) Gill JR, Bartter FC:Evidence for a prostaglandin-independent defect in chroride reabsorption in the loop of Henle as a proximal cause of Barrter's syndrome. Am J Med 65:766, 1978

• 4) Fichman MP, Telfer N, Zia P et al:Role of prostaglandins in the pathogenesis of Bartter's syndrome. Am J Med 60:785, 1976
  pubmed

• 5) Gitelman HJ, Graham JB, Welt LG:A new familial disorder characterized by hypokalemia, hypomagnesemia. Trans. Assoc Am Physicians 79:221, 1996

• 6) Simon DB, Karet FE, Hamdan JM et al:Bartter's syndrome, hypokalemic alkalosis with hypercalciuria is caused by mutations in the Na-K-2C1 cotransporter NKCC2. Nat Genet 13:183, 1996

• 7) Simon DB, Nelson-Williams C, Bia MJ et al:Gitelman's variant of Batter's syndrome, inherited hypokalemic alkalosis, is caused by mutations in the thiazine-sensitive Na-C1 cotransporter. Nat Genet 12:24, 1996

• 8) Simon DB, Karet FE, Rodriguez-Soriano J et al:Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K channel. Nat Genet 14:152, 1996

• 9) Gordon RD, Klemm SA, Tunny TJ:Renin in Bartter:s syndrome. In:The renin-angiotensin system ed. by Robertson JIS, Nicholls G, Gower Medical Publishing, London, 1993, pp.64. 1-64. 15

• 10) Arroyo V, Bosch J, Mauri M et al:Effect of angiotensin II blockade on systemic and hemo-dynamics and on the renin-angiotensin-aldos-terone system in cirrhosis with ascites. Eur J Clin Invest 11:221, 1981

• 11) Skorecki KL, Brenner BM:Body fluid home-ostasis in congestive heart failure with ascites. Am J Med 72:323, 1982

• 12) Rosoff L, Zia P, Reynolds T et al:Studies of renin and aldosterone in cirrhotic patients with ascites. Gastroenterol 69:698, 1975

• 13) Bernardi M, Trevisani F, Santini C et al:Aldosterone-related blood volume expansion in cirrhosis before and during the early phase of ascites formation. Gut 24:761, 1983
  pubmed

• 14) 辻井正, 植村正人:E.電解質異常. 肝硬変. 最新内科学大系第49巻, 井村裕夫ほか編, 中山書店, 東京, 1994, pp.134-144

• 15) Christieb AR, Kaldany A, D:Elia JA et al:Aldostrerone responsiveness in patients with diabetes mellitus. Diabetes 27:732, 1978

• 16) Gossain V, Werk EE, Sholiton LJ et al:Plasam renin activity in juvenile diabetes mellitus and effect of diazoxide. Diabetes 24:833, 1975

• 17) Perez GO, Lespier L, Jacobi J et al:Hyporeninemia and hypoaldosteronism in diabetes mellitus. Arch Intern Med 137:852, 1977
  pubmed

• 18) Fernandez-Cruz A Noth RH, Lassman MN et al:Low plasma renin activity in normosensitive patients with diabetes mellitus:relationship to neuropathy. Hypertension 3:87, 1981

• 19) Naruse M, Wasada T, Naruse K et al:Pathophysiological significance of plasma total renin and prorenin in patients with diabetes mellitus. Endocr J 42:225, 1995
  pubmed

• 20) Burden AC, Thurston H:Plasma renin activity in diabetes mellitus. Clin Sci 56:255, 1979
  pubmed

• 21) Brown EA, Markandu ND, Sagnella GA et al:Evidence that some mechanism other than the renin system auses sodium retension in nephrotic syndrome. Lancet 11:1237, 1982

Part2 / 臨床薬理編

P.64 掲載の参考文献

• 1) 塩之入洋, 成瀬雅彦, 高崎泉:ACE阻害薬の分類と作用機序. 医学のあゆみ 174:753-760, 1995
  Medical*Online

• 2) Wei L, Alhenc-Gelas F, Corvol P et al:The two homologous domains of human angiotensin I converting-enzyme are both catalitically active. J Biol Chem 266:9002-9008, 1991

• 3) Joint National committee:The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997

• 4) Committee on Evaluation and Managemant of Heart Failure:Guidelines for the evaluation and management of heart failure. J Am Coll Cardiol 26:1376-1398, 1995

• 5) 塩之入洋, 植田真一郎, 南澤康介ほか:高血圧診断と治療シリーズ-その10, アンジオテンシン変換酵素阻害薬. 横浜医学 48:703-711, 1997

• 6) Shionoiri H, Naruse M, Minamisawa K et al:Fosinopril:Clinical pharmacokinetics and clinical potential. Clin Pharmacoleinetics 32:460-480, 1997
  pubmed

• 7) Shionoiri H:Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacoleinetics 25:20-58, 1993
  pubmed

• 8) Shionoiri H, Minamisawa K, Ueda S et al:Pharmacokinetics and antihypertensive effects of lisinopril in hypertensive patients with normal and impaired renal function. J Cardiovasc Pharmacol 16:594-600, 1990
  pubmed

• 9) Shionoiri H, Ueda S, Minamisawa K et al:Pharmacokinetics and pharmacodynamics of benazepril in hypertesive patients with normal and impaired renal function. J Cardiovasc Pharmacol 20:348-357, 1992

• 10) Oguchi H, Miyasaka M, Koiwai T et al:Pharmacokinetics of temocapril and enalapril in patients with arious degrees of renal insufficiency. Clin Pharmacokinetics 24:421-427, 1993

• 11) Oguchi H, Tokoo M, Tokunaga S et al:Temocapril, a novel angiotensin converting enzyme inhibitor wit preferential biliary excretion. Cardiovasc Drug Rev 13:66-85, 1995

• 12) Ishizuka H, Konno K, Naganuma H et al:Temocaprilat, a novel angiotensin-converting enzyme inhibitor is excreted in bile Via an ATP-dependent activetransporter (cMOAT) that is deficient in Eisai hyperbilirubineic mutant rats (EHBR). J Pharmacol Exp Ther 280:1304-1311, 1997
  pubmed

• 13) Sioufi A, Pommier F, Godbillon J:Pharma. cokinetics of benazepril and benazeprilat in hypertensive patients with renal impairment. Europ J Drug Metab Pharmacokinet (special issue):99-104, 1993

• 14) Mannhold R:Trandolapril. Drugs of Today 28:479-486, 1992

• 15) 塩之入洋, 南澤康介, 植田真一郎ほか:ACE阻害薬TemocaprilとTrandolaprilの胆汁排泄機構の検討. 臨床薬理 29:319-320, 1998

• 16) 浦江明憲, 浦江隆次, 香川友利子ほか:アンジオテンシン変換酵素阻害薬RU44570の臨床第I相弛緩 (第3報) -健常人における薬物動態の検討. 臨床医薬8 (suppl 7):41-52, 1992

• 17) 小野山薫, 奥田誠也, 玉置清志ほか:アンジオテンシン変換酵素阻害薬Torandolaprilの腎機能障害患者における薬物動態の検討. 臨床医薬 9:39-51, 1993, 「文献17のErrata」, 臨床医薬 12:3659-3660, 1996

• 18) 厚生省・日本医師会編:高血圧診療の手引き. 厚生省・日本医師会1990

• 19) WHO Expert Committee:Hypertension control. WHO technical report series 862, Geneva, 1996

• 20) Lacourciere Y, Brunner HR, Irwin R et al:Effects of modulators of the renin-nagiotensin-aldosterone system on cough. J Hypertens 12:1387-1393, 1994

• 21) 荒川規矩男:ACE阻害薬新分類法の提案. Prog Med 13:2191-2195, 1993
  Medical*Online

• 22) 塩之入洋, 高崎泉, 杉本孝一ほか:ACE阻害薬 (imidapril) による咳吸・咽頭違和感発現のチャレンジ試験臨床薬理 26:209-210, 1995

• 23) Shionoiri, H, Takasaki I, Minamisawa K:Cough-challenge trial with a new angiotensin-converting enzyme inhibitor, imidapril. J Clin Pharmacol 38:442-446, 1998
  pubmed

• 24) Deddish PA, Marcic B, Jackman HL et al:Ndomain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme:Angiotensin-(1-7) and keto-ACE. Hypertension 31:912-917, 1998

• 25) Kubo M, Kato J, Ochiai T et al:Phamacological studies on (4S)-1-methyl-3-{(2S)-2-[N-{(1S)-1-ethoxycarbonyl-3-phenyl-propyl}amino] propionyl}-2-oxo-imidazolidine-4-carboxylic acid hydrochloride (TA-6366), a new ACE inhibitor. I. ACE inhibitory and antihypertensive activities. Jpn J Pharmacol 53:201-210, 1990

P.69 掲載の参考文献

• 1) Baumbach GL, Dobrin PB, Hart MN et al:Mechanics of cerebral arterioles in hypertensive rats. Circ Res 62:56-64, 1988
  pubmed

• 2) Baumbach GL, Heistad DD:Adaptive changes in cerebral blood vessels during chronic hypertension. J Hypertens 9:987-991, 1991
  pubmed

• 3) 藤井健一郎, 藤島正敏:高血圧と血管臓器障害. 脳血管障害. 現代医療 24:3297-3302, 1992

• 4) Fujii K, Sadoshima S, Okada Y et al:Cerebralblood flow and metabolism in normotensive and hypertensive patients with transient neurologicdeficits. Stroke 12:874-876, 1990

• 5) Cushman DW, Wang FJ, Fung WC et al:Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 2:294-306, 1988

• 6) Cushman DW, Wang FJ, Fung WC et al:Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme. Br J Clin Pharmacol 28:S115-S131, 1989

• 7) Brecher P, Tercyak A, Chobanian AV:Properties of angiotensin-converting enzyme in intact cerebral microvessels. Hypertension 3:198-204, 1981
  pubmed

• 8) Dzau VJ:Vascular renin-angiotensin system in hypertension. New insights into the mechanism of action of angiotensin converting enzyme inhibitors. Am J Med 84 (suppl 4A):4-8, 1988

• 9) Waldemar G, Paulson OB:Angiotensin converting enzyme inhibition and cerebral circulation-a review. Br J Clin Pharmacol 28:S177-S182, 1989

• 10) Rossi GP, Rossi A, Zanin L et al:Excess prevalence of extracranial carotid artery lesions in renovascular hypertension. Am J Hypertens 5:8-15, 1992
  pubmed

• 11) Bonithon-Kopp C, Ducimetiere P, Touboul P-Jet al:Plasma angiotensin-converting enzymeactivity and carotid wall thickening. Circulation 89:952-954, 1994

• 12) Clozel J-P, Kuhn H, Hefti F:Effects of cilazapril on the cerebral circulation in spontaneously hypertensive rats. Hypertension 14:645-651, 1989
  pubmed

• 13) Hajdu MA Heistad DD, Baumbach GL:Effects of antihypertensive therapy on mechanics of cerebral arterioles in rats. Hypertension 17:308-316, 1991

• 14) Powell JS, Clozel J-P, Muller RKM et al:Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245:186-188, 1989

• 15) 藤島正敏, 佐渡島省三, 石束隆男ほか:降圧薬と脳循環. 脳卒中 11:1-10, 1989

• 16) Barry DI, Paulson OB, Jarden JO et al:Effects of captoril on cerebral blood flow in normotensive and hypertensive rats. Am J Med 76:79-85, 1984

• 17) Paulson OB, Jarden JO, Vorstrup S et al:Effect of captopril on the cerebral circulation in chronic heart failure. Eur J Clin Invest 16:124-132, 1986
  pubmed

• 18) Rajagopalan B, Raine AEG, Cooper R et al:Changes in cerebral blood flow in patients with severe congestive cardiac failure before and after captopril treatment. Am J Med 76 (5B):86-90, 1984

• 19) Yang ST, Faraci FM, Heistad DD:Effcets of cilazapril on cerebral vasodilatation in hypertensive rats. Hypertension 22:150-155, 1993

• 20) Postiglione A BobkieWicz T, Vinholdt-PE et al:Cerebrovascular effects of angiotensin converting enzyme inhibition involve large artery dilatation in rats. Stroke 22:1362-1368, 1991

• 21) Waldemar G, Paulson OB:Angiotensin converting enzyme inhibition and cerebral circulation-a review. Br J Clin Pharmacol 28:S177-S182, 1989

• 22) Waldemar G, Paulson OB, Barry DI et al:Angiotensin converting enzyme inhibition and the upper limit of cerebral blood flow autoregulation:effect of sympathetic stimulation. Circ Res 64:1197-1204, 1989
  pubmed

• 23) Waldemar G, Schmidt JF, Andersen AR et al:Angiotensin converting enzyme inhibition and cerebral blood flow autoregulation in normotensive and hypertensive man. J Hypertens 7:229-235, 1989

• 24) 栗山良紘:CBF (cerebral blood flow) autoregulation および降圧治療. ACE Inhibitors:Innovative Clinical Applications. 猿田享男, 荒川規矩男, 國府達郎編, メディカルトリビューン, 東京, 1990, pp.89-96

• 25) Capdeville C, Bouhtoury FE, Parache RM et al:The angiotensin converting enzyme inhibitors, captopril and Wy-44, 655 attenuate the consequences of cerebral ischemia in renovascular hypertensive rats. Life Sci 47:539-546, 1990

• 26) Fulii K, Weno BL, Baumbach GL et al:Effect of antihypertensive treatment on focal cerebral infarction. Hypertension 19:713-716, 1992

• 27) Werner C, Hoffman WE, Kochs E et al:Captopril improves neurologic outcome from incomplete cerebral ischemia in rats. Stroke 22:910-914, 1991
  pubmed

• 28) Sadoshima S, Fujii K, Ooboshi H et al:Angiotensin converting enzyme inhibitors attenuate ischemic brain metabolism in hypertensive rats. Stroke 24:1561-1567, 1993
  pubmed

• 29) Barnes JM, Barnes NM, Costall B et al:Angiotensin II inhibits the release of [3H] acetylcholine from rat entorhinal cortex in vitro. Brain Res 491:136-143, 1989
  pubmed

• 30) Barnes JM, Barnes NM, Costall B et al:Angiotensin II inhibits cortical cholinergic function:implications for cognition. J Cardiovasc Pharmacol 16:234-238, 1990
  pubmed

• 31) Morgan JM, Routtenberg A:Angiotensin injected into the neostriatum after learning disrupts retension performances. Science 196:87-89, 1977

• 32) Costall B, Horovitz ZP, Kelly ME et al:Captopril improves basic performance and antagonises scopolamine impairment in a mouse habituationtest. Br J Pharmacol 93:882, 1988

• 33) Costall B, Coughlan J, Horovitz Z P et al:The effects of ACE inhibitors captopril and SQ29,852 in rodent tests of cognition. Pharmacol Biochem Behavior 33:573-579, 1989
  pubmed

• 34) Croog SH, Levine S, Testa MA et al:The effects of antihypertensive therapy on the quality of life. N Engl J Med 314:1657-1664, 1986

• 35) Nakai K, Itoh C, Miura Y et al:Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and inceased risk for CAD in the Japanese. Circulation 90:2199-2202, 1994

• 36) Markus HS, Barley J, Lunt R et al:Angiotensin-converting enzyme gene deletion polymorphism. A new risk factor for lacunar stroke but not carotid atheroma. Stroke 26:1329-1333, 1995

• 37) Doi Y, Yoshizumi H, Yoshinari M et al:Association between a polymorphism in the angiotensin-converting enzyme gene and microvascular complications in Japanese patients with NIDDM. Diabetologia 39:97-102, 1996
  pubmed

• 38) Catto A, Carter AM, Barrett JH et al:Angiotensin-converting enzyme insertion/deletion polymorphism and cerebrovascular disease. Stroke 27:435-440, 1996
  pubmed

• 39) Pullicino P, Kwen PL, Greenberg S et al:Angiotensin-converting enzyme gene and lacunar stroke. Stroke 27:569-570 (letter), 1996
  pubmed

P.76 掲載の参考文献

• 1) Lonn EM, Yusuf S, Jha P et al:Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90:2056, 1994
  pubmed

• 2) 筒井裕之, 竹下彰:心肥大を伴う高血圧の治療法. 臨床科学 31:120-121, 1995

• 3) Dahlof B, Pennert K Hansson L:Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 5:95, 1992
  pubmed

• 4) Neaton JD, Grimm RH Jr, Prineas RJ et al:Treatment of mild hypertension study. JAMA 270:713, 1993
  pubmed

• 5) Estacio RO, Jeffers BW, Hiatt WR et al:The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645, 1998
  pubmed

• 6) 筒井裕之, 竹下彰:心筋梗塞後における ACE阻害薬の有用性. 医学のあゆみ 174:783, 1995
  Medical*Online

• 7) 筒井裕之, 竹下彰:心筋梗塞を有する患者における ACE阻害薬の有用性. 綜合臨床 45:1963, 1996

• 8) Brown NJ, Vaughan DE:Angiotensin-converting enzyme inhibitors. Circulation 97:1411, 1998
  pubmed

• 9) CONSENSUS Trial Study Group:Effects of enalapril on mortality on severe congestive heart failure:results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429, 1987

• 10) The SOLVD Investigators:Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293, 1991
  pubmed

• 11) Cohn JN, Johnson G, Ziesche S et al:Acomparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J med 325:303, 1991

• 12) Yusuf S, Pepine CJ, Garces C et al:Effects of enalapril on myocardial infarction and unstable angina in patients with low ejection fraction. Lancet 340:1173, 1992
  pubmed

• 13) Pfeffer MA Braunwald E, Moye IA et al:Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327:669, 1992

• 14) Swedberg K Held P, Kiekshus J et al:Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction:results of the Cooperative North Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327:678, 1992

• 15) AIRE Study Group:Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821, 1993

• 16) ISIS Collaborative Group:ISSI-4:randomised study of oral captopril in over 50,000 patients with suspected acute myocardial infarction. Circulation 88 (suppl I):1-394, 1993

• 17) Gruppo Italiano per lo Studio della Sopravvivenzanell' Infarto Miocardico:GISSI-3:Effects oflisinopril an transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343:1115, 1994
  pubmed

• 18) Kober L, Torp-Pedersen C, Carlsen JE et al for the Trandolapril Cardiac Evaluation (TRACE) Study Group:A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333:1670, 1995

• 19) Ambrosioni E, Borghi C, Magnani B:The effects of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332:80, 1995
  pubmed

• 20) Pitt B, Segal R, Martinez FA et al:Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747, 1997
  pubmed

• 21) Yusuf S, Maggioni AP, Held P et al:Effects of candesartan, enalapril or their combination on exercise capacity and quality of life in heart failure:randomized evaluation of strategies for left ventricular dysfunction (Resolved). Circulation 96:1-452, 1997

P.85 掲載の参考文献

• 1) Anderson S, Rennke HG, Brenner BM:Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in rats. J Clin Invest 77:1993-2000, 1986
  pubmed

• 2) Kakinuma Y, Kawamura T, Bills T et al:Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 42:46-55, 1992
  pubmed

• 3) Kon V, Fogo A, Ichikawa I:Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 44:545-550, 1993
  pubmed

• 4) Siragy HM, Jatfa M Margolius HS:Stimulation of renal interstitial bradykinin by sodium depletion. Am J Hypertens 6:863-866, 1993

• 5) Hirata Y, Hayakawa H, Kakoki M et al:Nitric oxide release from kidneys of hypertensive rats treated with imidapril. Hypertension 27 (part 2):672-678, 1996

• 6) Siragy HM:Evidence that intrarenal bradykinin plays a role in regulation renal function. Am J Physiol 265:E648-E654, 1993

• 7) Yoshioka T, Shiraga H, Yoshida Y et al:"Intact nephrons"as the primary origin of proteinuria in chronic renal disease. Study in the rat model of subtotal nephrectomy. J Clin Invest 82:1614-1623, 1988
  pubmed

• 8) Lapinski R, Perico N, Remutti A et al:Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 7:653-660, 1996

• 9) Heeg JE, de Jong PE, van der Hem GK et al:Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition. Kidney Int 40:734-741, 1991

• 10) Tanaka R, Kon V, Yoshioka Y et al:Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 45:537-543, 1994

• 11) Arai M, Wada A Isaka Y et al:In vivo transfection of genes for renin and angiotensinogen into the glomerular cells induced phenotypic change of the mesangial cells and glomerular sclerosis. Biochem Biophys Res Comm 206:525-532, 1995
  pubmed

• 12) Nakamura T, Takahashi T, Mitsumine F et al:Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol 5:1492-1497, 1995

• 13) Kagami S, Border WA, Miller DE et al:Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93:2431-2437, 1994

• 14) Tanaka R, Sugiura K, Tatematsu A et al Internephron heterogeneity of growth factors and sclerosis-modulation of platelet-derived growth factor by angiotensin II. Kidney Int 47:131-139, 1995

• 15) Ishida S, Morrissey J, McCracken R et al:Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstraction. Kidney Int 47:1285-1294, 1995

• 16) Baricos WH, Cortez SL, El-Dahr SS et al:ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 47:1039-1047, 1995
  pubmed

• 17) Ikoma M, Kawamura T, Kakinuma Y et al:Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 40:195-202, 1991
  pubmed

• 18) Ichikawa I:Will angiotensin II receptor antagonists be renoprotective in human? Kidney Int 50:684-692, 1996
  pubmed

• 19) Apperloo AJ, de Zeeuw D, de Jong PE:A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 51:793-797, 1997

• 20) Gansevoort R de Zeeuw D, de Jong PE:Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabedc renal disease. Am J Kidney Dis 22:202-206, 1993
  pubmed

• 21) Eddy AA, McCulloch L, Adams J et al:Interstitial nephritis induced by proteinoverload proteinuria. Am J Pathol 135:719-733, 1989

• 22) Kees-Folts D, Sadow JL, Schreiner GF:Tubular catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int 45:1697-1709, 1994
  pubmed

• 23) Murakami M, Matsuda H, Kubota E et al:Role of angiotensin II generated by angiotensin converting enzyme-in dependent pathways in canine kidney. Kidney Int 52 (suppl 63):S132-S135, 1997

• 24) Arima S, Endo Y, Yaoita H et al:Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J Clin Invest 100:2816-2823, 1997
  pubmed

• 25) Endo Y, Arima S, Yaoita H et al:Function of angiotensin II type 2 receptor in the post-glomerular efferent arteriole. Kidney Int 52 (suppl 63):S205-S207, 1997

• 26) Otis M, Mackenzie HS, Troy JL et al:Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 9:224-230, 1998

• 27) Ichikawa I, Harris RC:Angiotensin actions in the kidney:renewed insight into the old hormone. Kidney Int 40:583-596, 1991

• 28) Matsusaka T, Hymes J, Ichikawa I:Angiotensin in progressive renal diseases; theory and practice. J Am Soc Nephrol 7:2025-2043, 1996
  pubmed

P.91 掲載の参考文献

• 1) Rutan GH, Kuller LH, Neaton JD et al:Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation 77:504-514, 1988
  pubmed

• 2) Mohiaddin RH, Underwood SR, Bogren HG et al:Regional aortic compliance studied by magnetic resonance imaging:the effects of age, training, and coronary artery disease. Br Heart J 62:90-96, 1989
  pubmed

• 3) Honda T, Yano K, Matsuoka H et al:Evaluation of aortic distensibility in patients with essential hypertension by using cine magnetic resonance imaging. Angiology 45:207-212, 1994
  pubmed

• 4) Chobanian AV:1989 Corcoran lecture:Adaptive and maladaptive responses of the arterial wall to hypertension. Hypertension 15:666-674, 1990
  pubmed

• 5) Toda N, Okunishi H, Miyazaki M:Lengthpasive tension relationships in cerebral and peripheral arteries isolated from spontaneously hypertensive and nomiotensive rats. Jpn Circ J 46:1088-1094, 1982
  pubmed

• 6) Winquist RJ, Bohr DF:Structural and functional changes in cerebral arteries from spontaneously hypertensive rats. Hypertension 5:292-297, 1983
  pubmed

• 7) Henry PD, Bentley KI:Suppression of atherosclerosis in cholesterol-fed rabbits treated with nifedipine. J Clin Invest 68:1366-1369, 1981

• 8) Chobanian AV, Brecher P, Chan C:Effect of propranolol on atherogenesis in cholesterol-fed rabbit. Circ Res 56:755-762, 1985
  pubmed

• 9) Matsumoto Y, Honda T, Hamada M et al:Evaluation of aortic distensibility inhemodialysis patients using cine magnetic resonance-A preliminary study. Intern J Angiol 6:190-192, 1996

• 10) Baumbach GL, Siems JE, Heistad DD:Effect of local reduction in pressure on distensibility and composition of cerebral arterioles. Circ Res 68:338-351, 1991
  pubmed

• 11) Baumbach GL, Heistad DD:Adaptive changes in cerebral blood vessels during chronic hypertension. J Hypertens 9:987-991, 1991
  pubmed

• 12) Asmar RG, Journo HJ, Lacolley PJ et al:Treatment for one year with perindopril:effect on cardiac mass and arterial compliance in essential hypertension. J Hypertens 6 (suppl 3):S33-S39, 1988

• 13) Simon AC, Levenson J, Bouthier JD et al:Effects of chronic administration of enalapril and propranolol on the large arteries in essential hypertension. J. Cardiovasc Pharmacol 7:856-861, 1985
  pubmed

• 14) Levy BI, Benessiano J, Poitevin P et al:Angiotensin-converting enzyme inhibition and compliance of the carotid artery in normotensive and hypertensive rats. J Human Hypertens 3:57-62, 1989

• 15) Benetos A Asmar R Vasmant D et al:Long lasting arterial effects of the ACE inhibitor ramipril. J Human Hypertens 5:363-368, 1991
  pubmed

• 16) Honda T, Hamada M, Shigematsu Y et al:Effect of and hypertensive therapy on aorticv distensibility in patients with essential hypertension:comparison with trichlormethiazide, nicardipine and alacepril (submitted).

• 17) Jaffe MD:High flow dilatation. Lancet i:1237-1238, 1981
  pubmed

• 18) Dobrin PB, Rovick AA:Influence of vascular smooth muscle on contractile mechanics and elasticity of arteries. Am J Physiol 217:1644-1652, 1969
  pubmed

• 19) Pohl V, Holtz J, Busse J et al:Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 8:37-44, 1986

• 20) Dzau VJ, Safar ME:Large conduit arteries in hypertension:role of the vascular renin-angiotension system. Circulation 77:947-953, 1988

• 21) Vidt DG, Bravo EL, Fouad RM:Captopril. N Engl J Med 306:214-219, 1982

• 22) Chobanian AV, Haudenscild CC, Nickerson Cet al:Anti atherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 15:327-331, 1990

• 23) Baumbach GL, Dobrin PB, Hart MN et al:Mechanics of cerebral arterioles in hypertensive rats. Circ Res 62:56-64, 1988
  pubmed

• 24) Hajdu MA Heistad DD, Baumbach GL:Effects of anti-hypertensive treatment of mechanics of cerebral arterioles in rats. Hypertension 17:308-316, 1991
  pubmed

P.99 掲載の参考文献

• 1) 松岡秀洋, 今泉勉:血管内皮細胞の多機能性, 血管内皮細胞障害と病態. 高血圧, Mebio 15:84-88, 1998

• 2) Vanhoutte PM, Mombouli JV:Vascular endothelium:vasoactive mediators. Prog Cardiovasc Dis 39:229-238, 1996
  pubmed

• 3) Luscher TF, Barton M:Biology of the endothelium. Clin Cardiol (suppl 2):II-310, 1997

• 4) 松岡秀洋, 今泉勉:新しく解明された内因性生理活性物質の血圧調節機構. 一酸化窒素, 内科 81:74-79, 1998

• 5) 一木和也, 松岡秀洋, 今泉勉ほか:血管傷害:冠危険因子とNO, 血管と内皮 7:61-74, 1997

• 6) Harrison DG:Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100:2153-215, 1997
  pubmed

• 7) De Meyer GR, Herman AG:Vascular endothelial dysfunction. Prog Cardiovasc Dis 39:325-342, 1997
  pubmed

• 8) Drexler H:Endothelial dysfunction:clinical implications. Prog Cardiovasc Dis 39:287-324, 1997
  pubmed

• 9) 松岡秀洋, 今泉勉:Data Analysis-ヒト血管内皮機能異常に対する治療的試み. 臨床高血圧 3:44-51, 1997

• 10) Celermajer DS:Endothelial dysfunction:does it matter? Is it reversible? J Am Coll Cardiol 30:325-333, 1997

• 11) Gibbons GH:Endothelial function as a determinant of vascular function and structure:a new therapeutic target. Am J Cardiol 79:3-8, 1997
  pubmed

• 12) Cooke Jp:Therapeutic interventions in endothelial dysfunction:endothelium as a target organ. Clin Cardiol 20 (suppl 2):II-4551, 1997

• 13) Rajagopalan S, Kurz S, Munzel T et al:Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97:1916-1923, 1996

• 14) Nakashima M, Mombouli JV, Taylor AA et al:Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest 92:2867-2871, 1993
  pubmed

• 15) Hirooka Y, Imaizumi T, Masaki H et al:Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension 20:175-180, 1992
  pubmed

• 16) Antony I, Lerebours G, Nitenberg A:Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hyper-tensive patients. Circulation 94:3115-3122, 1996

• 17) Lyons D, Webster J, Benjamin N:The effect of antihypertensive therapy on responsiveness to local intra-arterial NG-monomethyl-L-arginine in patients with essential hypertension. J Hypertens. 12:1047-1052, 1994

• 18) Panza JA Quyyumi AA, Callahan TS et al:Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 21:1145-1151, 1993
  pubmed

• 19) Creager Ma, Roddy MA:Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 24:499-505, 1994
  pubmed

• 20) Iwatsubo H, Nagano M, Sakai T et al:Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension 29:286-290, 1997
  pubmed

• 21) Tomiyama H, Kimura Y, Mitsuhashi H et al:Relationship between endothelial function and fibrinolysis in early hypertension. Hypertension 31:321-327, 1998
  pubmed

• 22) Kiowski W, Linder L, Nuesch R et al:Effects of cilazapril on vascular structure and function in essential hypertension. Hypertension 27:371-376, 1996
  pubmed

• 23) Schiffrin EL, Deng LY:Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 25:699-703, 1995
  pubmed

• 24) Thybo NK Stephens N, Cooper A et al:Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 25:474-481, 1995
  pubmed

• 25) Pieper GM:Review of alterations in endothelial nitric oxide production in diabetes:protective role of arginine on endothelial dysfunction. Hypertension 31:1047-1060, 1998
  pubmed

• 26) O'Driscoll G, Green D, Rankin Jet al:Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 100:678-684, 1997

• 27) Mullen MJ, Clarkson P, Donald AE et al:Effect of enalapril on endothelial function in young insulin-dependent diabetic patients:arandomized, double-blind study. J Am Coll Cardiol 31:1330-1335, 1998

• 28) Bijlstra PJ, Smits P, Lutterman JA et al:Effect of long-term angiotensin-converting enzyme inhibition on endothelial function in patients with the insulin-resistance syndrome. J Cardiovasc Pharmacol 25:658-664, 1995
  pubmed

• 29) Giugliano D, Marfella R, Acampora R et al:Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care 21:631-636, 1998
  pubmed

• 30) Nielsen FS, Rossing P, Gall MA et al:Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. Scand J Clin Lab Invest 57:427-434, 1997
  pubmed

• 31) Ferri C, Desideri G, Baldoncini R et al:Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnomalities. Diabetes 47:660-667, 1998

• 32) Takeshita A, Hirooka Y, Imaizumi T:Role of endothelium in control of forearm blood flow in padents with heart failure. J Card Fail 2:209S-215S, 1996

• 33) Hirooka Y, Imaizumi T, Tagawa T et al:Effects of L-arginine on impaired acetylcholineinduced and ischemic vasodilation of the forearm in patients with heart failure. Circulation 90:658-668, 1994
  pubmed

• 34) Nakamura M, Funakoshi T, Arakawa N et al:Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. J Am Coll Cardiol 24:1321-1327, 1994
  pubmed

• 35) Diet F, Pratt RE, Berry GJ et al:Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94:2756-2767, 1996
  pubmed

• 36) Zhuo JL, Froomes P, Casley D et al:Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the intemal mammary artery in patients with ischemic heart disease. Circulation 96:174-182, 1997

• 37) Mancini GB, Henry GC, Macaya C et al:Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 94:258-265, 1996
  pubmed

P.108 掲載の参考文献

• 1) 宮崎瑞夫:ACE阻害薬の作用, 抗動脈硬化作用. Therap Res 14:4545-4549, 1993

• 2) Rolland PH, Souchet T, Friggi A et al:Aorta Viscoelasticity and arterial histopathology of atherosclerotic pigs treated by angiotensin converting enzyme inhibition. J Hypertens (suppl 9):S178-S179, 1991
  pubmed

• 3) Schuh JR, Blehm DJ, Frierdich GE et al:Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 91:1453-1458, 1993
  pubmed

• 4) Rakugi H, Jacob HJ, Krieger JE et al:Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation 87:283-290, 1993
  pubmed

• 5) Rakugi H, Kim DK, Krieger JE et al:Induction of angiotensin coverting enzyme in the neointima after vascular injury. Possible role in restenosis. J Clin Invest 93:339-346, 1994

• 6) Rakugi H, Wang DS, Dzau VJ et al:Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 90:449-455, 1994
  pubmed

• 7) Ohishi M, Ueda M, Rakugi H et al:Upregulation of angiotensin-converting enzyme during the healing Process after injury at the site of percuta-neous transluminal coronary angioplasty in humans. Circulation 96:3328-3337, 1997

• 8) Ohishi M, Ueda M, Rakugi H et al:Immuno-cytochemical localization of angiotensin II, ACE, and chymase in human coronary atherosclerotic lesions. J Hypertens 14 (suppl 1):S136, 1996

• 9) Yamabe T, Imazu M, Yamamoto H et al:Effect of cilazapril on vascular restenosis after percuta-neous transluminal coronary angioplasty. Coron Artery Dis 6:573-579, 1995

• 10) Sith SC Jr, Blair SN, Criqui MH et al:Preventing heart attack death in tients with coronary disease. Circulation 92:2-4, 1995

• 11) Pepine CJ:Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary arery disease in patients with preserved left ventricular function. J Am Coll 27:1048-1052, 1996

• 12) Kitazono T, Padgett RC, Armstrong ML et al:Evidence that angiotensin II is present in human monocytes. Circulation 91:1129-1134, 1995
  pubmed

• 13) Bardy N, Merval R, Benessiano Jet al:Pressure and angiotensin II synergistically induce aortic fibronectin expression in organ culture model of rabbit aorta. Evidence for a pressure-induced tissue renin-angiotensin system. Circ Res 79:70-78, 1996

• 14) Nakamura Y, Rakugi H, Higaki Jet al:Pulsatile stretch on smooth muscle and endothelial cells plays an important role in the growth of smooth muscle cells. Circulation 88:1-184, 1993 (abstract)

• 15) Rieder MJ, Carmona R, Krieger JE et al:Suppression of angiotensin-converting enzyme expression and activity by shear stress. Circ Res 80:312-319, 1997
  pubmed

• 16) Ohishi M, Fujii K, Minamino T et al:A potent genetic risk factor for restenosis. Nat Genet 5:324-325, 1993
  pubmed

• 17) Amant C, Bauters C, Bodart JCet al:Dallele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stendng. Circulation 96:56-60, 1997

• 18) Samani NJ, Thompson JR, O'Toole L et al:A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 94:708-712, 1996

• 19) Fishel RS, Thourani V, Eisenberg SJ et al:Fibroblast growth factor stimulates angiotensin converting enzyme expression in vascular smooth muscle cells. Possible mediator of the response to vascular injury. J Clin Invest 95:377-387, 1995
  pubmed

• 20) Ohishi M, Ueda M, Rakugi H et al:Enhanced expression of angiotensin-converdng enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 15:1295-1302, 1997
  pubmed

• 21) Dzau VJ, Gibbons GH, Pratt RE:Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 18 (suppl II):II 100-II 105, 1991

• 22) Nakajima M, Hutchinson HG, Fujinaga Met al:The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the ATl receptor:gain-of-function study using gene transfer. Proc Natl Acad Sci USA 92:10663-10667, 1995

• 23) Keidar S, Kaplan M, Hoffman A et al:Angiotensin II stimulates macrophage-mediated oxidation of low density Upoproteins. Atheroslerosis 115:201-215, 1995

• 24) Scheidegger KJ, Butler S, Witztum JL:Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem 272:21609-21615, 1997

• 25) Kerins DM, Hao Q, Vaughan DE:Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 96:2515-2520, 1995
  pubmed

• 26) Kamide K, Nagano M, Nakano N et al:Insulin resistance and cardiovascular complications in patients with essential hypertension. Am J Hypertens 9:1165-1171, 1996
  pubmed

P.114 掲載の参考文献

• 1) Reaven GM:Banting Lecture 1988:Role ofinsulin resistance in human disease. Diabetes 37:1595-1607, 1988

• 2) DeFronzo RA, Tobin JD, Andres R:Glucose clamp technique:amethod for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979

• 3) Shimamoto K, Hirata A, Fukuoka M et al:Insulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patients. Hypertension 23 (suppl 1):129-133, 1994

• 4) Agata J, Masuda A, Shimamoto K et al:High plasma immunoreactive leptin level in essential hypertention. Am J Hypertens 10:1171-1174, 1997

• 5) Miyazaki Y, Ura N, Shimamoto K et al:Effects of Aging on the Insulin Actions for the Glucose Metabolism and Renal Function in Normotensives and Essential Hypertensives, Am J Hypertens 11:(in press) , 1998

• 6) Pollare T, Lithell H, Berne C:A comparison of the effects of hydro-chlorothiazide and captoril on glucose and lipid metabolism in patients with hypertension. J Hum Med 321:868-873, 1989

• 7) Paolisso G, Gamardella A, Verza M et al:ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 6:175-179, 1992

• 8) Rett K, Lotz N, Wicklmayr M et al:Improved insulin action by ACE inhibition in type II diabetics. Ditsch Med Wochenschr 113:243-249, 1988

• 9) Leighton B, Alison L, Sanderson ME et al:Effects of treatment of spontaneously hypertensive rats with the angiotensin-converting enzyme inhibitor trondolapril and the calcium antagonist verapamil on the sensitivity of glucose metabolism to insulin in rat soleus muscle in vitro. Diabetes 45 (suppl 1):S120-S124, 1996

• 10) Tomiyama H, Kushiro T, Abeta H et al:Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 23:450-455, 1994

• 11) Shimamoto K, Ura N, Nakagawa M et al:The mechanisms of the improvement of insulin sensitivity by angiotensin converting enzymeinhibitor. Clin Exp Hypertens 18:247-266, 1996

• 12) Chen S, Kashiwabara H, Kosegawa I et al:Bradykinin may not be improved in improvement of insulin resistance by angiotensin converting enzyme inhibitor. Clin Exp Hypertens 18:625-636, 1996

• 13) Miyazaki Y, Murakami H, Hirata Aet al:Effects of angiotensin converting enzyme inhibitor, temocapril, on insulin sensitivity and insulin actions to renal sodium handling and the pressor system in essential hypertensives, Am J Hypertens 11:(in press) , 1998

P.119 掲載の参考文献

• 1) Veterans Administraion Cooperative Study Group on Antihypertensive Agents:Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 213:1143-1152, 1970

• 2) The Medical Research Council working party:MRC trial of treatment of mild hypertension:Principal results. Br Med J 291:97-104, 1985

• 3) Multiple Risk Factor Intervention Trial research group:Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Msk Factor Intervention Trial. Am J Cardiol 55:1-15, 1985

• 4) Hypertension Detection and Follow-Up Program Cooperative Group:The effect of antihypertensive drug treatment on mortality in the presence of resdng electrocardiographic abnormalities at baseline:the HDFP experience. Circulation 70:996-1003, 1984

• 5) Holme I, Helgeland A, Hjermann I et al:Treatment of mild hypertension with diuretics. The importance of ECG abnormalities in the Oslo Study and in MRFIT. JAMA 251:1298-1299, 1984
  pubmed

• 6) Beme C, Pollare T, Lithell H:Effect of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 14 (suppl 4):39-47, 1991

• 7) Lithell H:Insulin resistance and cardiovascular drugs. Clin Exp Hypertens A 14:151-162, 1992
  pubmed

• 8) Jauch KW, Guenther B, Hart W et al:Improvement of postoperative insulin action by bradykinin. Biol Chem Hoppe Seyler 367:207-210, 1991

• 9) Ishimitsu T, Yagi S, Ebihara A et al:Long-term evaluation of combined antihypertensive therapy with lisinopril and a thiazide diuretic in patients with essential hypertension. Jpn Heart J 38:831-840, 1997

• 10) Sasaki K, Arakawa K:Effects of captopril on serum lipoproteins in mild essential hypertension. Curr Ther Res Clin Exp 40:898-902, 1986

• 11) Weinberger MH:Innuence of an angiotensin-converting enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 5 (suppl III):132-138, 1983

• 12) Chobanian AV, Haudenschild CC, Nickerson C et al:Trandolapril inhibits atherogenesis in the Watanabe heritable hyperlipidemic rabbit. Hypertension 20:473-477, 1992
  pubmed

• 13) Schuh JR, Blehm DJ, Frierdich GE et al:Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 91:453-1458, 1993

• 14) Yang Z, Arnet U, von Segesser L et al:Different effects of angiotensin-converting enzyme inhibition in human arteries and veins. J Cardiovasc Pharmacol 22 (suppl5):17-22, 1993

• 15) Pepine CJ:Improved endothelial function with angiotensinconverting enzyme inhibitors. Am J Cardiol 79 (suppl 5A):29-32, 1997

• 16) Clozel M, Kuhn H, Hefti F et al:Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Effect of angiotensin converting enzyme inhibition. Hypertension 18:132-141, 1991
  pubmed

• 17) Linas S:Calcium channel blockers versus angiotensinconverting enzyme inhibitors:renal effects. Am J Kidney Dis 16 (suppl 1):15-19, 1990

• 18) Rimmer JM, Hom JF, Gennari FJ:Hyperkalemia as a complication of drug therapy. Arch Intern Med 147:867-869, 1987

• 19) Abu-Hamdan DK, Desai H, Sondheimer J et al:Taste acuity and zinc metabolism in captopril-treated hypertensive male patients. Am J Hypertens 1:303S-308S, 1988
  pubmed

• 20) Bao G, Gohlke P, Unger T:Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models. J Cardiovasc Pharmacol 20 (suppl9):S96-S99, 1992

• 21) Johnston CI, McGrath BP, Millar JA et al:Long-term effects of captopril (SQ 14, 225) on blood pressure and hormone levels in essential hypertension. Lancet 2:493-495, 1979
  pubmed

• 22) Ogihara T, Maruyama A, Hata T et al:Hormonal responses to long-term converting enzyme inhibition in hypertensive patients. Clin Pharmacol Ther 30:328-335, 1981

• 23) 石光俊彦, 山門実, 多川斉:血液透析患者における angiotensin I 変換酵素阻害薬captoprilの急性降圧機序に関する検討. 日本腎臓学会誌 28:447-454, 1986

• 24) Fogari R Zoppi A, Tettamanti F et al:Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhibitors:a double-blind, randomized, cross-over study. J Cardiovasc Pharmacol 19:670-673, 1992

• 25) Nicholls MG, Gilchrist NL:Sulindac and cough induced by converting enzyme inhibitors. Lancet 1:872, 1987
  pubmed

• 26) Croog SH, Levine S, Testa MA et al:The effects of antihypertensive therapy on the quality of life. N Engl J Med 314:1657-1644, 1986

• 27) Kaada B, Woie L:Effects of an angiotensin con-verting enzyme (ACE) inhibitor on plasma endorphin level. Gen Pharmacol 21:693-695, 1990

• 28) Melzig MF, Heder G:Dcxamcthasone induced enhanced enkephalin degradation by angiotensin-converting enzyme (ACE) of endothelial cells. Pharmazie 50:139-141, 1995
  pubmed

• 29) Costall B, Coughlan J, Horovitz ZB et al:The effects of ACE inhibitors captopril and SQ29, 852 in rodent tests of cognition. Pharmacol Biochem Behav 33:573-579, 1989

• 30) Usinger P, Hock FJ, Wiemer G et al:Hoe 288:Indications on the memory-enhancing effects of a peptidase inhibitor. Drug Dev Res 14:315-324, 1988

• 31) Barnes JM, Barnes NM, Costall B et al:Angiotensin II inhibits the release of [3H] acetylcholine from rat entorhinal cortex in vitro. Brain Res 491:136-143, 1989
  pubmed

• 32) Wiemer G, Becker R, Gerhards H et al:Effectson acetylcholine metabolism in rat brain by Hoe 065, a compound structurally related to angiotensin converting enzyme inhibitors. Eur J Pharmacol 166:31-39, 1989

• 33) Gould AB, Goodman S, DeWolf R et al:Interrelation of the renin system and erythropoietin in rats. J Lab Clin Med 96:523-534, 1980
  pubmed

• 34) Islam MS, Bourbigot B, Codet Jp et al:Captopril induces correction of postrenal transplant erythremia. Transpl Int 3:222-225, 1990
  pubmed

• 35) Katz RJ, Levy WS, Buff L et al:Prevention of nitrate tolerance with angiotensin converting enzyme inhibitors. Circulation 83:1271-1277, 1991
  pubmed

• 36) Pizzulli L, Hagendorff A, Zirbes M et al:Influence of captopril on nitroglycerin-mediated vasodilation and development of nitrate tolerance in arterial and venous circulation. Am Heart J 131:342-34, 1996
  pubmed

• 37) Magrini F, Shimizu M, Roberts N et al:Angiotensin converting enzyme inhibition andcoronary blood flow. Circulation 75 (suppl I):1168-1173, 1987

• 38) Daly P, Rouleau JL, Cousineau D et al:Acute effects of captopril in hypertensive patients withstable angina. Postgrad Med J 2 (suppl I):54-58, 1986

• 39) Strozzi C, Cocco G, Portaluppi F et al:Ergometric evaluation of the effects of captoprilin hypertensive patients with stable angina. Curr Ther Res Clin Exp 41:301-304, 1987

• 40) Pfeffer MA, Braunwald E, Moye LA et al:Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. N Engl J Med 327:669-677, 1992

• 41) Kober L, Torp-Pedersen C, Carlsen JE et al:A clinical trial of the angiotensin-convertingenzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333:1670-1676, 1995

• 42) Correa FJ, Eiser AR:Angiotensin-converting enzyme inhibitors and lithium toxicity. Am J Med 93:108-109, 1992
  pubmed

• 43) Teitelbaum M:Asignificant increase in lithium levels after concomitant ACE inhibitor administration. Psychosomatics 34:450-453, 1993

• 44) Hearings RMC, de Boer A Stricker BHCH et al:Hypoglycemia associated with use of inhibitorsof angiotensin converting enzyme. Lancet 345:1194-1198, 1995

• 45) Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure:The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med 153:154-183, 1993
  pubmed

• 46) Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure:The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC VI). Arch Intern Med 157:2413-2446, 1997

Part3 / 治療編

P.129 掲載の参考文献

• 1) Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure:the Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 153:154-183, 1993
  pubmed

• 2) Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure:The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood pressure. Arch Intern Mad 157:2413-2446, 1997

• 3) Guidelines Sub-committee:Guidelines for the management of mild hypertension:memorandum from a World Health Organination/International Society of Hypertension meeting. J Hypertens 7:689-693, 1993

• 4) 厚生省・日本医師会:高血圧診療のてびき, 日本醫事新報社, 東京, 1990

• 5) 上原誉志夫, 百村伸一, 松本昌泰ほか:高血圧の治療に関するアンケート-結果とその分析-Therapeutic Research 16:1937-1964, 1995

• 6) Pfeffer MA, Lamas GA, Vaughan DE et al:Effects of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med 31:80-86, 1988
  pubmed

• 7) The SOLVD investigators:Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302, 1991
  pubmed

• 8) Lewis EJ, Hunsicker LG, Bain RP et al:for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993

• 9) Maschio G, Alberti D, Janin G et al:for the Angiotensin-Converting-Enzyme Inbition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996

P.134 掲載の参考文献

• 1) Guidelines Sub-Committee:1993 Guidelines for the management of mild hypertension:memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 11:905-918, 1993
  pubmed

• 2) Postma CT, Dennesen PJW, deBoo T et al:First dose hypotension after captopril:can it be predicted? A study of 240 patients. J Hum Hypertens 6:205-209, 1992

• 3) 斉藤郁夫, 河邊博史, 猿田享男ほか:Ca拮抗薬, ACE阻害薬, β遮断薬による降圧療法の効果. 日本醫事新報 3683:27-31, 1994
  Medical*Online

• 4) 尾前照雄, 松岡博昭, 荒川規矩男ほか:軽・中等症高血圧症における ACE阻害薬と Ca拮抗薬の比較試験-GLANT研究から-. 日本医事新報 3630:26-34, 1993

• 5) Warner NJ, Rush JE:Safety profiles of the angiotensin-converting enzyme inhibitors. Drugs 35 (suppl5):89-97, 1988

• 6) Os I, Bratland B, Dahlof B et al:Female preponderance for lisinopril-induced cough in hypertension. Am J Hypertens 7:1012-1015, 1994
  pubmed

• 7) Elliott WJ:Higher incidence of discontinuation of angiotensin convening enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther 60:582-588, 1996

• 8) Woo KS, Nicholls MG:High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 40:141-144, 1995
  pubmed

• 9) Charlon V, Dollow S, Fidel J et al:Reproducibility of angiotensin convening enzyme inhibitorinduced cough:a double-blind randomised study. Br J Clin Pharmacot 39:125-129, 1995

• 10) Lacourciere Y, Brunner H, Irwin R et al:Effects of modulators of the renin-angiotensin-aldos-terone system on cough. J Hypertens 12:1387-1393, 1994

• 11) Pillans PI, Coulter DM, Black P:Angiooedema and urticaria with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol 51:123-126, 1996
  pubmed

• 12) 猿田享男:高血圧における薬物療法の現況. 臨床医薬 13:4024-4029, 1997

• 13) Croog SH, Levine S, Testa MA et al:The effects of antihypertensive therapy on the quality of life. N Engl J Med 314:1657-1664, 1986

• 14) Schoenberger JA, Croog SH, Sudilovsky A et al:Self-reported side effects from antihypertensive drugs. A clinical trial. Am J Hypertens 3:123-132, 1990
  pubmed

• 15) deLame PA, Droussin AM, Thomson M et al:The effects of enalapril on hypertension and quality of life. A large multicenter study in Belgium. Acta Cardiol 44:289-302, 1989

• 16) Testa MA, Anderson RB, Nackley JF et al:Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. N Engl J Med 328:907-913, 1993

• 17) Dustan HP, Caplan LR Curry CL et al:Report of the task force on the availability of cardiovascular drugs to the medically indigent. Circulation 85:849-860, 1992

• 18) Hilleman DE, Mohiuddin SM, Lucas BD:Cost analysis of initial antihypertensive therapy [Abstract]. Circulation 88 (suppl 1):I-263, 1993

• 19) Joint National Committee:The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413-2446, 1997

• 20) Hricik DE, Browning PJ, Kopelman R et al:Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med 308:373-376, 1983
  pubmed

• 21) Kaplan NM:Individualized therapy. In:Clinical Hypertension, ed. by Kaplan NM, Williams & Wilkins, Baltimore, 1998, pp.232-237

• 22) Shotan A Widerhorn J, Hurst A et al:Risks of angiotensin-converting enzyme inhibition during pregnancy:experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 96:451-456, 1994
  pubmed

• 23) Feldkamp M, Jones K L, Ornoy A et al:Post-marketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy. MMWR 46:240-242, 1997

• 24) Salvetti A, Pedrinelli R, Magagna A et al:Differential effects of selective and non-selective prostaglandin-synthesis inhibition on the pharmacological responses to captopril in patients with essential hypertension. Clin Sci 63 (suppl):S261-S263, 1982

• 25) Pollare T, Lithell H, Berne C:A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321:868-873, 1989

• 26) Haenni A, Berglund L, Reneland R et al:The alterations in insulin sensitivity during angiotensin converting enzyme inhibitor treatment are related to changes in the calcium/magnesium balance. Am J Hypertens 10:145-151, 1997
  pubmed

• 27) Schmieder RE, Martus P, Klingbeil A:Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275:1507-1513, 1996
  pubmed

• 28) Antony I, Lerebours G, Nitenberg A:Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 94:3115-3122, 1996
  pubmed

• 29) Ikram H, Low CJS, Shirlaw TM et al:Angiotensin converting enzyme inhibition in chronic stable angina:effects on myocardial ischaemia and comparison with nifedipine. Br Heart J 71:30-33, 1994

• 30) Cleland JGF, Erhardt L, Murray G et al:Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. Eur Heart J 18:41-51, 1997

• 31) Annane D, Bellissant E, Pussard E et al:Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. Circulation 94:1316-1324, 1996
  pubmed

• 32) Garg R Yusuf S:Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273:1450-1456, 1995
  pubmed

• 33) Anderson S, Rennke. HG, Brenner BM:Therapeutic advantage, of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000, 1986

• 34) Dworkin L, Benstein JA, Parker M et al:Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 43:808-814, 1993
  pubmed

P.144 掲載の参考文献

• 1) NoVick A Scoble J, Hamilton G:Renal Vascular Disease, WB Saunders Co, London, 1996

• 2) Case D, Laragh J:Reactive hyper-reninemia in renovascular hypertension after angiotensin blockadge with saralasin or converting enzyme inhibitor. Ann Intern Med 91:153-160, 1979
  pubmed

• 3) Muller F, Sealey J, Atlas S et al:The captopril test for identifying renovascular disease in hypertensive patients. Am J Med 80:633-644, 1986
  pubmed

• 4) Frederickson E, Wilcox C, Bucci C et at:A prospective evaluation of a simplified captopril test for the detection of renovascular hypertension. Arch Intern Med 150:569-572, 1990

• 5) Lyons D, Streck W, Kem D et al:Captopril stimulation of differential renins in renovascular hypertension. Hypertension 5:615-622, 1983
  pubmed

• 6) Jackson B, McGrath B, Matthews P et al:Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension. Hypertension 8:650-654, 1986
  pubmed

• 7) Jonker G-J, de Zeeuw D, Huisman R:Angiotensin converting enzyme inhibition improves diagnostic procedures for renovascular hypertension in dogs. Hypertension 12:411-419, 1988
  pubmed

• 8) Postma C, van der Steen P, Hoefnagels W et al:The captopril test in the detection of renovascular disease in hypertensive patients. Arch Interm Med 150:625-628, 1990

• 9) Sfakianakis G, Bourgoignie J, Jaffe D et al:Single-dose captopril scintigraphy in the diagnosis of renovascular hypertension. J Nucl Med 28:1383-1392, 1987
  pubmed

• 10) Tomoda F, Takata M, Ohashi S et al:Captopril-stimulated renal vein renin in hypertensive pateints with or without renal artery steonis. Am J Hypertens 3:918-926, 1990
  pubmed

• 11) Setaro J, Saddler M, Chen C et al:Simplified captopirl renography in diagnosis and treatment of renal artery stenosis. Hypertension 18:289-298, 1991
  pubmed

• 12) Dondi M:Captopril renal scintigraphy with 99 mTc-mercaptoacetyltriglycine (99 mTc-MAG3) for detecting renal artery stenosis. Am J Hypertens 4:S737-S740, 1991

• 13) Svetkey L, Wilkinson R, Dunnick N et al:Captopril renography in the diagnosis of renovascular disease. Am J Hypertens 4:S711-S715, 1991

• 14) Nally J, Chen C, Fine E et al:Diagnostic criteria of renovascular hypertension with captopril renography. Am J Hypertens 4:S749-S752, 1991

• 15) Geyskes G, de Bruyn A:Captopril renography and the effect of percutaneous transluminal angioplasty on blood pressure in 94 patients with renal artery stenosis. AM J Hypertens 4:S685-S689, 1991

• 16) Svetkey L, Wilkinson J, R., Dunnick N et al:Captopril renography in the diagnosis of renovascular disease. AM J Hypertens 4:S711-S715, 1991

• 17) Dondi M, Fanti S, De Fabritiis A et al:Prognostic value of captopril renal scintigraphy in renovascular hypertension. J Nucl Med 33:2040-2044, 1992
  pubmed

• 18) Nally J, Black H:State-of-the-Art Review:Captopril renography-Pathophysiological considerations and clinical observations. Semin Nucl Med 22:85-97, 1992
  pubmed

• 19) Nally J, Clarke HJ, Grecos G et al:effect of captopril on 99 mTc-diethylenetriaminepentaacetic acid renograms in two-kidney, one-clip hypertension. Hypertension 8:685-693, 1986

• 20) Blaufbx M, Dubovsky E, Hilson et al:Report of the working party group on determining the radionuclide of choice. Am J Hypertens 4:S747-S748, 1991

• 21) Sweny P:Medical management of atherosclerotic renovascular disease. In:Renal Vascular Disease eds by Novick A Scoble J, Hamilton G, WB Saunders, London, 1996, 351-361

• 22) Pohl M:Medical management of renovascular hypertension. In:Renal Vascular Disease eds by Novick A, Scoble J, Hamilton G, WB Saunders, London, 1996, 339-349

• 23) Lyons G:Single dose of captopril as a diagnostic test for primary aldosteronism. J Clin Endocrinol Metab 57:892-000, 1983

• 24) Luderer J:Converting enzyme inhibition with captopril in patients with primary aldosteronism. Clin Pharmacol Ther 31:305-000, 1982
  pubmed

• 25) Israeli A, Gottehrer N, Gavish D et al:Captopril and phaeochromocytoma. Lancet ii:278-279, 1985

• 26) Loute G, Guffens P, Waucquez J-L et al:Effect of captopril on hypertension due to phaeochromocytoma. Lancet ii:175, 1984

• 27) Muratani H, Kawasaki T, Kawano Y et al:Activation of renin-angiotensin system in maintenance of high blood pressure in uncomplicated pheochromocytoma. A case report. Jap J Med 22:227-230, 1983

• 28) Plouinm P-F, Chatellier G, Rougeot M-A et al:Plasma renin activity in phaeochromocytoma:effects of beta-blockade and converting enzyme inhibition. J Hypertens 6:579-585, 1988

• 29) Oishi S, Sato T:Plasma renin activity, aldosterone and catecholamines in phaeochromocytoma:effect of converting enzyme inhibition. J human Hypertens 8:923-924, 1994
  pubmed

• 30) Salathe M, Weiss P, Ritz R:Rapid reversal of heart failure in a patient with pheochromocytoma and catecholamine-induced cardiomyopathy who was treated with captopril. Br Heart J 68:527-528, 1992

• 31) Saruta, T., Suzuki, H., Handa, M et al:Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 62:275-279, 1986

P.150 掲載の参考文献

• 1) The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) . Arch Intern Med 157:2413-2446, 1997

• 2) Kawazoe N, Eto E, Abe I et al:Pathophysiology in malignant hypertension:with special reference to the renin-angiotensin sysytem. Clin Caridiol 10:513-518, 1987

• 3) Kawazoe N, Eto E, Abe I et al:Long-term prognosis of malignant hypertension; difference between underlying diseases such as essential hypertension and chronic glomerulonephritis. Clin Nephrol 29:53-57, 1988

• 4) Strandgaard S, Paulson OB:Cerebral blood flow and its pathophysiology in hypertension. Am J Hypertens 2:486-492, 1989
  pubmed

• 5) Bidani AK, Griffin KA, Plott W et al:Renal ablation acutely transforms 'benign' hypertension to 'malignant' nephrosclerosis in hypertensive rats. Hypertension 24:309-316, 1994
  pubmed

• 6) Gifford RWJ:Management of hypertensive crisis. JAMA 266:829-835, 1991

• 7) Haas DC, Streeten DHP, Kim RC et al:Death from cerebral hypoperfusion during nitroprusside treatment of acute angiotensin-dependent hypertension. Am J Med 75:1071-1076, 1983

• 8) 柊山幸志郎:高血圧緊急症. 医学のあゆみ 153 (13):992-994, 1990
  Medical*Online

• 9) 瀧下修一:高血圧緊急症の治療. medicina 28 (13):2118-2120, 1991

• 10) Houston MC:The comparative effects of clonidine hydrochloride and nifedipine in the treatment of hypertensive crises. Am Heart J 115:152-159, 1988
  pubmed

• 11) Grossman E, Messerli FH, Grodzicki T et al:Should a moratorium be placed on sublingual nifedipine capusules given for hypertensive emergencies and pseudoemergencies? JAMA 276:1328-1331, 1996

• 12) Isles CG:Malignant hypertension and hypertensive encephalopathy. In:Textbook of Hypertension, ed by Swales JD, Blackwell Scientific Publications, Oxford, 1994, pp.1233-1248

• 13) 藤島正敏:脳血管障害の血圧管理 (急性期-慢性期). 日内会誌 80:553-558, 1991

• 14) DeSanctis RW, Doroghazi RM, Austen WG et al:Aortic dissection. N Engl J Med 317:1060-1067, 1987
  pubmed

• 15) Crawford ES:The diagnosis and management of aortic dissection. JAMA 264:2537-2541, 1990
  pubmed

• 16) Calhoun DA, Oparil S:Treatment of hypertensive crisis. N Engl J Med 323:1177-1183, 1990
  pubmed

• 17) Cigarroa JE, Isselbacher EM, DeSanctis RW et al:Diagnostic imaging in the evaluation of suspected aortic dissection, old standards and new directions. N Engl J Med 328:35-43, 1993
  pubmed

• 18) Houston M:Hypertensive emergencies and urgencies:pathophysiology and clinical aspects. Am Heart J 111:205-210, 1986
  pubmed

• 19) Vidt DG:Current concepts in treatment of hypertensive emergencies. Am Heart J 111:220-225, 1986
  pubmed

• 20) Cunningham FG, Lindheimer MD:Hypertension in pregnancy. N Engl J Med 326:927-932, 1992
  pubmed

• 21) Rose BD, Black RM:Hypertensive urgencies and emergencies. In:Manual of clinical problems in nephrology, Little, Brown and Company, Boston, 1988, pp.104-112

• 22) Houston MC:Abrupt cessation of treatment in hypertension. Am Haert J 102:415-430, 1981

• 23) Metz S, Klein C, Morton N:Rebound hypertension after discontinuation of transdermal clonidine therapy. AM J Med 82:17-19, 1987
  pubmed

P.158 掲載の参考文献

• 1) Nakamaru M, Ogihara T:Effect of age on active and inactive plasma renin in normal subjects and patients with essential hypertension. J Am Ger Soc 29:379-382, 1981

• 2) Ogihara T, Hata T, Maruyama A et al:Studies on the renin-angiotenshin aldosterone system in elderly hypertensive patients with an angiotensin II antagonist. Clin Sci 57:461-463, 1979
  pubmed

• 3) Wikstrand J, Warnold I, Olsson G et al:Primary prevention with metoprolol in patients with primary hypertension. Mortality results from the MAPHY study. JAMA 259:1976-1982, 1988
  pubmed

• 4) 荻原俊男ほか:老年者本態性高血圧症に対する塩酸カルテオロールの有用性-Quality of Life を含めて-. Geriatric Medicine 28:577-591, 1990

• 5) Case DB, Atlas SA, Laragh JH et al:Clinical experience with blockade of the renin angiotensin aldosterone system by an oral converting enzyme inhibitor (SQ 14225, captopril) in hypertensive patients. Progr Cardiovasc Dis 21:195-206, 1978

• 6) Ogihara T, Maruyama A, Hata T et al:Hormonal responses to long-term converting enzyme inhibition in hypertensive patients. Clin Pharmacol Ther 30:328-335, 1981

• 7) 蔵本築:本態性高血圧における年齢とカプトプリルの有用性-カプトプリル二重盲検試験の検討-. Prog Med 4 (suppl):134, 1984

• 8) Jenkins AC, Knill JR, Dreslinski GR.:Captopril in the treatment of the elderly hypertensive patient. Arch Intern Med 145:2029-2031, 1985
  pubmed

• 9) Gomez HJ, Smith SG, Moncloa F:Efffcacy and safety of lisinopril in older patients with essential hypertension. Am J Med 85 (suppl 3B):35-37, 1988

• 10) Poncelet P, Werquin S, Warembourg A et al:A double-blind, randomized, comparative study of nitrendipine and enalapril in elderly hypertensive patients. J Cardiovasc Pharmacol 18 (suppl 1):S67-S70, 1991

• 11) Applegate WB, Phillips HL, Schnaper H et al:A randomized controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in older women. Arch Intern Med 151:1817-1823, 1991
  pubmed

• 12) 栗山良紘:老年者高血圧症例の脳循環と降圧剤療法. 医学のあゆみ158:576-579, 1991

• 13) Frei A, Muller-Brand J:Cerebral blood flow and antihypertensive treatment with enalapril. J Hypertens 4:365-368, 1986
  pubmed

• 14) The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997
  pubmed

• 15) SHEP Cooperative Research Group:Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 265:3255-3264, 1991

• 16) Staessen JA, Fagard R, Thijs L et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.:Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350:757-764, 1997
  pubmed

• 17) 荻原俊男, 森本茂人, 中橋毅ほか:本邦における老年者高血圧に対する治療方針に関する検討. 日老医誌 31:396-403, 1994

• 18) 荻原俊男, 日和田邦男, 松岡博昭ほか:老年者の高血圧治療ガイドライン, 1995 (長寿科学総合研究班試案) 日老医誌 33:945-975, 1996

• 19) Croog SE, Levin S, Testa MA et al:The effects of antihypertensive therapy on the quality of life. N Engl J Med 314:1657-1664, 1986

• 20) Mikami H, Ogihara T, Nakamaru M et al:Quality of life in the treatment of hypertension in the elderly. In:How should elderly hypertensive patients be treated, ed. by Omae T, Zanchetti T, Springer-Verlag, Tokyo, 1989, pp.219-225

• 21) 荻原俊男:老年者高血圧治療とQOL血圧 2:342-348, 1995

• 22) 荒川規矩男:Angiotensin Converting Enzyme Inhibitor臨床応用のその後. BIOmedica 6 (10), 999-1003, 1991

• 23) 荻原俊男:降圧療法におけるQOLの評価と課題. 臨床医薬 8:751-758, 1992
  Medical*Online

• 24) 原一男:高血圧治療のポイント-私の降圧薬選択方針 MEDICAMENT NEWS 1334:8-9, 1991

• 25) Blowers D, Chalmers D:Postmarketing surveillance of enalapril I. Br MED J 297:1269-1270, 1988

• 26) 藤森勝也, 布施克也, 佐藤昭英ほか:アンギオテンシン変換酵素 (ACE) 阻害薬によって誘発される咳嗽の検討. 日胸 48:994-998, 1989

P.163 掲載の参考文献

• 1) National Heart, Lung, and Blood Institute:Update on the 1987 Task Force on High Blood Pressure in Children and Adolescents:A Working Group Report from the National High Blood Pressure Education Program. Pediatr 98:649-657, 1996

• 2) Dillon MJ:Drug treatment of hyper-tension. In:Pediatric Nephrology 2nd ed., ed. by Holliday, MA et al, Williams & Wilkins, 1987, pp.758-765

• 3) 内山聖:小児高血圧とACE阻害薬. ACE阻害薬のすべて (改訂版) , 荻原俊男, 猿田享男, 日和田邦男編, 1994, 先端医学社, 東京, pp.145-153

• 4) Dillon MJ:The diagnosis of renovascular disease. Pediatr Nephrol 11:366-372, 1997
  pubmed

• 5) Fossali E, Intermite R, Minoja M et al:The captopril test in children with renovascular and renal hypertension. Acta Paediatr. 85:1129-1131, 1996
  pubmed

• 6) Ng CS, de Bruyn R Gordon I:The investigation ofrenovascular hypertension in children:the accuracy of radio-isotopes in detectingrenovascular disease. Nucl Med Commun 18:1017-1028, 1997

• 7) Sfakianakis GN, Sfakianaki A, Paredes A et al:Single dose captopril scintigraphy in the neonate with renovascular hypertension:prediction of renal failure, a side effect of captopril therapy. Biol Neonat 54:246-253, 1988

• 8) Norsi MR, Madina EH, Anglo AA et al:Evaluation of captopril versus reserpine and frusemide in treating hypertensive children with acute post-streptococcal glomerulonephritis. Acta Paediatr 81:145-149, 1992

• 9) Schneeweiss A:Cardiovascular drugs in children:angiotensin-converting enzyme inhibitors. Pediatr. Cardiol 9:109-115, 1988
  pubmed

• 10) Cichocka E, Wyszynska T, Januszewicz P et al:Evaluation of the efficacy and safety of monotherapy for significant essential hypertension in adolescents with use of enalapril (Polish). Pediatr Pol 70:145-151, 1995
  pubmed

• 11) Wood EG, Buchman TE, Lynch RE:Captopril-induced reversible acute renal failure in an infant with coarctation of the aorta. Pediatr 88:816-818, 1991

P.170 掲載の参考文献

• 1) Zucchelli P, Santoro A Zucchala A:Genesis and control of hypertension in hemodialysis patients. Semin Nephrol 8:163-168, 1988
  pubmed

• 2) Casati F, Passerini P, Campese MR et al:Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Brit Med J 295:1017-1020, 1987

• 3) Hand MF, Haynes WG, Johnstone HA et al:Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 48:806-813, 1995
  pubmed

• 4) Naruse M, Nakamura N, Naruse K et al:Plasma immunoreactive endothelin levels are increasedin hemodialysis patients with hypertension following erythropoietin therapy. Hypertens Res 15:11-16, 1992

• 5) DelGreco F, Davies WA, Simon NM et al:Hypertension of chronic renal failure; Role of sodium in the renal pressor system. Kidney Int 7:S176-S183, 1975

• 6) Onoyama K Iseki K, Hori K et al:Plasma renin activity and its regulatory factor in chronic maintenance hemodialysis patients. NZ Med J 96:899-901, 1991

• 7) Hirakata H, Iseki K Onoyama K et at:Long-term hemodynamic response to captopril in hypertensive hemodialysis patients. Clin Nephrol 19:87-91, 1983

• 8) Wu SG, Lin SL, Shiao WY et al:Comparison of sublingual captopril, nifedipine and prazosin in hypertensive emergencies during hemodialysis. Nephron 65:284-287, 1993
  pubmed

• 9) Oldenberg B, MacDonald GJ, Shelley S:Controlled trial of enalapril in patients with chronic nuid overload undergoing dialysis. Brit Med J 296:1089-1091, 1988

• 10) Rabelink TJ, Koomans HA:Endothelial function and the kidney. An emerging target fbr cardiovascular therapy. Drugs (suppl 1):11-19, 1997

• 11) Kakinuma Y, Kawamura T, Bills T et al:Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 42:46-55, 1992
  pubmed

• 12) Ono H, Ono Y, Frolich ED:ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertension 27:176-183, 1996

• 13) Rigat B, HUbert C, Alhenc-Gelas F et al:An insertion/deletion polymorphism in the angiotensin I-Converting enzyme gene accounting for half of the variance of serum enzyme levels. J Clin Invest 86:1343-1346, 1990
  pubmed

• 14) Marre M, Bernadet P, Gallois Y et al:Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43:384-388, 1994
  pubmed

• 15) Yoshida H, Mitarai T, Kawamura T et al:Role of the deletion polymorphism of the angiotensin conventing enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 96:2162-2169, 1995

• 16) 臨床透析編集委員会編:降圧薬と心血管作動薬腎不全時の薬物使用 適正投与法のガイドライン1998 臨床透析 (4月特別増刊号) 14:62-99, 1998

• 17) Onoyama K, Hirakata H, Abe I et al:Side effects of captopril in hypertensive patients with various grades of kidney dysfunctions. Curr Ther Res 40:333-336, 1986

• 18) Hirakata H, Onoyama K, Iseki K et al:Worsening of anemia induced by long-term use of captopril in hemodialysis patients. AM J Nephrol 4:355-360, 1984
  pubmed

• 19) Hirakata H, Onoyama K, Hori K et al:Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients. Clin Nephrol 26:27-32, 1986
  pubmed

• 20) Gossmann J, Thurmann P, Bachmann T et al:Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 50:973-978, 1996
  pubmed

• 21) Matsumura M, Nomura H, Koni I et al:Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients. Nephron 77:164-168, 1997
  pubmed

• 22) Albitar S, Genin R, Fen-Chong M et al:High dose enalapril impairs the response to erythropoietin treatment i haemodialysis patients. Nephrol Dial Transplant 13:1206-1210, 1998
  pubmed

• 23) Daugirdas JT, Ing TS, Roxe DM et al:Severe anaphylactoid reactions to cuprammonium cellulose hemodialysis. Arch Intem Med 145:489-494, 1985

• 24) Van der Niepen P, Sennesael JJ, Verbeelen DL:Kinin kinetics during different dialysis protocols with AN69 dialyser in ACEI-treated patients. Nephrol Dial Transplant 10:1689-1695, 1995
  pubmed

P.180 掲載の参考文献

• 1) Imai Y, Abe K, Munakata M et al:Circadian blood pressure variation under different patho-physiological conditions. J Hypertens 8:125-132, 1990

• 2) Verdecchia P, Schillaci G, Gatteschic et al:Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events. Circulation 88:986-992, 1993
  pubmed

• 3) Ohkubo T, Imai Y, Tsuji I et al:Relation between nocturnal decline in blood pressure and mortality:The Ohasama Study. Am J Hypertens 10:1201-1207, 1997
  pubmed

• 4) Kario M, Mastuo T, Kobayashi H et al:Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients:advanced silent cerebrovascular damage in extreme dippers. Hypertension 27:130-135, 1996

• 5) Watanabe N, Imai Y, Nagai K et al:Nocturnal blood pressure and silent cerebrovascular lesions in elderly Japanese. Stroke 27:1319-1327, 1996
  pubmed

• 6) Nishiyama A, Imai Y, Ohkubo T et al:Determinants of circadian blood pressure variation:A community-based study in Ohasama. Tohoku J Exp Med 185:1-20, 1997

• 7) Frattola A, Parati G, Cuspidi C et al:Prognostic value of 24-hour blood pressure variability. J Hypetens 11:1133-1137, 1993
  pubmed

• 8) Parati G, Pomidossi G, Albini F et al:Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 5:93-98, 1987
  pubmed

• 9) Imai Y, Aihara A Ohkubo T et al:Factors that affect blood pressure variability. A community-based study in Ohasama, Japan. Am J Hypertens 10:1281-1289, 1997
  pubmed

• 10) Portaluppi F, Vergnani L, Manfredini R et al:Endocrine mechanisms of blood pressure rhythms. In Time-Department Structure and Control of Arterial Blood Pressure. Ann N Y Acad Sci 783:113-131, 1996

• 11) Abe K, Sato M, Imai Y et al:Renal Kallikreinkinin:Ists relation to renal prostaglandins and renin angiotensin aldosterone in man. Kidney Int 19:869-880, 1981

• 12) Imai Y, Abe K Nishiyama A et al:Evaluation of the antihypertensive effect of barnidipine calcium entry blocker, as determined by the ambulatory blood pressure level averaged for 24h, daytime and nighttime. Am J Hypertens 10:1415-1419, 1997

• 13) Imai Y, Sekino M, Abe K et al:The mode of action of antihypertensive drugs determined by ambulatory blood pressure monitoring:Is there difference among antihypertensive drugs. J Hypertens 15 (S4):S38, 1997

• 14) Ashida T, Abe K, Kawano Y et al:Effect of nifedipine SR and enalapril on office, home and ambulatory blood pressure in "white-coat" systemic hypertension. Am J Cardiol 66:498-501, 1990

• 15) Herpin D, Vaisse B, Pitiot M et al:Comparison of angiotensin-converting enzyme inhibitors and calcium antagonists in the treatment of mild to moderate systemic hypertension, according to baseline ambulatory blood pressure. Am J Cardiol 69:923-926, 1992
  pubmed

• 16) Imai Y, Abe K, Sato M et al:Evaluation of the chronotropic property of captopril in hypertensive patients. Am Heart J 104:1339-1345, 1982
  pubmed

• 17) Mancia G, Sega R, Milesi C et al:Blood pressure control in the hypertensive population. Lancet 349:454-457, 1997
  pubmed

• 18) Zannad F, Matzinger A Larche J:Trough/Peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 9:633-643, 1996
  pubmed

• 19) Vaur L, Dutrey-Dugagne C, Boussac J et al:Differential effect of missed dose of trandrapril and enalapril on blood pressure control in hypertensive patients. J Cardiovasc Pharmacol 26:180 127-131, 1995

• 20) Morgan T, Anderson A:Clinical efficacy of perindopril in hypertension. Clin Exp Pharmacol Physiol 19 (S9):61-65, 1992

• 21) Imai Y:Clinical significance and cost effectiveness of 24-hour ambulatory blood pressure monitoring. Tohoku J Exp Med 176:1-15, 1995
  pubmed

P.185 掲載の参考文献

• 1) 山口武典, 大坪亮一, 豊田一則:特殊な高血圧患者の診療のポイント:脳血管疾患. Practitioners 1:65-67, 1992

• 2) 河野雄平, 山口武典:ACE阻害薬と脳保護作用. ACE阻害薬のすべて (改訂版) , 荻原俊男, 猿田享男, 日和田邦男編, 先端医学社, 東京, 1994, pp.66-70

• 3) 山口武典:脳血管障害を合併した高血圧. 心臓病プラクテイス15高血圧を識る, 菊地健次郎編, 文光堂, 東京, 1997, pp.240-245

• 4) Wardemar G, Schmidt JF, Andersen AP et al:Angiotensin converting enzyme inhibition and cerebral blood flow autoregulation in normotensive and hypertensive man. J Hypertens 7:229-235, 1989

• 5) Demolis P, Carville C, Giudiecelli JF:Effects of an angiotensin-converting enzyme inhibitor, lisinopril, on cerebral blood flow auroregulation in healthy volunteers. J Cardiovasc Pharmacol 22:373-380, 1993

• 6) Hajue MA, Heistad DD, Ghoneim S et al:Effects of an antihypertensive treatment on composition of cerebral arterioles. Hypertension 18 (suppl II):II15-II21, 1991

• 7) 木村和美, 矢坂正弘, 山口武典:アテローム血栓性脳梗塞急性期における降圧薬投与の梗塞巣と予後の及ぼす影響. 臨床神経学 34:114-117, 1994

• 8) Irie K, Yamaguchi T, Minematsu K et al:The J-curve phenomenon in stroke recurrence. Stroke 24:1844-1849, 1993

• 9) Nakamura K, Oita J, Yamaguchi T:Nocturnal blood pressure dip in stroke survivors:a pilot study. Stroke 26:1373-1378, 1995
  pubmed

• 10) Mori S, Sadoshima S, Fujii K et al:Decrease in cerebral blood flow with blood pressure reductions in patients with chronic stroke. Stroke 24:1376-1381, 1993
  pubmed

• 11) Rodgers A MacMahon S, Gamble G et al:Blood pressure and risk of stroke in patients with cerebrovascular disease. Br Med J 313:147, 1996

• 12) The INDIANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collabolators:Effect of antihypertensive treatment in patients having already suffered from stroke:gathering the evidence. Stroke 28:2557-2562, 1997

• 13) Collins R, Peto R, MacMahon S et al:Blood pressure, stroke and coronary heart disease:Part 2. shortterm reductions in blood pressure:overview of randomized drug trials in their epidemiological context. Lancet 335:827-838, 1990
  pubmed

• 14) Insua JT, Sacks HS, Lau TS et al:Drug treatment of hyper-tension in the elderly:a meta-analysis. Ann Intern Med 121:355-362, 1994

• 15) Staessen JA, Fagard R,:Thijs L et al:Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350:757-764, 1997
  pubmed

• 16) 河野雄平, 山口武典:脳血管障害とACE阻害薬. 医学のあゆみ 174:824-827, 1995
  Medical*Online

• 17) Stier CT Jr, Benter IF, Ahmed S et al:Enalapril prevents stroke and kidney dysfunction in saltloaded spontaneously hypertensive rats. Hypertension 13:115-121, 1989

• 18) The GLANT Study Group:A 12-month comparison of ACE inhibitor and Ca antagonist therapy in mild to moderate essential hypertension-The GLANT Study. Hypertens Res 18:235-244, 1995

• 19) Yamaguchi T, Minematsu K, Ishihara N et al:Effects of ACE inhibitor (captopril) on blood pressure and cerebral blood flow in patients with chronic stage cerebrovascular disease:a cooperative study. In:Current Advances in ACE Inhibition, ed. by MacGregor G A, Severs P S, Churchil Livingston, Edinburgh, 1989, pp.217-221

• 20) Neal B, MacMahon S:The PROGRESS Study:rationale and design. J Hypertens 13:1869-1873, 1995
  pubmed

P.193 掲載の参考文献

• 1) Kannel W, Wolf P, Verter J et al:Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study. JAMA 214:301-10, 1970
  pubmed

• 2) Kannel W:Prevalence and clinical aspects of unrecognized myocardial infarction and sudden unexpected death. Circuration 75:II4-II5, 1987

• 3) Iriarte M, Caso R, Murga N et al:Microvascular angina pectoris in hypertensive patients with left ventricular hypertrophy and diagnostic value of exercise thalium 201 scintigraphy. Am J Cardiol 76:746-747, 1995

• 4) Brush J, I Cannon RO, Scenke W:Angina due to coronary microvascular disease in hypertensive patients without lefe ventricular hypertrophy. N Engl J Med 319:1302-1307, 1988

• 5) Vogt M, Motz, W Strauer BE:Long-term treatment in arterial hypertension for protecting hypertrophic myocardium. Basic Res Cardiol 3:223-33, 1991

• 6) Lucarini A, Picano E, Salvetti A:Coronary microvascular disease in hypertensives. Clin Exp Hypertens A14:55-66, 1992

• 7) Parodi O, Neglia D, Sambuceti G et al:Regional myocardial blood flow and coronary reserve in hypertensive patients. The effect of therapy. Drugs 1:48-55, 1992

• 8) Schwartzkopff B, Motz W, Frenzel H et al:Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 88:993-1003, 1993
  pubmed

• 9) Strasuer B, Schwartzkopff B:Left ventricular hypertrophy and coronary microcirculation in hypertensive heart disease. Blood Press 2 (suppl):6-12, 1997
  pubmed

• 10) Iiyama K, Nagano M, Yo Y et al:Impaired endothelial function with essential hypertension assesed by ultrasonography. Am Heart J 132:779-782, 1996

• 11) Fujita H, Takeda K, Nakamura K et al:Role of nitric oxide in impaired coronary circulation and improvement by angiotensin II receptor antagonist in spontaneously hypertensive rats. Clin Exp Phamacol Physiol 22 (suppl 1):S148-S150, 1995

• 12) Crabos M, Coste P, Paccalin M et al:Reduced basal NO-mediated dilation and decreased endothelin NO-synthase expression in coronary vessels of spontaneously hypertensive rats. J Mol Cell Cardiol 29:55-65, 1997

• 13) Egashira K, Suzuki S, Hirooka Y et al:Impaired endotheliumdependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acethylcholine and subustance P. Hypertension 25:201-206, 1995

• 14) Quyyumi A, Mulcahy D, Andrews N et al:Coronary vascular nidric oxide activity in hypertension and hypercholesterolemia. Circulation 95:104-110, 1997
  pubmed

• 15) Miki S, Takeda K, Kiyama M et al:Augmented response of ETA and ETB receptor stimulation in coronary artery of hypertensive heart. j Cardiovasc, Pharmacol 31 (suppl 1):S94-S98, 1998

• 16) Rizzoni D, Porteri E, Castellano M et al:Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. Hypertension 31 (part 2):335-341, 1998

• 17) Nalbantgil I, Onder R, Altintig A et al:Therapeutic benefits of cilazapril in patients with syndrome X. Cardiology 89:130-133, 1998
  pubmed

• 18) Iriarte M, Caso R Murga N et al:Microvascular angina in systemic hypertension:diagnosis and treatment with enalapril. Am J Cardiol 76:31D-34D, 1995
  pubmed

• 19) Motz W, Strauer B:Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension 27:1031-1038, 1996
  pubmed

• 20) Mancini G, Henry G, Macaya C et al:Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease-The TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation 94:258-265, 1996
  pubmed

• 21) Strauer B, Schwartzkopff B:Hypertension and coronary microvascular disease. Adv Exp Med Biol 432:207-213, 1997
  pubmed

• 22) Iwatubo H, Nagano M, Sakai T et al:Converting enzyme inhibitor improves forarm reactive hyperemia in essential hypertension. Hypertension 29 (part 2):286-290, 1997

• 23) Creager M, Roddy M:Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 24:499-505, 1994
  pubmed

• 24) Thybo N, Stephens N, Cooper A et al:Effect of antihypertensive treatment on small arteries of patients with previously untreated essentiessential hypertension. Hypertension 25 (suppl 1):474-481, 1995

• 25) Schiffrin E, Deng L, Larochelle P:Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 23:83-91, 1994

• 26) Koren MJ, Devereux RB, Casale PN et al:Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114:345-352, 1991
  pubmed

• 27) Kannel W:Left ventricular hypertrophy as a risk factor in arterial hypertenison. Eur Heart J 13 (suppl D):82-88, 1992

• 28) Weber K Brilla C:Pathological hypertrophy and the cardiac interstitum:Fibrosis and the renin angiotensin-aldosterone system. Circulation 83:1849-1865, 1991

• 29) Brilla C, Jannicki J, Weber K:Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 83:1771-1779, 1991

• 30) Levy D, Salomon M, D:Agostino R et al:Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 90:1786-1793, 1994
  pubmed

• 31) Muiesan M, Salvetti M, Rizzoni D et al:Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertension 13:1091-1095, 1995
  pubmed

• 32) Verdecchia P, Schillaci G, Borgioni C et al:Prognostic significance of serial chages in left ventricular mass in essential hypertension. Circulation 97:48-54, 1998

• 33) Gottdiener J, Reda D, Massie B et al:Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension:Comparison of six antihypertensive agents. The department of veterans affairs cooperative study group on antihypertensive agents. Circulation 95:1983-19825, 1997

• 34) Daholf B, Pennert K, Hansson L:Reversal of left ventricular hypertrophy in hypertensive padents. Am J Hypertens 5:95-110, 1992

• 35) Aepfelbacher F, Messerli F, Nunez E et al:Disparate effects of ACE inhibitors and calcium antagonists on left ventricular structure and function in essential hypertenison. J Hum Hypertens 11:321-325, 1997

• 36) Liebson P, Grandits G, Dianzumba S et al:Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritionalhygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 91:698-706, 1995
  pubmed

• 37) Estacio R, Jeffers B, Hiatt W et al:The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients witn non-insulindependent diabetes and hypertension. N Engl J Med 338:645-652, 1998

• 38) Tatti P, Pahor M, Byington R et al:Outcome results of the Fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension apd NIDDM. Diabetes care 21:597-609, 1998

• 39) Pfeffer M, Braunwald E Moye L et al:Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 327:669-77, 1992

• 40) ISIS-4-Collaborative-Group:ISIS-4:Arandomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345:669-685, 1995

• 41) The-Acute-Infarction-Ramipril-Efficacy-(AIRE)-study-investation:Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821-828, 1993

• 42) GISSI-Study-Group:GISSI-3:effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343:1115-1122, 1994

• 43) Kober L, Trop-Oedersen C, Carisen J et al:A clinical trial of the angiotensinconverting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Eng J Med 333:1670-1676, 1995

• 44) ACE-inhibitor-myocardial-infarction-collaborative-group:Indications for ACE inhibitors in the elderly treatment of acute myocardial infarction. Circulation 97:2202-2212, 1998

• 45) Hennekens C, Albert C, Godfried S et al:Adjunctive drug therapy of acute myocardial infarction-evidence from clinical trial. N Engl J Med 335:1660-1667, 1996
  pubmed

• 46) Ray S, McAlpine H, Morton J et al:Important of RAA system and the treatment of patients with ACE inhibition after myocardial infarction. Angiology 42:268-272, 1991
  pubmed

• 47) Hansson L, Zanchetti A, Carruthers S et al:Effects of intensive bloodpressure lowering and acetylsalicylic acid in patients with hypertesnion:principal results of the Hypertension optimal Treatment (HOT) randomised trial. Lancet 351:1775-1762, 1998

P.201 掲載の参考文献

• 1) Levy D, Garrison RJ, Savage DD et al:Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 322:1561-1566, 1990
  pubmed

• 2) Liao Y, Cooper RS, McGee DL et al:The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 273:1592-1597, 1995
  pubmed

• 3) O'Brien E, Scheridan J, O'Malley K:Dipper and non-dippers (letter):Lancet 2:397, 1988

• 4) Porro T, Colombo F, Azzola FL et al:Diurnal blood pressure variability in essential hypertension and vascular reactivity to isometric stress. J Human Hypertens 9:329-335, 1995
  pubmed

• 5) Shimada K, Kawamoto A, Matsubayashi K et al:Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens 10:875-878, 1992
  pubmed

• 6) 羽野卓三, 中村千種, 西尾一郎:血圧日内変動と血圧変動因子 日本臨牀 639:314-319, 1992

• 7) Verdecchia P, Porcellati C, Schillaci G et al:Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 24:793-801, 1994
  pubmed

• 8) Schilaci G, Verdecchia P, Borgioni C et al:Lack of association between blood pressure variability and left ventricular mass in essential hypertension. Am J Hypertens 11:515-522, 1998
  pubmed

• 9) The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. National Institutes of Health, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program NIH Publication, No 98-4080, 1997

• 10) Mazzolai L, Nussberger J, Aubert J et al:Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension 31:1324-1330, 1998
  pubmed

• 11) Gottdiener JS, Reda DJ, Massie BM et al:Effects of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation 95:2007-2014, 1997
  pubmed

• 12) De Luca N, Rosiello G, Lamenza F et al:Reversal of cardiac and large artery structural abnormalities induced by long-term antihypertensive treatment with trandolapril. Am J Card 70:52D-59D, 1992
  pubmed

• 13) Franz I, Tronesmann U, Muler JFM:Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors. Am J Hypertens 11:631-639, 1998

• 14) Yang CM, Kandsawamy V, Young D et al:Changes in collagen phenotypes during progression and regresion of cardiac hypertrophy. Cardiovac Res 36:236-245, 1997

• 15) Picca M, Biscerglin J, Zocca A et al:Effects of enalapril and amlodipine on left ventricular hypertrophy and function in essential hypertension. Clin Drug Invest 13 (suppl 1):29-35, 1997

• 16) Manolis AJ, Beldekos D, Handanis S et al:Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy. Am J Hypertens 11:640-648, 1998
  pubmed

• 17) Magometschnigg D, Brandt D, Hofmann R et al:Treatment of left ventricular hypertrophy in hypertensive patients with a combination by verapamil and captopril-a multicenter study. Int J Con Pharmacol Therap 35:389-396, 1997

• 18) Levy D, Salmon M, D'Agostino et al:Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 90:1786-1796, 1994

• 19) Muiesan ML, Zulli R, Rizzoni D et al:Effect of changes in blood pressure and left ventricular mass induced by antihypertensive treatment on ventricular arrhythmias in essential hypertension. J Hypertens 11 (suppl 5):S104-S105, 1993

• 20) Papademetriou V, Narayan P, Kollinos P:Effects of diltiazem, metoprolol. enalapril and hydrochlorothazide on frequency of ventricular premature complexes. Am J Cardiol 73:242-246, 1994

P.209 掲載の参考文献

• 1) The Hypertension in Diabetes Study Group:Hypertension in diabets study (HDS). II. Increaed risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 11:319-325, 1993. 1. Ferrannini E et al, N Engl J Med 317:350, 1987

• 2) Reaven JM:Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988

• 3) Kaplan NM:The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 149:1514-1520, 1989
  pubmed

• 4) Klag MJ, Whelton PK, Randall BL et al:Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18, 1996

• 5) National Institute of Health, National Heart, Lung and Blood Institute:The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure.

• 6) The Natinal High Blood Pressure Education Program Working Group:National high blood pressure education program working group report on hypertension in diabetes. Hypertension 23:145-158, 1994

• 7) Hansson L, Zanchetti A, Carruthers SG et al:Effects of intensive blood-pressure lowering and acetylsalicylic acid in patients with hypertension:principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998
  pubmed

• 8) Rett K, Lotz N, Wicklmayer M et al:Verbesserte Insulinwirkung durch ACE-Hemmung beim Typ-II-Diabe-tiker. Dtsch Med Wochenschr 113:243-249, 1988

• 9) Pollare T, Lithell H, Berne C:A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321:868-873, 1989

• 10) Kodama J, Katayama S, Tanaka K et al:Effects of captopril on glucose metabolism. Possible role of augmented postprandial forearm blood flow. Diabetes Care 13:1109-1111, 1990
  pubmed

• 11) Katayama S, Inaba M, Maruno Y et al:Glucose intolerance in spontaneously hypertensive rats and Wistar-Kyoto rats:enhanced gene expression and synthesis of skeletal muscle glucose transporter 4. Hypertens Res 20:279-286, 1997
  pubmed

• 12) Chen S, Noguchi Y, Izumida T et al:A comparison of the hypotensive and hypoglycemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. J Hypertens 14:1325-1330, 1996
  pubmed

• 13) Estacio RO, Jeffers BW, Hiatt WR et al:The eefct of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998
  pubmed

• 14) Tatti P, Pahor M, Byington RP et al:Outocome results of the fosinopril versus amlodipine cardiovascular events randamized trila (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597-603, 1998

• 15) Iwatsubo H, Nagano M, Sakai T et al:Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension 29 (part 2):286-290, 1997

• 16) Volpert OV, Warda WF, Lingen MW et al:Captorpil inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671-679, 1996

• 17) Chaturvedi N, Sjolie AK, Stephenson JM et al:Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 351:28-31, 1998
  pubmed

P.217 掲載の参考文献

• 1) Kannel WB:Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol. 37:269-282, 1976
  pubmed

• 2) 厚生省特定疾患・原発性高脂血症調査研究班:昭和61年度研究報告書

• 3) The Lipid Research Clinics Program:The Lipid Research Clinics Program Coronary Primary Prevention Trial. Results (I) (II). JAMA 251:351-374, 1984

• 4) Sacks FM, Dzau VJ:Adrenergic effects on plasma lipoprotein metabolism. Am J Med 80 (suppl 2A):71-81, 1986

• 5) Ferrannini E, Buzzigoli G, Bonadonna R et al:Insulin resistance in essential hypertension. N Engl J Med 317:350-357, 1987
  pubmed

• 6) Ferrari P, Weidmann P:Insulin, insulin sensitivity and hypertension. J Hypertens 8:491-500, 1990
  pubmed

• 7) Weinberger MH:Antihypertensive therapy and lipids. Am J Med 80 (suppl 2A):64-70, 1986

• 8) Leren P, Helgeland A, Hjermann I et al:The Oslo study:CHD risk factors, socioeconomic influences, and intervention. Am Heart J 106:1200-1206, 1983
  pubmed

• 9) Veterans Administration Cooperative Study Group on Antihypertensive Agents:Effects of treatment on morbidity in hypertension. JAMA 213:1143-1151, 1970

• 10) Kuramoto K, Matsushita S, Shibata S:Effects of hypertension and antihypertensive drugs on cardiovascular complications in the elderly. Jpn Circul J 52:1-8, 1988

• 11) Berk BC, Vekshtein V, Gordon H M et al Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 13:305-314, 1989
  pubmed

• 12) Powell JS, Clozel J-P, Muller RKM et al:Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vasular injury. Science 245:186-188, 1989

• 13) Chobanian AV, Haudenschild CC, Nickerson C et al:Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 15:327-331, 1990
  pubmed

• 14) Lichtlen PR, Hugenholtz PG, Rafflenbeul W et al:Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclertic Therapy (INTACT). Lancet 335:1109
  pubmed

• 15) Waters D, Lesperance J, Francetich M et al:A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 82:1940-1953, 1990 , 1990
  pubmed

• 16) 日本動脈硬化学会高脂血症診療ガイドライン検討委員会:日本動脈硬化学会高脂血症診療ガイドライン. 動脈硬化 25:1-34, 1997

P.222 掲載の参考文献

• 1) Hamet P:Metabolic aspects. In:Hypertension, McGraw-Hill, NY, 1983, pp.408-427

• 2) Breckenridge A:Hypertension and hyperuricaemia. Lancet i:15-18, 1996

• 3) Ramsay LE:Hyperuricaemia in hypertension. Role of alcohol. BMJ i:653-654, 1979

• 4) Saito I, Saruta T, Kondo K et al:Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriat Soc 26:241-247, 1978
  pubmed

• 5) Messerli F, Frohlich ED, Dreslinski GR et al:Serum uric acid in essential hypertension:An indicator of renal vascular involvement. Ann Intern Med 93:817-821, 1980
  pubmed

• 6) Modan M, Halkin H, Karasik A et al:Elevated serum uric acid-a facet of hyperinsulinaemia. Diabetologia 30:713-718, 1987
  pubmed

• 7) Muscelli E, Natali A, Bianchi S et al:Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 9:746-752, 1996
  pubmed

• 8) Kaplan NM:Long-term effectiveness of non-pharmacological treatment of hypertension. Hypertension 18 (suppl I):I153-I160, 1991

• 9) Puddey IB, Beilin LJ, Vandongen R:Regular alcohol use raises blood pressure in treated hypertensive subjects. A randomised controlled trial. Lancet 1:647-651, 1987
  pubmed

• 10) Parker M, Puddey IB, Beilin LJ et al:Two-way factorial study of alcohol and salt restriction in treated hypertensive men. Hypertension 16:398-406, 1990
  pubmed

• 11) Stamler R, Stamler J, Grimm R et al:Nutritional therapy for high blood pressure. JAMA 257:1484-1491, 1987
  pubmed

• 12) The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:The Sixth report of the Joint National Committee on Detection, Prevention, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997
  pubmed

• 13) 1993 Guidelines for the Management of Mild Hypertension:Memorandum from a WHO/ISH meeting. ISH Hypertension News June 1993:pp.3-16

• 14) 厚生省, 日本医師会:合併症を伴う高血圧の治療. 高血圧診療のてびき, 日本醫事新報社, 東京, 1989, pp.40-45

• 15) Saito I, Misumi J, Kondo K et al:Effects of furosemide and cholorothiaside on blood pressure and plasma renin activity. Cardiovasc Res 10:149-152, 1976
  pubmed

• 16) カプランNM:高血圧の治療, カプラン臨床高血圧, 医学書院MYW, 東京, 1995, pp.174-292

• 17) Neutel JM:Metabolic manifestations of low-dose diuretics. Am J Med 101 (suppl 3A):71S-82S, 1996

• 18) Report of Medical Research Council Working Party on Mild to Moderate Hypertension:Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 2:539-543, 1981

• 19) 齊藤郁夫, 河邊博史, 猿田享男ほか:Ca拮抗薬, ACE阻害薬, β遮断薬による降圧療法の効果, 日本醫事新報 3683, 27-31, 1994

• 20) Neaton JD, Grimm RH, Prineas RJ et al:Treatment of mild hypertension study. JAMA 270:713-724, 1993
  pubmed

• 21) Tsunoda K, Abe K Hagino T et al:Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 6:28-32, 1993
  pubmed

• 22) Houston MC:New insights and new approaches for the treatment of essential hypertension:Selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertension. Am Heart J 1117:911-951, 1989

• 23) Sever P, Beevers G, Bulpitt C et al:Management guidelines in essential hypertension:report of the second working party of the British Hypertension Society. Br Med J 306:983-987, 1993

• 24) Langford RG, Blaufox MD, Borhani NO et al:Is thiazide-produced uric acid elevation harmful? Ann Intern Med 147:645-649, 1987

• 25) Staessen J:The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly Trial. Am J Med 90 (suppl 3A):3A50S-3A54S, 1991

• 26) SHEP Cooperasive Research Group:Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 254:3255-3264, 1991

P.228 掲載の参考文献

• 1) Sekizawa K, Ujiie Y, Itabashi S et at:Lack of cough reflex in aspiration pneumonia. Lancet 335:1228-1229, 1990

• 2) Nakazawa H, Sekizawa K Ujiie Y et al:Risk of aspiration pneumonia in the elderly. Chest 103:1636-1637, 1993
  pubmed

• 3) Kobayashi H, Sekizawa K, Sasaki H:Aging effects on swallowing reflex. Chest 111:1466, 1997
  pubmed

• 4) Hedlung J U, Ortqvist A B, Kalin M et al:Risk of pneumonia in patients previously treated in hospital for pneumonia. Lancet 340:396-397, 1992

• 5) Pinto A Yanai M, Nakagawa T et al:Swallowing reflex in the night. Lancet 344:820-821, 1994
  pubmed

• 6) Nakagawa T, Ohrui T, Sekizawa K et al:Sputum substance P in aspiration pneumonia. Lancet 345:1447, 1995
  pubmed

• 7) Nakagawa T, Sekizawa K, Arai H et al:High incidence of pneumonia in elderly patients with basal ganglia infarction. Arch Intern Med 157:321-324, 1997
  pubmed

• 8) Ebihara T, Sekizawa K, Nakazawa H et al:Capsaicin and swallowing reflex. Lancet 341:432, 1993
  pubmed

• 9) Jin Y, Sekizawa K, Fukushima T et al:Capsaicin desensitization inhibits swallowing reflex in guinea pigs. Am J Respir Crit Care Med 149:261-263, 1994
  pubmed

• 10) Zhou Q-Y, Palmiter RD:Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83:1197-1209, 1995
  pubmed

• 11) Xu M, Moratalla R, Gold L H et al:Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 79:729-742, 1994
  pubmed

• 12) Kummer W:Sensory ganglia as a target of automic and sensory nerve fibres in guinia-pig. Neuroscience 59:739-754, 1994

• 13) Jia YX, Sekizawa K, Ohrui T et al:Dopamine D1 receptor antagonist inhibits swallowing reflex in guinea pigs. Am J Physiol:R76-80, 1998
  pubmed

• 14) Ebihara T, Sekizawa K, Ohrui T et al:Angiotensin-converting enzyme inhibitor and danazol increase sensitivity of cough reflex in female guinea pigs. Am J Respir Crit Care Med 153:812-819, 1996
  pubmed

• 15) Tomaki M, Ichinose M, Miura M et al:Angiotensin converting enzyme (ACE) inhibitor-induced cough and substance P. Thorax 51:199-201, 1996z
  pubmed

• 16) Sekizawa K, Jia YX, Ebihara T et al:Role of substance P in cough. Pulm Pharmacol 9:323-328, 1996
  pubmed

• 17) Widdicombe JG:Neurophysiology of the cough reflex.Eur Respir J 8:1193-1202, 1995
  pubmed

• 18) Fox AJ, Lalloo UG, BelVisi MG et al:Bradykinin-evoked sensitization of airway sensory nerves:a mechanism for ACE-inhibitor cough. Nat Med 2:814-817, 1996
  pubmed

• 19) Nakayama K, Sekizawa K, Sasaki H:ACE inhibitor and swallowing reflex. Chest 113:1425, 1998
  pubmed

P.232 掲載の参考文献

• 1) Leung NW, Nicholis MG:The renin system in liver disease. In:The Renin Angiotensin System, ed by Robertson and Nicholls, Gower Medical Publishing, London, 1993, pp.78.1-78.14, J Hepatol 17:40-47, 1993

• 2) Takahashi D, Tamura K, Ushikubo Tet al:Relationship between hepatic angiotensinogen mRNA expression and plasma angiotensinogen in patients with chronic hepatitis. Life Sci 60:1623-1633, 1997

• 3) Arnal JF, Cudek P, Plouin PF et al:Low angiotensinogen levels are related to the severity and liver dysfunction of congestive heart failure:implications for renin measurements. Am J Med 90:17-22, 1991

• 4) Laffi G, La Villa G, Pinzani M et al:Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 17:530-548, 1997
  pubmed

• 5) Ohnishi A, Murakami S, Harada M et al:Renal and hormonal responses to repeated treatment with enalapril in non-azotemic cirrhosis with ascites. J Hepatol 20:223-230, 1994
  pubmed

• 6) Espiner EA Nicholls MG:Hormones and fluid retention in cirrhosis. Lancet ii:501-502, 1982
  pubmed

• 7) Ibarra FR, Affone C, Garzon D et al:Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis. Eur J Clin Pharmacol 43:477-482, 1992

• 8) Dillon JF, Nolan J, Thomas H et al:The correction of autonomic dysfunction in cirrhosis by captopril. J Hepatol 26:331-335, 1997
  pubmed

• 9) Chiang HT, Cheng JS, Lin M et al:Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. J Gastroenterol Hepatol 10:256-260, 1995
  pubmed

• 10) Pidlich J, Cichini GM, Reinisch W et al:Angiotensin-converling enzyme inhibition in cirrhotic patients-pharmacokinetics of ramipril. Acta. Med Austriaca 24:15-18, 1997
  pubmed

• 11) Hoogkamer JF, Kleinbloesem CH, Nokhodian A et al:Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with impaired liver function. Eur J Clin Pharmacol 51:489-491, 1997

• 12) Ford NF, Lasseter KC, Van Harken DR et al:Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. J Clin Pharmacol 35:145-150, 1995
  pubmed

• 13) Gross V, Treher E, Haag K et al:Angiotensinconverting enzyme (ACE)-inhibition in cirrhosis. Phamlacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). J Hepatol 17:40-47, 1993
  pubmed

• 14) Grass P, Gerbeau C, Kutz K:Spirapril:pharmacokinetic properties and drug interactions. Blood Press suppl 2:7-13, 1994
  pubmed

• 15) Krahenbuhl S, Grass P, Surve A et al:Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease. Eur J Clin Pharmacol 45:247-253, 1993
  pubmed

• 16) Thiollet M, Funck-Brentano C, Grange JD et al:The pharmacokinetics of perindopril in patients with liver cirrhosis. Br J Clin Pharmacol 33:326-328, 1992
  pubmed

• 17) Baba T, Murabayashi S, Tomiyama T et al:The pharmacokinetics of enalapril in patients with compensated livercirrhosis. Br J Clin Pharmacol 29:766-769, 1990

P.237 掲載の参考文献

• 1) 本間光夫, 藤井隆夫, 秋月正史:全身性エリテマトーデスの経過中に見られる高血圧とループス腎炎の予後に関する研究. 特殊疾病に関する研究報告書 平成5年度:57-68, 1995

• 2) 西間木友衛, 高木徹, 粕川礼司ほか:膠原病における肺高血圧症の治療アンケート調査. 厚生省特定疾患混合性結合組織病調査研究班. 昭和62年度研究報告書:42-53, 1988

• 3) MItas JA, Levy SB, Holle R et al:Urinary kallikrein in the hypertension of renal parenchynal disease. N Engl J Med 299:162-165, 1978
  pubmed

• 4) Almeida FA, Stella RC, Voos A et al:Malignant hypertension:A syndrome associated with low plasam kininogen and kinin potensiation factor. Hypertension 3:II46-49, 1981

• 5) Maekawa K, Fujimoto T, Uemura S et al:Successfull treatment for pulmonary hypertension with angiotensin I converting enzyme inhibitorin a patient with mixed connective tissue disease. Nihon Rinsho Meneki Galeleai Kaishi 20:79-85, 1997

• 6) Sten VD, Constantino JP, Shapiro AP et al:Outocome of renal crisis in systemic sclerosi; relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113:352-357, 1990

• 7) Ruiz-Ortega M, Gonzalez S, Seron D et al:ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 48:1778-1791, 1995

• 8) Weinstock JV, Blum AM:Effects of granulama modulation induced by regulatory-T-lyumphocyte activity on angiotensin II/III production by granulama macrophages in murine schistosomiasis mansoni. Cell Immunol 94:558-567, 1985

• 9) Dzau VJ:Significance of the vascular reninangiotensin pathway. Hypertension 8:553-559, 1986
  pubmed

• 10) Powell JS, Clozel JP, Muller RKM et al:Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascualr injury. Science 245:186-188, 1989

• 11) Parish RC, Miller LJ:Adverse effects of angiotensin converting enzyme inhibitors. Drug Saf 7:14-31, 1992
  pubmed

P.241 掲載の参考文献

• 1) Roberts DH, Tsao Y, McLoughlin GA et al:Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intemlittent claudication. Lancet 2:650-653, 1987
  pubmed

• 2) Van de Van LL, Van Leeuwen JT, Smit AJ:The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. Vasa 23:357-362, 1994

• 3) Libretti A, Catalano M:Captopril in the treatment of hypertension associated with claudication. Postgrad Med J 62 (suppl 1):34-37, 1986

• 4) Roberts DH, Tsao Y, Limge K et al:Double-blind comparison of captopril with nicardipine in hypertension complicated by intermittent claucication. Angiolgy 43:748-756, 1992

• 5) Bernardi D, Bartoli P, Ferreri A et al:Assessment of captopril and nicardipine effects on chronic occlusive arterial disease of the lower extremity using Doppler ultrasound. Angiology 39:942-952, 1988
  pubmed

• 6) Novo S, Abrignani MG, Pavone G et al:Effect of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudicadon. Int Angiol 15:169-174, 1996
  pubmed

• 7) Hertzer NR:The natural history of peripheral vascular disease. Implications for its management. Circulation 83 (suppl):I12-I19, 1991

• 8) Wachtell K, Ibsen H, Olsen MH et al:Prevalence of renal artery stenosis in patients with peripheral vascular disease and hypertension. J Hum Hypertens 10:83-85, 1996
  pubmed

• 9) Leach SD, Toole AL, Stern H et al:Effect of beta-adrenergic blockade on the growth rate of abdominal aortic aneurysms. Arch Surg 123:606-609, 1988
  pubmed

• 10) Gadowski GR, Pilcher DB, Ricci MA:Abdominal aortic aneurysm expansion rate:effect of size and beta-adrenergic blockade. J Vasc Surg 19:727-731, 1994

• 11) Chakkour K, Gouny P, Nussaume O et al:Medical treatment of aortic anuerysms using beta-blockers. J Mal Vasc 20:288-289, 1995

• 12) Shores J, Berger KR, Murphy EA et al:Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 330:1335-1341, 1994
  pubmed

• 13) Pitt MP, Bonser RS:The natural history of thoracic aortic aneurysm disease:an overview. J Card Surg 12 (2 suppl):270-278, 1997

• 14) Coselli JS, de Figueiredo LF:Natural history of descending and thoracoabdominal aortic aneurysms. J Card Surg 12 (2 suppl):285-289, 1997

• 15) Juvonen T, Ergin MA, Galla JD et al:Prospective study of the natural history of thoracic aortic aneurysms. Ann Thorac Surg 63:1533-1545, 1997
  pubmed

P.248 掲載の参考文献

• 1) Benedict C R, Johnstone D E, Weiner D H et al:Relation of neurohumonal activation to clinical variables and degree of ventricular dysfunction:a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 23:1410-1420, 1994

• 2) White H D, Norris R M, Brown M A et al:Leff ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76:44-51, 1987

• 3) Ghali J K, Liao Y, Simmons B et al:The prognostic role of left ventricular hypertrophy in patients with and without coronary artery disease. Ann Intern Med 117:831-836, 1992
  pubmed

• 4) Levy D, Garrison RJ, Savage D D et al:Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561-1566, 1990
  pubmed

• 5) Pfeffer M A, Braunwald E, Moye L A et al:Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327:669-677, 1992

• 6) Sutton M J, Pfeffer M A, Plappert T et al:Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 89:68-75, 1994

• 7) The SOLVD investigators:Effect of enalapril onsurvival in patients with reduced ventricular ejection fractions and congestive heart failure. N Engl Med 325:293-302, 1991

• 8) Konstam M A, Rousseau M F, Kronenberg M W et al:Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 86:431-438, 1992

• 9) Dahlof B, Pennert K Hansson L:Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. J Hypertens 5:95-110, 1992

• 10) McDonald K M, Mock J, D:Aloia A et al:Bradykinin antagonism inhibits antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 91:2043-2048, 1995

• 11) The CONSENSUS Trial Study Group:Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med 316:1429-1435, 1987

• 12) The SOLVD investigators:Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection. N Engl J Med 327:685-691, 1992
  pubmed

• 13) Committee on Evaluation and Management of Heart Failure:Guideline for the evaluation and management of heart failure. Circulation 92:2764-2784, 1995
  pubmed

• 14) Dougherty A H, Naccarelli G V, Gray E L et al:Congestive heart failure with normal systolic function. Am J Cardiol 54:778-782, 1984
  pubmed

• 15) Soufer R, Wohlgelemter D, Vita N A et al:Intact systolic left ventricular function in clinical congestive heart failure. Am J Cardiol 55:1032-1036, 1985

• 16) Friedrich S P, Lorell B H, Rousseau M F et al:Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 90:2761-2771, 1994
  pubmed

• 17) Carson P, Johnson G, Fletcher R et al:Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%):Baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT). J Am Coll Cardiol 27:642-649, 1996

P.257 掲載の参考文献

• 1) Captopril Multicenter Research Group:A place bo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 2:755-763, 1983

• 2) Francis GS, Cohn JN, Johnson G et at, for the VHeFT VA Cooperative Studies Group:Plasma norepinephrine, plasama renin actuvity, and congestive heart failure. Relation to survival and the effects of therapy in V-HeFT II. Circulation 87 [suppl VI]:VI40-VI48, 1993

• 3) The CONSENSUS Trial Study Group:Effect of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . New Engl J Med 316:1429-1435, 1987

• 4) Cohn JN, Johnson G, Ziesche S et al:A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303-310, 1991
  pubmed

• 5) The SOLVD Investigators:Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med 325:293-302, 1991
  pubmed

• 6) Pfeffer MA, Braunwald E, Moye LA et al on behalf of the SAVE Investigators:Effect of captopril on mortality and morbidity in patients withleft ventricular dysfunction after myocardial infarction. Results of the Survival and ventricular Enlargement Trial. N Engl J Med 327:669-677, 1992

• 7) The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators:Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821-828, 1993

• 8) Kober L, Torp-Pedersen C, Carlsen JE et al, for the Trandolapril Cardiac Evaluation (TRACE) Study Group:A clinical trial of the angiotensinconverting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333:1670-1676, 1995

• 9) The SOLVD investigators:Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Engl J Med 327:685-691, 1992
  pubmed

• 10) Kostis JB:The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens 8:909-914, 1995
  pubmed

• 11) GISSI-3:Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell' infarto Miocardico. Lancet 343:1115-1122, 1994
  pubmed

• 12) ISIS-4:A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulpate in 58,050 patients with suspected acute myocardial infarction ISIS-4 (Forth International Study of lnfarct Survival) Collaborative Group. Lancet 345:669-685, 1995

• 13) Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators:The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332:80-85, 1995

• 14) Rouleau JL, Moye LA, de Champlain J et al Activation of neurohumoral systems following acute myocardial infarction. Am J Cardiol 68:80D-86D, 1991
  pubmed

• 15) Swedberg K Held P, Kjekshus J et al, on behalf of the CONSENSUS II Study Group:Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) . N Engl J Med 327:678-684, 1992

• 16) Yusuf S, Pepine CJ, Garces C et al:Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340:1173-1178, 1992
  pubmed

• 17) Sharpe N, Smith H, Murphy J et al:Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-convering-enzyme inhibition. Lancet 337:872-876, 1991

• 18) Komstam MA, Rousseau MF, Kronenberg MW et al, for the SOLVD Investigators:Effects of the angiotennsion converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 86:431-438, 1992

• 19) Fletcher RD, Cintron GB, Johnson G et al, for the V-HeFT II VA Cooperative Studies Group:Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. Circulation 87 [suppl VI]:VI 49-VI 55, 1992

P.264 掲載の参考文献

• 1) Mitchell GF, Pfeffer MA:Left ventricular remodeling after myocardial infarction. In:The Guide to Cardiology, ed by Kloner RA, 3rd Ed. LeJacq Communication, N Y, 1995, pp. 317

• 2) Kloner RA:Coronary angioplasty:A treatment option for left ventricular remodeling after myocardial infarction? J Am Coll Cardiol 20:314-316, 1992
  pubmed

• 3) Pheffer MA, Braunwald E:Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81:1161-1172, 1990
  pubmed

• 4) Sasayama S, Gallagher KP, Kemper WS et al:Regional left ventricular wall thickness early and late after coronary occlusion in the conscious dog. Am J Physiol 240:H293-H299, 1981
  pubmed

• 5) Grossman W, Jones D, McLaurin LP:Wall stress and pattems of hypertrophy in the human left ventricle. J Clin Invest 56:56-64, 1975

• 6) Olivetti G, Capasso JM, Sonnenblick EH et al:Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res 67:23-34, 1990
  pubmed

• 7) Herzog E, Gu A, Kohmoto T et al:Early metalloproteinase activation after myocardial infarction occurs in infarct and non-infarct zones. An experimental rat model [abstract]. Circutation 94:1-126, 1996

• 8) Narula J, Haider N, Virmani R et al:Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335:1182-1189, 1996
  pubmed

• 9) McDonald KM:Prevention of ventricular remodeling. J Lab Clin Med 131:124-129, 1998
  pubmed

• 10) Katz AM:Scientific insights from clinical studies of converting-enzyme inhibitors in the failing heart. Trends Cardiovasc Med 5:37-44, 1995
  pubmed

• 11) Olsen EN:Regulation of muscle transcription by the MyoD family:The heart of the matter. Circ Res 72:1-6, 1993

• 12) Chien KR, Zhu H, Knowlton KU et al:Transcriptional regulation during cardiac growth and development. Annu Rev Physiol 55:77-95, 1993
  pubmed

• 13) Tam SK, Gu W, Mahdavi V et al:Cardiac myocyte terminal differentiation:Potential for cardiac regeneration. Ann N Y Acad Sci 752:72-79, 1995
  pubmed

• 14) Danser AHJ, van Kesteren CAM, Bax WA et al:Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts:Evidence for renin binding. Circulation 96:220-226, 1997

• 15) Thienelt CD, Weinberg EO, Bartunek J et al:Load-induced growth responses in isolated adult rat hearts:Role of the AT1 receptor. Circulation 95:2677-2683, 1997
  pubmed

• 16) Inoko M, Kihara Y, Morii I et al:Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. Am J Physiol 267:H2471-H2482, 1994
  pubmed

• 17) Iwanaga Y, Kihara Y, Sasayama S:Different pathophysiological roles of angiotensin II versus endothelin-1 in the ventricular myocardium during transition from pressure-overload hypertrophy to heart failure in Dahl hypertensive rats. Circulation 96 (suppl):I-406, 1997 (Abstract)

• 18) Wiesner RJ, Ehmke H, Faulhaber J et al:Dissociation of left ventricular hypertrophy, β-myosin heavy chain gene expression, and myosin isoform switch in rats after ascending aortic stenosis. Circulation 95:1253-1259, 1997

• 19) Weinberg EO, Lee MA, Weigner M et al:Angiotensin AT1 receptor inhibition:Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. Circulation 95:1592-1600, 1997
  pubmed

• 20) Kudoh S, Komuro I, Mizuno T et al:Angiotensin II stimulates c-jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. Circ Res 80:139-146, 1997
  pubmed

• 21) Schunkert H, Sadoshima J, Cornelius T et al:Angiotensin II-induced growth responses in isolated adult rat hearts:Evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res 76:489-497, 1995
  pubmed

• 22) Pfeffer JM, Pfeffer MA, Fletcher PJ et al:Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol 260:H1406-H1414, 1991
  pubmed

• 23) Pfeffer JM, Pfeffer MA, Brawnwald E:Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 57:84-95, 1985

• 24) Pfeffer MA, Braunwald E, Moye LA et al:Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction-Results of the survival and ventricular enlargement trial. N Engl J Med 327:669-677, 1992

• 25) The CONSENSUS Trial Study Group:Effects of enalapril on motality in severe congestive heart failure:Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429-1435, 1987

• 26) The SOLVD Investigators:Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685-691, 1992
  pubmed

• 27) Kober L, Torp-Pedersen C, Carlsen JE et al for the Trandolapril Cardiac Evaluation (TRACE) Study Group:A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333:1670-1676, 1995

• 28) Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3:Effects of lisinopril and transdermal nitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343:1115-1122, 1994
  pubmed

• 29) Sutton MSJ, Pfeffer MA, Moye L et al:Cardiovascular death and left ventricular remodeling two years after myocardial infarction:Baseline predictors and impact of longterm use of captopril:information from the survival and ventricular enlargement (SAVE) trial. Circulation 96:3294-3299, 1997

• 30) Philbin EF:Current community practices in heart failure:understanding the under utilization of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 29 (suppl A):325A, 1997

• 31) Urata H, Healy B, Stewart RW et al:Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 66:883-890, 1990
  pubmed

• 32) Asano K, Dutcher DL, Port JD et al:Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation 95:1193-1200, 1997
  pubmed

• 33) Haywood GA, Gullestad L, Katsuya Tet al:AT1 and AT2 angiotesin receptor gene expression in human heart failure. Circulation 95:1201-1206, 1997

• 34) Ohkubo N, Matsubara H, Nozawa Y et al:Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 96:3954-3962, 1997
  pubmed

• 35) Azizi M, Guyene T-T, Chatellier G et al:Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 29:634-640, 1997
  pubmed

• 36) Kim S, Kawamura M, Wanibuchi H et al:Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery. Circulation 92:88-95, 1995

• 37) Furukawa Y, Matsumori A, Hirozane T et al:Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Circulation 93:333-339, 1996

• 38) Pitt B, Dickstein K, Benedict CR et al for the RAAS Investigator:The randomized angiotensin receptor antagonist-ACE inhibitor study (RAAS)-Pilot Study. Circulation 94 (suppl I):I-428, 1996

• 39) Lang RM, Elkayam U, Yellen LG et al:Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol 30:983-991, 1997
  pubmed

• 40) Pitt B, Segal R, Martinez FA et al on behalf of ELITE Study Investigators:Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747-752, 1997

• 41) Konstam MA, Thomas I, Ramahi TM et al:Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure:results of the ELITE ventricular function substudy. Circutation 96 (suppl I):I-452, 1997

• 42) Yusuf S, Maggioni AP, Held P et at:Effects of candesartan, enalapril or their combination on exerclse capacity, ventricular function, clinical deterioration and quality of life in heart failure:randomized evaluation of strategies for left ventricular dysfunction (RESOLVD). Circulation 96 (suppl I):I-452, 1997

P.272 掲載の参考文献

• 1) Packer M, Medina N, Yushak M et al:Hemodynamic patterns of response during long-term captopril therpy for severe chronic heart failure. Circulation 68:803-812, 1983

• 2) Osterziel KJ, Dietz R, Schmid W et al:ACE inhibition improves vagal reactivity in patients with heart failure. Am Heart J 120:1120-1129, 1990
  pubmed

• 3) Packer M, Medina N, Yushak M et al:Usufulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heaert failure. Experience in 100 consecutive patients. Br Heart J 54:298-304, 1985

• 4) Konstam MA, Rousseau MF, Kronenberg MW et al:Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with heart failure. Circulation 86:431-438, 1992

• 5) Konstam MA, Kronenberg MW, Rousseau MF et al:Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 88 (part 1):2277-2283, 1993

• 6) Raya TE, Gay RG, Aguirre Met al:Importance of venodilation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats:a comparison of captopril and hydralazine. Circ Res 64:330-337, 1989

• 7) Pfeffer MA, Pfeffer JM, Braunwald E:Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Cir Res 57:84-95, 1985

• 8) Pfeffer MA, Pfeffer JM, Steinberg C et al:Survival after an experimental myocardial infarcion:beneficial effects of long-term therapy with captopril. Circulation 72:406-412, 1985

• 9) Pfeffer MA, Lamas GA, Vaughan DE et al:Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319:80-86, 1988
  pubmed

• 10) Gohlke P, Linz W, Sholkens BA et al:Angiotensin-converting enzyme inhibition improves cardiac fucntion. Role of bradykinin. Hypertension 23:411-418, 1994

• 11) LindpainterK, Ganten D:The cardiac reninangiotensin system:an appraisal of current experimental and clinical evidence. Circ Res 68:905-921, 1991

• 12) Schunkert H, Dzau VJ, Tang SS et al:Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy:effects on coronary resistance, contractility, and relaxation. J Clin Invest 86:1913-1920, 1990
  pubmed

• 13) Iwai N, Shimoike H, Kinoshita M:Cardiac reninangiotensin system in the hypertrophied heart. Circulation 92:2690-2696, 1995
  pubmed

• 14) Bentivegna LA, Ablin LW, Kihara Y et al:Altered calcium handling in left ventricular pressure-overload hypertrophy as detected with aequorin in the isolated, perfused ferret heart. Cir Res 69:1538-1545, 1991

• 15) Eberli FR, Apstein CS, Ngoy S et al:Exacerbation of left ventricular ischemic diastolic dysfuntion by pressure-overload hypertrophy:modification by specific inhibition of cardiac angiotensin converting enzyme. Circ Res 70:931-943, 1992

• 16) Haber HL, Powers ER, Gimple LW et al:Intracoronary angiotensin-converting enzyme inhibition improves diastolic function in patients with hypertensive left ventricular hypertrophy. Circulation 89:2616-2625, 1994
  pubmed

• 17) Friedrich SP, Lorell BH, Rousseau MF et al:Intracardiac ACE inhibition improves diastolic distensibility in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 90:2761-2771, 1994

• 18) Weinberg EO, Schoen FJ, George D et al:Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 90:1410-1422, 1994
  pubmed

• 19) Greenberg B, Quinones MA, Koilpillai C et al:Effects of long-term enalapril therapy on cardiac sturcture and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiographic subsutdy. Circulation 91:2573-2581, 1995

• 20) Nakamura M, Ishikawa M, Funakoshi T et al:Attenuated endothelium-dependent peripheral vasodilation and clinical characteristics inpadents with chronic heart failure. Am Heart J 128:1164-1169, 1994
  pubmed

• 21) Mancini DM, Walter G, Reichek N et al:Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 85:1364-1373, 1992
  pubmed

• 22) Mancini DM, Wilson JR, Bolinger L et al:In vivo magnetic resonance spectroscopy measurement of deoxymyoglobin during exercise in patients with heart failure:Demonstration of abnormal muscle metabolism despite adequate oxygenadon. Circulataion 90:500-508, 1994

• 23) Drexler H, Banhardt U, Meinertz T et al:Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heat hailure:A double-blind, placebo-controlled trial. Circulation 79:491-502, 1989

• 24) Captopril Multicenter Research Group:A placebo controlled trial of captopril in refractory chrinic congestive heart failure. J Am Coll Cardiol 2:755-763, 1983

• 25) Dickenstein K, Chang P, Willenheiumer R et al:Comparison of the effects of losartan and enalapril on clinical status and exercise perormance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 26:438-445, 1995
  pubmed

• 26) Lang RM, Elkayam U, Yellin LG et al:Comparative effects in losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol 30:983-991, 1997

P.280 掲載の参考文献

• 1) Christlieb AR, Kaldany A, D' Elia JA et al:Aldosterone responsiveness in patients with diabetes mellitus. Diabetes 27:732-737, 1978
  pubmed

• 2) Moss S, Oster JR, Perez GO et al:Renin-aldosterone responsiveness in uncomplicated juvenile-type diabetes mellitus. Horm Res 9:130-136, 1978
  pubmed

• 3) Drury PL, Bodansky HJ:The relationship of the renin-angiotensin system in type I diabetes to microvascular disease. Hypertension 7 (suppl II):84-89, 1985

• 4) O'Hare JA, Ferriss JB, Brady D et al:Exchangeable sodium and renin in hypertensve diabetic patients with and without nephropathy. Hypertension 7 (suppl II):43-48, 1985

• 5) Wiseman MJ, Drury PL, Keen H et al:Plasma renin activity in insulin-dependent diabetics with raised glomerular filtration rate. Clin Endocrinol 21:409-414, 1984
  pubmed

• 6) Ferriss JB, Sullivan PA, Gonggrijp H et al:Plasma angiotensin II and aldosterone in unselected diabetic patients. Clin Endocrinol 17:261-269, 1982
  pubmed

• 7) Perez GO, Lespier L, Jacobi J et al:Hyporeninemia and hypoaldosteronism in diabetes mellitus. Arch Intern Med 137:852-855, 1977
  pubmed

• 8) Feldt-Rasmussen B, Mathiesen ER, Deckert T et al:Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type I diabetes mellitus Diabetologia 30:610-607, 1987
  pubmed

• 9) Villoria JG, Nunez JF, Miralles JM et al:Hyporeninemic hypoaldosteronism in diabetic patients with chronic renal failure. Am J Nephrol 8:127-137, 1988

• 10) Luetscher JA, Kraemer FB, Wilson DM et al:Increased plasma inactive renin in diabetes mellitus. N Engl J Med 312:1412-1417, 1985
  pubmed

• 11) Bryer-Ash M, Fraze EB, Luetscher JA:Plasma renin and prorenin (inactive renin) in diabetes mellitus:effect of intra-venous furosemide. J Clin Endocriol Metab 66:454-458, 1988

• 12) Luetscher JA, Kraemer FB:Microalbuminuria and increased plasma prorenin:prevalence in diabetics followed up four years. Arch Intern Med 148:937-941, 1988
  pubmed

• 13) Hostetter TH, Troy JL, Brenner BM:Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 19:410-415, 1981

• 14) Zatz R, Meyer TW, Rennke HG et al:Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 82:5963-5967, 1985
  pubmed

• 15) Okamura T, Miyazaki M, Inagami T et al:Vascular renin-angiotensin system in two-kidney one clip hypertensive rats. Hypertension 8:560-565, 1986
  pubmed

• 16) Baranowski RL, Westenfelder C:In vivo renal angiotensin converting enzyme activity decreases in glycerol-induced acute renal failure. Kidney Int 34:321-326, 1988
  pubmed

• 17) Ho SC, Michelakis AM:Multiple defects in the renin-anglotensin system in alloxan diabetic kidney. Proc Soc Exp Biol Med 178:297-303, 1985

• 18) Valentovic MA, Elliot CW, Ball JG:The effect of streptozotocin-induced diabetes and insulin treatment on angiotensin converting enzyme activity. Res Commun Chem Path Pharmacol 58:27-39, 1987

• 19) Maeda S, Kikkawa R, Haneda M et al:Reduced activity of renal angiotensin-converting enzyme in streptozotocin-induced diabetic rats. J Diabet Complications 5:225-229, 1991
  pubmed

• 20) Ikemoto F, Song GB, Tominaga M et al:Angiotensin converting enzyme predominance in the inner cortex and medulla of the rat kidney. Biochem Biophys Res Commun 144:915-921, 1987
  pubmed

• 21) Kikkawa R, Kitamura E, Fujiwara Y et al:Impaired contractile responsiveness of diabetic glomeruli to angiotensin II:a possible indication of mesangial dysfunction in diabetes mellitus. Biochem Biophys Res Commun 136:1185-1190, 1986
  pubmed

• 22) Mizuiri S, Kobayashi Y, Nakanishi T et al:Renal angiotensin-converting enzyme localization in diabetic rats and the effect of low protein diet. Nephron 76:186-191, 1997

• 23) Anderson S, Jung FF, Ingelfinger JR:Renin-angiotensin system in diabetic rats:Functional, immunohistochemical, and molecular biologic correlations. Am J Physiol 265:F477-F486, 1993
  pubmed

• 24) Ortola FV, Ballermann BJ, Anderson S et al:Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. J Clin Invest 80:670-674, 1987
  pubmed

• 25) Haneda M, Kikkawa R, Koya D et al:Alteration of mesangial response to ANP and angiotensin II by glucose. Kidney Int 44:518-526, 1993
  pubmed

• 26) Barnett R, Ortiz PA, Blaufox S et al:Atrial natriuretic factor alters phospholipid metabolism in mesangial cells. Am J Physiol 258 (1 Pt 1):C37-45, 1990

• 27) Christensen CK, Mogensen CE:Effect of antihypertensive treatment on progression of incipient diabetic nephropathy. Hypertension 7 (suppl II):109-113, 1985

• 28) Hommel E, Mathiesen E, Edsberg B et al:Acute reduction of arterial blood pressure reduces urinary albumin excretion in type I (insulin-dependent) diabetic patients with incipient nephropathy. Diabetologia 29:211-215, 1986
  pubmed

• 29) Christensen CK, Mogensen CE:Acute and long-term effect of antihypertensive treatment on exercise-induced albuminuria in incipient diabetic nephropathy. Scand J Clin Lab Invest 46:553-559, 1986
  pubmed

• 30) Zatz R, Dunn BR, Meyer TW et al:Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
  pubmed

• 31) Anderson S, Rennke HG, Garcia DL et al:Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36:526-536, 1989

• 32) Marre M, Chatellier G, Leblanc H et al:Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 297:1092-1095, 1988

• 33) Mathiesen ER, Hommel E, Giese J et al:Captopril postpones and even prevent development of diabetic nephropathy (Abstract). Diabetes 39 (suppl I):72A, 1990

• 34) Romanelli G, Giustina A, Bossoni S et al:Short-term administration of captopril and nifedipine and exercise-induced albuminuria in normotensive diabetic patients with early-stage nephropathy. Diabetes 39:1333-1338, 1990
  pubmed

• 35) Morelli E, Loon N, Meyer T et al:Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 39:76-82, 1990
  pubmed

• 36) Mogensen CE:Long-term antihypertensive treatment inhibiting progression of diabetic diabetic nephropathy. Br Med J 1285:685-688, 1982

• 37) Parving H-H, Andersen AR, Smidt UM et al:Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 294:1443-1447, 1987

• 38) Parving H-H, Hommel E, Smidt UM:Protection of kidney function and decrease albuminuria by captopril in insulin dependent diabetics with nephropathy. Br Med J 297:1086-1091, 1988

• 39) Bjorck S, Nyberg G, Mulec H et al:Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 293:471-474, 1986

• 40) Taguma Y, Kitamoto Y, Futaki G et al:Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 313:1617-1620, 1985
  pubmed

• 41) Marre M, Jeunemaitre X, Gallois Y et al:Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes. J Clin Invest 99:1585-1595, 1997

• 42) Doria A, Warram JH, Krolewski AS:Genetic predisposition to diabetic nephropathy:Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 43:690-695, 1994
  pubmed

• 43) Parving HH, Tarnow L, Rossing P:Genetics of diabetic nephropathy. J Am Soc Nephrol 7:2509-2517, 1996
  pubmed

• 44) Jeffers BW, Estacio RO, Raynolds MV et al:Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy. Kidney Int 52:473-477, 1997
  pubmed

• 45) Fujisawa T, Ikegami H, Shen G-Q et al:Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy in NIDDM. Diabetes Care 18:983-985, 1995
  pubmed

• 46) Kasiske BL, Kalil RSN, Ma JZ et al:Effect of antihypertensive therapy on the kidney in patients with diabetes:A meta-regression analysis. Ann Intern Med 118:129-138, 1993

P.288 掲載の参考文献

• 1) Joint National Committee:The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 157:2413, 1997

• 2) Lewis EJ, Hunsicker LG, Bain RP et al:The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456, 1993
  pubmed

• 3) Klahr S, Levey AS, Beck, GJ et al:The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330:877, 1994
  pubmed

• 4) Maschio G, Albelti D, Janin G et al:Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufffciency. N Engl J Med 334:939, 1996

• 5) Brenner BM, Hostetter TH, Humes HD:Molecular basis of proteinuria of glomerular origin. N Engl J Med 298:826, 1978
  pubmed

• 6) Edwards RM:Segmental effects of norepinephrine and angiotensin II on isolated renal microvessels. Am J Physiol 244:F526, 1983
  pubmed

• 7) Yoshioka T, Rennke HG, Salant DJ et al:Role of abnormally high transmural pressure in the permselectivity defect of glomerular capillary wall:A study in early passive Heymann nephritis. Circ Res 61:531, 1987

• 8) Cartwright ME, Jaenke RS:Effects of dietary protein and captopril on glomerular permselectivity in rats with unilateral nephrectomy. Lab Invest 59:492, 1988
  pubmed

• 9) Remuzzi A, Perticucci E, Ruggenenti P et al:Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 39:1267, 1991
  pubmed

• 10) Thomas DM, Hills AN, Coles GA et al:Enalapril can treat the proteinuria of membranous glomerulonephritis without detriment to systemic or renal hemodynamics. Am J Kidney Dis 18:38, 1991
  pubmed

• 11) Gansevoort RT, de Zeeuw D, de Jong PE:Longterm benefits of the antiproteinuric effects of angiotensin-converting inhibition in non diabetic renal disease. Am J Kidney Dis 22:202, 1993

• 12) Kawamura Y, Takahashi T, Ogawa M et al:Modulation of mesangial cell growth by extracellular matrix derived from glomerular endothelial cells stimulated by angiotensin-converting enzyme inhibitor. J Am Soc Nephrol 4:655, 1995

• 13) Kon V, Fogo A, Ichikawa I:Bradykinin causes selective efferent arteriolar dilatation during angiotensin I converting enzyme inhibition. Kidney Int 44:545, 1993
  pubmed

• 14) Tanaka R, Kon V, Yoshioka T et al:Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanism. Kidney Int 45:537, 1994
  pubmed

• 15) Hutchison FN, Cui X, Webster SK et al:The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. J Am Soc Nephrol 6:1216, 1995
  pubmed

• 16) Abbound HE:Platelet-derived growth factor and mesangial cells. Kidney Int 41:581, 1992

• 17) Roberts AB, Spon MB, Assoian RK et al:Transforming growth factor type β:Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167, 1986

• 18) Yoshida Y, Kawamura T, Ikoma M et al:Effects of antihypertensive drugs on glomerular morphlogy. Kidney Int 36:626, 1989

• 19) Fogo A, Yoshida Y, Glick AD et al:Serial micropuncture analysis of glomeruler function in two rat models of glomerular sclerosis. J Clin Invest 82:322, 1988

• 20) Yamaguchi T, Ogura T, Oishi T et al:The angiotensin I-converting enzyme inhibitor, cilazapril inhibits the platelet-derived growth factor B chain expression in glomeruli of spontaneously hypertensive rats. Ren Physiol Biochem 18:237, 1995

• 21) King AJ, Brenner BM, Anderson S:Endothelin:a potent renal and systemic vasoconstrictor peptide. Am J Physiol 256:F1051, 1989
  pubmed

• 22) Firth JD, Ratcliffe PJ:Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest 90:1023, 1992
  pubmed

• 23) Kawaguchi H, Sawa H, Yasuda H:Endothelin Stimulate angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol 22:839, 1990
  pubmed

• 24) Kohno M, Yasunari K, Yokikawa K et al:Inhibition by arterial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J Clin Invest 87:1999, 1991

• 25) Chan DP, Clavell A, Keisor J et al:Effects of renin-angiotensin system in mediating endothelin-induced renal vasoconstriction:therapeutic imphcations. J Hypertens 12 (suppl 4):S43, 1994

• 26) Ruiz-Ortega M, Gomez-Garre D, Liu XH et al:Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis. J Am Soc Nephrol 8:756, 1997

• 27) Taguma Y, Kitamoto Y, Futaki G et al:Effect of captopril on heavy proteinuria in azotemic diabetes. N Engl J Med 313:1617, 1985
  pubmed

• 28) Kasiske BL, Kalil RSN, Ma JZ et al:Effect of antihypertensive therapy on the kidney in patients with diabetes:a meta-regression analysis. Ann Intern Med 118:129, 1993

• 29) Sauter ER, Bakris GL:The effects of enalapril on urinary protein excretion in patients with idiopathic membranous nephropathy. J Clin Pharmacol 30:155, 1990
  pubmed

• 30) Praga M, Hernandez E, Montoyo C et al:Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 20:240, 1992
  pubmed

• 31) Rekola S, Bergstrand A, Bucht H:Deterioration rate in hypertensive IgA nephropathy:comparison of a converting enzyme inhibitor and β-blocking agents. Nephron 59:57, 1991

• 32) Kamper AL, Strandgaard S, Leyssac PP:Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 5:423, 1992
  pubmed

• 33) Hannedouche T, Landais P, Goldfarb B et al:Randomized controlled trial of enalapril and β blockers in non-diabetic chronic renal failure. BMJ 309:833-837, 1994

• 34) Zucchelli P, Zuccala A, Borghi M et al:Longterm comparison between captopril and nifedipine in the progression of renal insuficiency. Kidney Int 42:452, 1992

• 35) Ihle BU, Whitworth JA, Shahinfar S et al:Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insuficiency:A controlled double-blind trial. Am J Kidney Dis 27:489, 1996

• 36) The GISEN Group:Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857, 1997
  pubmed

• 37) Giatras I, Lau J, Levey AS:Effect of angiotensin-converting enzyme inhibitor on the progression of nondiabetic renal disease:A meta-analysis of randomised trials. Ann Intern Med 127:337, 1997
  pubmed

P.299 掲載の参考文献

• 1) Spitzer WO, Dobson AJ, Hall J et al:Measuring the quality of life of cancer patients. A concise QL-index for use by physicians. J Chronic Dis 34:585-579, 1981
  pubmed

• 2) Stewart AL, Greenfield S, Hays RD et al:Functional status and well-being of patients with chronic conditions. JAMA 262:907-913, 1989
  pubmed

• 3) Dimenas ES, Wiklund IK, Dahlhof CG et al:Differences in the subjective well-being and symptoms of normotensives, borderline hypertensives and hypertensives. J Hypertens 7:885-890, 1989

• 4) Ogihara T et al:Usefulness of the β-blocker carteolol and its effect on quality of life in elderly hypertensive patients. Curr Ther Res Clin Exp 49:38-46, 1991

• 5) Levine S, Croog SH:What constitutes quality of life? In:Assessment of quality of life in clinical trials of cardiovascular therapy, Le Jacq Publishing, NY, 1986, p. 46

• 6) Testa MA, Sudilovsky A, Rippei RM et al:A short form for clinical assessment of quality of life among hypertensive patients. Am J Prev Med 5:82-89, 1989

• 7) 荻原俊男, 三上洋, 中丸光昭ほか:高齢者高血圧の変換酵素阻害薬による治療とQuality of lifeに関する研究. 老年医学 26:291-299, 1988

• 8) 長嶋紀一ほか:高齢者循環器疾患患者のQOL評価法の開発. Therapeutic Research 14:107-111, 1993

• 9) Croog SE, Levine S, Testa MA et al:The effects of antihypertensive therapy on the quality of 1ife. N Engl J Med 314:1657-1664, 1986

• 10) Mikami H, Ogihara T, Nakamaru M et al:Quality of life in the treatment of hypertension in the elderly. In:How should elderly hypertensive patients be treated? Springer-Verlag, Tokyo, 1989, pp. 219-225

• 11) Steiner SS, Friedhoff AJ, Wilson BL et al:Antihypertensive therapy and quality of life:a comparison of atenolol, captopril, enalapril and propranolol. J Human Hypertens 4:217-225, 1990
  pubmed

• 12) Testa MA Anerson RB, Nackley JF et al:Quality of life and antihypertensive therapy in men. A comaprison of captopril with enalapril. N Engl J Med 4328:907-913, 1993

• 13) Correspondence:Captopril, enalapril, and quality of life. Letter to the Editor, and the author's reply. N Engl J Med 329:505-507, 1993

• 14) Croog SH, Levine S, Sudilovsky A et al:Sexual symptoms in hypertensive patients. A clinical trial of antihypertensive medications. Arch Int Med 148:788-794, 1988

• 15) Govantes C, Marin J:Effect of angiotensin converting enzyme inhibitors on quality of life in hypertensive patients. Pharmacodynamic basis. Fundam Clin Pharmacol 10:400-405, 1996
  pubmed

• 16) Beto JA Bansal VK:Quality of life in treatment of hypertension. A meta-analysis of clinical trials. Am J Hypertens 5:125-133, 1992
  pubmed

• 17) Hjemdahl P, Wiklund IK Quality of life on antihypertensive drug therapy:scientific end-point or marketing exercise? J Hypertens 10:1437-1446, 1992
  pubmed

P.307 掲載の参考文献

• 1) The Joint National Committee on Prevention, Detection. Evaluation, and Treatment of High Blood Pressure, The National High Blood Pressure Education Program Coordinating Committee:The sixth report of the Joint Naional Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997

• 2) WHO Expert Committee on Hypertension Control:Management of hypertension. In:Hypertension control. Report of a WHO Expert Committee. WHO Technical Report Series 892, World Health Organization, Geneva, 1996, pp. 52-63

• 3) Mancia G, Serevalle G, Vailati S et al:Benefits versus risk of calcium antagonists in hypertensive patients with concomitant risk factors. J Hypertens 14 (suppl 4):S33-S38, 1996

• 4) Guidelines Sub-Committee:1993 Guideline for the management of mild hypertension:memorandum form a World Health Organization/International Society of Hypertension meeting. J Hypertens 11:905-918, 1993

• 5) Fogari R, Zoppi A, Tettamanti F et al:Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhivitors:A double-blind randomized, cross-over study. J Cardiovasc Pharmacol 19:670-673, 1992

• 6) 築山久一郎, 大塚啓子:降圧薬との薬物相互作用. 老年者高血圧の診療-最新知見からみた問題点と解説-. メディカルレビュー社, 東京, 1997, pp. 225-248

• 7) de Leeuw PW, Notter T, Zilles P:Comparison of different fixed anti-hypertensive combination drugs:a double-blind, placebo-controlled parallel group study. J Hypertens 15:87-91, 1997

• 8) Hager WD, Davis BR, Riba A et al, for the SAVE Investigators:Absence of deleterious effects of calcium blockers in patients with left ventricular dysfunction after myocardial infaction:The SAVE study experience. Am Heart J 135:406-413, 1998

• 9) Hansen JF, Hagerup L, Sigurd B et al for the Danish Verapamil Infarction Trial (DAVIT) study Group:Treatment with verapamil and trandolapril in patients with congestive heart failure after myocardial infarction. J Hypertens 15 (suppl2):S119-S122, 1997

• 10) Homuth V, Faulhaber H-D, Loose U et al:Usefulness of piretanide plus ramipril for systolic hypertension:A muticenter trial. Am J Cardiol 72:666-671, 1993

• 11) Plat F, Saini R:Management of hypertension. The role of combination therapy. Am J Hypertens 10 (10part 2):S262-S271, 1997

• 12) Black HR:Metabolic considerations is the choice of therapy for the patinets with hypertension. Am Heart J 121:707-715, 1991

• 13) Belz GG:Beta-blockers and ACE inhibitors. In:Combination drug therapy for hypertension, ed. by Opie LH, Messerli FH, Authers' Publishing House, Lippencott-Raven Publishers, Philadelphia, 1997, pp. 76-90

• 14) Swedish Lisinopril Study Group:Lisinopril combined with atenolol in the treatment of hypertension. J Cardiovasc Pharmacol 18:457-461, 1991

• 15) Soininen K, Gerlin-Piira L, Suihkonen J et al:A study of the effects of lisinopril when used in addition to atenolol. J Hum Hypertens 6:321-324, 1992
  pubmed

• 16) Ketelhut R, Franz IW, Beher U:Preserved pump function after marked reduction of left ventricular mass. J Am Coll Cardiol 20:864-868, 1992

• 17) Klein WW, Khurmi NS, Eber B et al:Effects of benazepril and metoprolol OROS alone and in combination on myocardial ischemia in patients with chronic stable angina. Am J Coll Cardiol 16:948-956, 1990

• 18) Pfeffer MA, Lamas GM, Vaughan DE et al:Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med 319:80-86, 1988

• 19) Vantrimpont P, Rouleau, JL, Wun C-C et al, for the SAVE Investigators:Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. J Am Coll Cardiol 29:229-236, 1997
  pubmed

• 20) Yusuf S, Pepine CJ, Garces C et al:Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fraction. Lancet 340:1173-1178, 1992
  pubmed

• 21) Aronow WS, Ahn C, Kronzon I:Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≧ 40% treated with diuretics plus, angiotensin convening enzyme inhibitors. Am J Cardiol 80:207-209, 1997

• 22) Packer M, Bristow MR, Cohn JN et al, for the Carvedilol Heart Failure Study Group:The effect of carvedilol on morbidity and mortality in patients with chronic heart failire. N Engl J Med 334:1349-1355, 1996

• 23) Australia/New Zealand Heart Failure Research Collaborative Group:Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 92:212-218, 1995

• 24) The Task Force of the Working Group of Heart Failure of the European Society of Cardiology:The treatment of heart failure. Eur Heart J 18:736-753, 1997

• 25) Uzubalis RI, Frewin DB, Bushell MK et al:The effect of angiotensin converting enzyme inhibitors (ACE-I) and selective β1 antagonists on bronchial reactivity and the cough reflex in man. Eur Clin Pharmacol 37:467-470, 1989

• 26) Lau WAK, Rechtman MP, Boura ALA et al:Synergic potentiation by captopril and propranolol of bradykinin-induced bronchoconstiction in the guinea-pig. Clin Exp Pharmacol Physiol 16:849-857, 1989

• 27) Kaplan NM:Alpha-blocker combination. In:Combination drag therapy fot hypertension, ed. by Opie LH, Messerli FH, Authers' Publishing House, Lippencott-Raven Publishers, Philadephia, 1997, pp. 107-113

• 28) Brown MJ, Dickerson JEC:Synergism between alpha1-blockade and angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 9 (suppl 6):S362-363, 1991

• 29) Stokes GS, Johnston HJ, Okoro EO et al:Comparative and combined efficacy of doxazosin and enalapril in hypertensive patients. Clin Exper Hypertens 16:709-727, 1994

• 30) Azizi M, Chatellier G, Guyene T-T et al:Additive effects of combined angiotensin-converting enayme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 92:825-834, 1995

• 31) Azizi M, Guyene T-T, Chatellier G et al:Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 9:634-640, 1997

• 32) Nedogoda S, Prtov V:Enalapril, losartan and the combined treatment at hypertension (abstr) . J Hypertens 14 (suppl 1):S224, 1996

• 33) Hamroff G, Brayfarb I, Mancini D et al:Angiotensin II receptor blockade further reduces afterload safely in patients maximally treated with ACE inhibitors for heart failure (abstr). Circulation 94 (suppl I):S428-S429, 1996

• 34) Packer M, Gheorghiade M, Young JB et al, for the RADIANCE Study:Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. N Engl J Med 329:1-7, 1993
  pubmed

• 35) Shionoiri H:Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacokinet 25:20-58, 1993
  pubmed

• 36) van Glist WH, de Graeff PA, de Leeuw MJ et al:Concerting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo-and endogenous nitrovasodilators. J Cardidiovasc Pharmacol 18:429-436, 1991

• 37) Katz JR, Levy WS, Buff L et al:Prevention of nitrate tolerance with angiotensin converting enzyme inhibitors. Circulation 83:1271-1277, 1991

• 38) Nabel EG, Topol EJ, Galeana A et al:A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissuetype plasminogen activator therapy in acute mycardial infarction. J Am Coll Cardiol 17:467-473, 1991

• 39) Johnson AG, Nguyen TV, Day RO:Do nons-teroidal anti-inflammatorty drugs affect blood pressure? A meta-analysis. Ann Intern Med 121:289-300, 1994

• 40) Gurwitz JH, Avorn J, Bohn RL et al:Initiation of antihypertensive treatment during nonsteridal anti-inflammatory drug therapy. JAMA 272:781-786, 1994

• 41) Brooks PM, Day RO:Nonsteroidal antiinflammatory drugs-differences and similarities. N Engl J Med 324:1716-1725, 1991
  pubmed

• 42) Oates JA:Antagonism of antihypertensive drug therapy by non-steriodal antiinflammatory drugs. Hypertension 11 (suppl II):S4-S6,1988

• 43) Heeg JE, de Jong PE, Vriesendrorp R et al:Additive antiproteinuric effects of the NSAID indomethacin and the ACE inhibitor lisinopril. Am J Nephrol 10 (suppl 1):S94-S97, 1990

• 44) van Zwieten PA:Lipids-lowering drugs, with an emphasis on their use in hypertensive patients. In:Hypertension, athorosclerosis and lipids (International Congress and Syposium Series) , ed. by van Zwieten PA, Mancia G, Brodde OE, Royal Society of Medidcine Services, London, 1992, pp. 57-66

• 45) Scanferla F, Toffoletto PP, Roncall D et al:Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase+angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects. Am J Hypertens 4:868-869, 1991

• 46) Pandit MK Burke J, Gustafson AB et al:Drug-induced disorders of glucose tolerance. Ann Intern Med 118:529-539, 1993
  pubmed

• 47) Rett K, Wicklmayr M, Dietz GJ:Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides and captopril. N Engl J Med 319:1609, 1988

• 48) McMurray J, Frazer DM:Captopril, enalapril and blood glucose. Lancet i:1035, 1988

• 49) Berne C:Metabolic effects of ACE inhibitors. J Intern Med 229 (suppl 2):S119-S125, 1991

• 50) Stockley IH:ACE inhibitors + miscellaneos drugs. In:Drug Interactions. A source book of drug interactions, their mechanisms, clinical importance and management (2nd Ed) . Blackwell Scientific Publications, London, 1991, pp. 262-263

• 51) Kochak GM, Rakhit A, Thompson TN et al:Pentopril-cimetidine interaction caused by a reduction in hepatic blood flow. J Clin Pharmacol 28:222-227, 1988
  pubmed

• 52) Stockley IH:ACE inhibitors + allopurinol. In:Drng interactions. A source book of drug interactions their mechanisms, clinical importance and management (2nd ed). Blackwell Scientific Publicadons, London, 1991, pp. 261

• 53) Singhvi SM, Duchin KL,, Willard DA et al:Renal handling of captopril:effect of probenecid. Clin Pharmacol Ther 32:182-189, 1982

• 54) Onoyama K, Sanai T, Motomura K et al:Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodyalysis patients. J Cardivasc Pharmacol 13 (suppl 3):S27-S30, 1989

P.319 掲載の参考文献

• 1) Stumpe KO, Kolloch R, Overlack A:Captopril and enalapril:Evaluation of therapeutic efficacy and safety. Pract Cardiol 7:111-124, 1984

• 2) Rush JE, Merill DD:The safety and tolerability of licinopril in clinical trials. J Cardiovascul Pharmacol 9 (suppl 3):S99-107, 1987

• 3) Cooper WD, Sheldon D, Brown D et al:Postmarketing surveillance of enalapril:experience in 11710 hypertensive patients in general practice. J R Coll Gen Pract 37:346-349, 1987

• 4) Chalmers D, Dombey SL, Lawson DH:Postmarketing surveillance of captopril (for hypertension):A preliminary report. Br J clin Pharmacol 24:343-349, 1987
  pubmed

• 5) Inman WHW, Rawson NSB, Wilton LV et al:Postmarketing surveillance of enalapril. I:Results of prescription-event monitoring. Br Med J 297:826-829, 1988

• 6) Frank GJ, Knapp LE, McLain RW:Overall tolerance and safety of quinapril in clinical trials. Angiology 40:405-415, 1989
  pubmed

• 7) Schoenberger JA, Testa M, Ross AD et al:Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice. Arch Intern Med 150:301-306, 1990
  pubmed

• 8) Chalmers D, Whitehead A, Lawson DH:Postmarketing surveillance of captopril for hypertension. Br J clin Pharmacol 34:215-223, 1992
  pubmed

• 9) Fallowfield JM, Blenkinsopp J, Raza A et al:Postmarketing surveillance of lisinopril in general practice in the UK Br J Clin Pract 47:296-304, 1993
  pubmed

• 10) Huckell VF, Belanger LG, Kazimirski M et al:Lisinopril in the treatment of hypertension:A Canadian postmarketing surveillance study. Clin Ther 15:407-422, 1993
  pubmed

• 11) Larochelle P, Haynes B, Maron N et al:A postmarketing surveillance evaluation of quinapril in 3742 Canadian hypertensive patients:The ACCEPT Study. Clin Ther 16:838-853, 1994

• 12) Frohlich ED, Cooper RA, Lewis EJ:Review of the overall experience of captopril in hypertension. Arch Intern Med 144:1441-1444, 1984
  pubmed

• 13) Jett GK, Captopril-induced angioedema. Ann Emerg Med 13:489-490, 1984
  pubmed

• 14) Megerian CA, Arnord JE, Berger M:Angioedema:5years' experiance, with a review of the disorder's presentation and treatment. Laryngoscope 102:256-260, 1992

• 15) Hedner T, Samuelsson O, Lindholm L et al:Precipitation of angioedema by antihypertensive drugs. J Hypertens 9 (suppl 6):S360-S361, 1991

• 16) Gabb GM, Ryan P, Wing LMH et al:Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med 26:777-782, 1996

• 17) Agah R, Bandi V, Guntupalli KK:Angioedema:the role of ACE inhibitors and factors associated with poor clinical outcome. Intensive Care Med 23:793-796, 1997
  pubmed

• 18) Cicardi M, Conciato L, Afostoni A:Angioedema due to angiotensin-converting enzyme inhibition:an association frequently unrecognized. Ann Ital Med Int 12:8-10, 1997
  pubmed

• 19) Israili ZH, Hall WD:Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 117:234-242, 1992
  pubmed

• 20) Pavledc AJ:Angioedema after long-term use of angiotensin-converting enzyme inhibitor. J Am Board Fam Pract 10:370-373, 1997

• 21) Sciller PI, Messmer SL, Haefeli WE et al:Angiotensin-converting enzyme inhibitor-induced angioedema:late onset, irregular course, and potential role of triggers. Allergy 52:432-435, 1997

• 22) Acker CG, Greenberg A:Angioedema induced by the angiotensin II blocker losartan. N Engl J Med 33:1572, 1995

• 23) Irvin JD, Vian JM:Safety profiles of the angiotensin converting enzyme inhibitors, captopril and enalapril. Am J Med 81 (suppl 4C):46-50, 1986

• 24) Singer DRJ, MacGregor GA:Angioneurotic edema associated with two angiotensin converting enzyme inhibitors. Br Med J 293:1243, 1986

• 25) Slater EE, Merrill DD, Guess HA et al:Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 260:967-970, 1988
  pubmed

• 26) Hedner T, Samuelsson O, Lunde H et al:Angio-oedema in relation to treatment with angiotensin convening enzyme inhibitors. BMJ 304:941-946, 1992

• 27) Pillans PI, Coulter DM, Black P:Angiooedema and urticaria with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol 51:123-126, 1996
  pubmed

• 28) Brown NJ, Snowden M, Griffin MR:Recurrent angiotensin-converting enzyme inhibitor-associated angio-edema. JAMA 278:232-233, 1997
  pubmed

• 29) Brown NJ, Ray WA, Snowden M et al:Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 60:8-13, 1996
  pubmed

• 30) Seidman MD, Lewandowski CA, Sarpa JR et al:Angioedema related to angiotensin-converting enzyme inhibitors. Otolaryngol Head Neck Surg 102:727-731, 1990
  pubmed

• 31) Gianos ME, Maustermeyer WB, Kuroharra M et al:Enalapril induced angioedema. Am J Emerg Med 8:124-126, 1990

• 32) Thompson T, Frable AS:Durg-induced, life-threatening angioedema revisited Laryngoscope 103:10-12, 1993

• 33) BoydI W:Angio-oedema and ACE inhibitors. Austr N Z J Med 25:746-747, 1995 (letter)

• 34) Roberts JR Wuerz RC:Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema. Ann Emerg Med 20:555-558, 1991
  pubmed

• 35) Bielory L, Lee SS, Holland CL et al:Long-acting ACEinhibitors-induced angioedema. Allergy Proc 13:85-87, 192

• 36) Shionoiri H, Takasaki I, Hirawa N et al:A case report of angioedema during long-term (66 months) angiotensin converting enzyme inhibition therapy with enalapril. Jpn Circ J 60:166-170, 1996
  pubmed

• 37) Eberhart GD, Aundson DE, Lin FL:Angioedema associated with angiotensin-converting enzyme inhibitors. Ann Allergy Asthma Immunol 78:80 (letter) , 1997

• 38) Chu TJ, Chow N:Advers effects of ACE inhibitors. Ann Intern Med 118:314 (letter) , 1993

• 39) Suarez M, Ho PWL, Johnson ES et al:Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy. Am J Med 81:336-338, 1986

• 40) Giannoccaro PJ, Wallace GJ, Higginson IAJ et al:Fatal angioedema associated with enalapril. Can J Cardiol 5:335-336, 1989

• 41) Jason DR:Fatal angioedema associated with captipril. J Forensic Sci 37:1418-1421, 1992
  pubmed

• 42) Ulmer JL, Garvey MJ:Fatal angioedema associated with lisimopril. Ann Pharmacother 26:1245-1246, 1992
  pubmed

• 43) Oike Y, Ogata Y, Higashi D et al:Fatal angioedema associated with enalapril. Int Med 32:308-310, 1993

• 44) Wemze H:Angioneurotische Oedem unter ACE-Hemmern:Haufigkeit, klinische Charakteristik, Auslosemechanismen. Z Kardiol 77 (suppl 3):61-64, 1988

• 45) Barna JS, Frable MAS:Life-threatening angioedema. Otolaryngol Head Neck Surg 103:795-798, 1990

• 46) Finley CJ, Silverman MA, Nunez AE:Angiotensin-converting enzyme inhibitor-induced angioedema:Still unrecognized. Am J Emerg Med 10:550-552, 1992
  pubmed

• 47) Weiner JM:Failure to recognise the associadon of life-threatening angio-oedema and angiotensin-converting enzyme inhibitor therapy. Aust N Z J Med 25:241-242, 1995
  pubmed

• 48) Pigman EC, Scott JL:Angioedema in emergency department:The impact of angiotensin-converting enzyme inhibitors. Am J Emerg Med 11:350-354, 1993
  pubmed

• 49) Farraye FA, Peppercorn MA, Steer ML et al:Acute small-bowel mucosal edema following enarapril use. JAMA 259:3131, 1988 (letter)

• 50) Matsumura M, Haruki K, Kajinami K et al:Angioedema likely related to angiotensin converting enzyme inhibitors. Int Med 32:424-426, 1993

• 51) Jacobs RL, Hoberman LJ, Goldstein HM:Angioedema of the small bowel caused by an angiotensin-converting enzyme inhibitor. Am J Gastroenterol 89:127-128, 1994
  pubmed

• 52) Guy C:Suspected angioedema of abdominal viscera. Ann Intern Med 121:900, 1994 (letter)
  pubmed

• 53) Gregory KWP, Davis RC:Angioedema of the intestine. N Engl J Med 334:1641, 1996 (image)

• 54) Abdelmalek MF, Douglas DD:Lisinopril-induced isolated visceral angioedema. Review of ACE-inhibitor induced small bowel angioedema. Dig Dis Sci 42:847-850, 1997
  pubmed

• 55) 丹羽真理子, 永仮邦彦, 高須昭彦ほか:Enaraprilによる血管神経性浮腫によって上気道閉塞を生じた1例. 内科 73:954-957, 1994

• 56) 神木茂樹, 森田展雄, 湯浅祥司ほか:アンジオテンシン変換酵素阻害薬により誘発された舌, 口底部血管神経性浮腫の1例. 日口外会誌 42:726-728, 1996

• 57) 加藤理加, 渡部浩, 小野邦彦ほか:ACE阻害剤服用中に血管性浮腫を生じた2症例. 日耳鼻会報 99:1492-1493, 1996

• 58) Sesoko S. Kaneko Y:Cough associated with the use of captopril. Arch Intern Med 145:1524, 1985
  pubmed

• 59) Yeo WW, Ramsay LE:Persistent dry cough with enalapril:incidence depends on method used. J Hum Hypertens 4:517-520, 1990

• 60) Poole MD, Postma D:Characterization of cough associated with angiotensin-convening enzyme inhibitors. Otolaryngol Head and Neck Surg 105:714-716, 1991

• 61) Lunde H, Hedner T, Samuelsson O et al:Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 308:18-21, 1994
  pubmed

• 62) Town GI, Hallwright GP, Maling TJB et al:Angiotensin converting enzyme inhibitors and cough. N Z Med J 100:161-163, 1987

• 63) Inman WHW:Enalapril-induced cough. Lancet 2:1218, 1986

• 64) Strocchi E, Valtancoli G, Ambrosioni E:The incidence of cough during treatment with angiotensin converting enzyme inhibitors. J Hypertens 7, (suppl 6):S308-S309, 1989

• 65) Os I, Bratland B, Dahlof B et al:Female sex as an important determinant of lisinopril-induced cough. Lancet 339:372, 1992
  pubmed

• 66) Gibson GR:Enalapril-induced cough. Arch Intern Med 149:2701-2703, 1989
  pubmed

• 67) Simon SR, Black HR, Moser M et al:Cough and ACE inhibitors. Arch Intern Med 152:1698-1700, 1992
  pubmed

• 68) 広田憲威, 立岡雅子:重回帰分析法によるEnalapril誘発咳嗽の患者背景因子に関する研究. 臨床薬理 26:737-742, 1995

• 69) Sebastian JL, McKinney WP, Kaufman J et al:Angiotensin-converting enzyme inhibitors and cough. Prevalence in an outpatient medical clinic population. Chest 99:36-39, 1991

• 70) Goldszer RC, Lilly LS, Solomon HS:Prevalence of cough during angiotensin-converting enzyme inhibitor therapy. Am J Med 85:887, 1988
  pubmed

• 71) Just PM:The positive association of cough with angiotensin-converting enzyme inhibitors. Pharmacotherapy 9:82-87, 1989
  pubmed

• 72) Visser LE, Stricker BHCH, Van der Velden J et al:Angiotensin converting enzyme inhibitor associated cough:A population-based case-control study. J Clin Epidemiol 48:851-857, 1995

• 73) Yeo W, Foster G, Ramsay L:Prevalence of persistent cough during long-term enalapril treatment:controlled study versus nifedipine. Q J Med 81:763-770, 1991

• 74) Moore N, Noblet C, Joannides R et al:Cough and ACE inhibitors. Lancet 1:61, 1993

• 75) 賀来俊, 山崎英文, 原田信行ほか:老年者におけるアンジオテンシン変換酵素阻害薬による乾咳副作用. 日老医誌 28:365-70, 1991

• 76) Berkin KE:Respiratory effects of angiotensin convening enzyme inhibition. Eur Resp J 2:198-201, 1989

• 77) Puolijoki HJ, NieminenMM, Sittonen LO:Is a simultaneous beta-blocker therapy:a risk factor for enalapril-induced cough? Respirat 55:127-128, 1989

• 78) Coulter DM, Edwards IR:Cough associated with captopril and enalapril. Brit Med J 294:1521-1523, 1987

• 79) Bucknall CE, Neilly JB, Calter Ret al:Bronchial hyperreactivity in patients with cough after receiving angiotensin converting enzyme inhibitors. Br Med J 296:86-88, 1988

• 80) Popa V:Captopril-related (and-induced?) asthma. Am Rev Respir Dis 136:999-1000, 1987
  pubmed

• 81) Lipworth BJ, McMurray JJ, Clark RA, et al:A development of persistent late onset asthma following treatment with captopril. Eur Resp J 2:586-588, 1989

• 82) Kaufman J, Casanova JE, Riendl P et al:Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors. Chest 95:544-548, 1989
  pubmed

• 83) Sala H, Abad J, Juanmiquel L et al:Captopril and bronchial reactivity. Postgrad Med J 62:76-77, 1986
  pubmed

• 84) Dixon CMS, Fuller RW, Barnes PJ:The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects. Br J Clin Pharmacol 23:91-93, 1987

• 85) Overlack A Muller B, Schmidt L et al:Airway responsiveness and cough induced by angiotensin converting enzyme inhibition. J Hum Hypertens 6:387-92, 1992
  pubmed

• 86) Boulet LP, Milot J, Lampron N et al:Pulmonary function and air way responsiveness during long-term therapy with captopril. JAMA 261:413-416, 1989

• 87) Kaufmann J, Schmitt S, Barnard J:Angiotensin-converting enzyme inhibitors in patients with bronchial responsiveness and asthma. Chest 101:922-925, 1992

• 88) 上田英之助, 前倉亮治, 奥田佳久ほか:慢性呼吸不全を有する高血圧患者に対するカプトプリルの有用性と安全性の検討. Prog Med 11:1269-76, 1991
  Medical*Online

• 89) Furuya K, Yamaguchi E, Hirabayashi T et al:Angiotensin-converting enzyme gene polymorphism and susceptibility to cough. Lancet 343:354, 1994 (letter)
  pubmed

• 90) Kreft-Jais C, Laforest L, Bonnardeaux A et al:ACE inhibitors, cough, and genetics. Lancet 343:740, 1994 (letter)
  pubmed

• 91) Chadwick IG, Yeo WW, Higgins KS et al:Lancet 343 740-741 (letter)
  pubmed

• 92) Hargreaves MR, Benson MK:Inhaled sodium cromoglycate in angiotensin-converting enzyme inhibitor cough. Lancet 345:13-16, 1995
  pubmed

• 93) Reisin L, Schneeweiss A:Spontaneous disapperarance of cough induced by angiotensin-converting enzyme inhibitors. (captopril or enalapril) Am J Cardiol 70:398-9, 1992

• 94) Erslev AJ, Alexander JC, Caro J et al:Hematologic side effects of captopril and associated risk factors. Cardiovascul Rev Rep 3:660-671, 1982

• 95) Cooper RA:Captopril-associated neutropenia. Who is at risk? Arch Intern Med 143:659-60 , 1983
  pubmed

• 96) Elis A, Lishner M, Lang R et al:Agranulocytosis associated with enalapril. DICP, Ann Pharmacol 25:461-462, 1991

• 97) Gavras I, Graff LG, Rose BD et al:Fatal pancy-topenia associated with the use of captopril. Ann Intern Med 94:58-59, 1981

• 98) Strair RK Mitch WE, Faller DV et at:Reversible captopril associated bone-marrow aplasia. Can Med Assoc J 132:320-322, 1985
  pubmed

• 99) Hirakata H, Onoyama K, Iseki K et al:Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol 14:355-360, 1984

• 100) Teruel JL, Juarez GF, Marcen R et al:Effect of angiotensin-converting enzyme inhibitors on anemia in hemodilyzed patients, Nephron 73:113, 1996 (letter)

• 101) Onoyama K, Sanai T, Motomura K et al:Worsening anemia by angiotensin converting enzyme inhibitors and its prevention by antie-strogenic steroid in chronic hemodialysis padents. J Cardiovasc Pharmacol 13 (suppl 3):S27-S30, 1989

• 102) Matsumura M, Nomura H, Koni I et al:Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients, Nephron 77:164-168, 1997
  pubmed

• 103) Walsh KP, Walsh MJ, Brangal Jp:Reversible severe thrombocytopenia associated with captopril therapy. Br Med J 79:43-44, 1986

• 104) Khan MA Bashi SA, Noah MS:Captopril associated isolated thrombocytopenia. Br Med J 80:101, 1987

• 105) Grosbois B, Milton D, Beneton C et al:Thrombocytopenia induced by angiotensin converting enzyme inhibitors. Br Med J 298:189-190, 1989

• 106) Pujol M, Sudrez JRD, Vega CM et al:Autoimmune thrombocytopenia in three patients treated with captopril. Vox Sang 57:218, 1989

• 107) Case DB, AtlasSA, Mouradian JA:Proteinuria during long-term captopril therapy. JAMA 244:346-349, 1980

• 108) Report from the Captopril Collaborative Study Group. Does captopril cause renal damage in hypertensive patients? Lancet 1:988-990, 1982

• 109) Lewis EJ:Angiotensin-converting enzyme inhibitors:Considerations regarding Proteinuria. Am J Kidney Dis 10 (suppl 1):30-38, 1987

• 110) Davies RO, Irvin JD, Kramsch DK et al:Enalapril worldwide experience. Am J Med 77 (2A):23-35, 1984
  pubmed

• 111) Materson BJ:Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril. Am J Cardiol 69:C46-C53, 1992

• 112) Ikeda T, Nakayama D, Gomi T et al:Captopril, an angiotensin I-converting enzyme inhibitor, decreases proteinuria in hypertensive patients with renal diseases. Nephron 52:72-75, 1989
  pubmed

• 113) Katz RA, Hood AF:Pemphigus-like eruption from captopril. Arch Dermatol 123:20-1, 1987
  pubmed

• 114) Ruocco V, Satriano RA, Guerrera V:Two-step pemphigus induction by ACE-inhibitors. Int J Dermatol 31:33-36, 1992
  pubmed

• 115) 大橋武志, 筒井清広, 野村佳弘ほか:アンギオテンシン変換酵素阻害剤により誘発された薬剤性天疱瘡の2例皮膚臨床 39:415-418, 1997

• 116) Coulter DM, Pillans PI:Angiotensin-convening enzyme inhibitors and psoriasis. N Z Med J:392-3, 1993

• 117) Motel PJ:Captopril and alopecia:A case report and review of known cutaneous reactions in captopril use. J AM Acad Dermatol 23:124-125, 1990
  pubmed

• 118) Moots RJ, Keeling PJ, Morgan SH:Adult Schoenlein-Henoch purpura after enalapril. Lancet 340:304-305, 1992
  pubmed

• 119) Reardon LC, Macpherson DS:Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 158:26-32, 1998
  pubmed

• 120) Packer M, Lee WH:Provocation of hyper-and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure. AM J Cardiol 57:347-348, 1986
  pubmed

• 121) Hume AL, Jack BW, Levinson P:Severe hyponatremia:an association with lisinopril P DICP, Ann Pharmacol 24:1169-1172, 1990

• 122) Edwards IR, Coulter DM, Beasley DMG et al:Captopril:4years of post marketing surveillance of all patients in New Zealand. Br J Clin Pharmacol 23:529-536, 1987

• 123) Boyd I:Captopril-induced taste disturbance. Lancet 342:304, 1993
  pubmed

• 124) Zazgornik J, Kaiser W, Biesenbach G:Captopril-induced dysgeusia. Lancet 341:1542, 1993
  pubmed

• 125) Goldblatt J, Bryer A:Huntintonls disease:deterioration in clinical state during treatment with angiotensin converting enzyme inhibitor. Br Med J 294:1659-1660, 1987

• 126) Patterson JF:Depression associated with enalapril. South Med J 82:402-403, 1989
  pubmed

• 127) Zubenko GS, Nixon RA:Mood-elevating effect of captopril in depressed patients. Am J Psychiatry 141:110-111, 1984
  pubmed

• 128) Herings RMC, de Boer A, Stricker BHC et al:Hypoglycemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 345:1195-1198, 1996

• 129) Morris AD, Boyle DIR, McMahon AD et al:ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. Diabetes Care:1363-1367, 1997

• 130) Markusse HM, Meyboom RHB:Gynecomastia associated with captopril. Br Med J 296:1262-1263, 1988

• 131) Nakamura Y, Yoshimoto K, Saima S:Gynecomastia induced by angiotensin converting enzyme inhibitor. Br Med J 300:541, 1990

• 132) Katayama S, Inaba M, Maruno Y et al:Captopril-induced creatinine kinase elevation. A possible role of the sulfhydryl group. Hypertension 10:234-236, 1987

• 133) Stein GH, Stein SM, Quay GP:Antinuclear anti-bodies with enalapril. J Hum Hypertens 7:105-106, 1993

• 134) Tilkemeieri P, Thompson PD:Acute pancreatitis possibly related to enalapril. N Engl J Med 318:1275-1276, 1988 (letter)

• 135) Roush MK McNutt RA, Gray TF:The adverse effect dilemma:Quest for accessible information. Ann Intern Med 114:298-299, 1991
  pubmed

• 136) Dabaghi S:ACE inhibitors and pancreatitis. Ann Intern Med 115:330-331, 1991 (letter)
  pubmed

• 137) Standridge JB:Fulminant pancreatitis associated with lisinopril therapy. South Med J 87:179-181, 1994
  pubmed

• 138) Marinella MA, Billi JE:Lisinopril therapy associated with acute pancreatitis. West J Med 163:77-78, 1995
  pubmed

P.328 掲載の参考文献

• 1) Slater EE, Merrill DD, Guess HA et al:Clinicalprofile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 260:967-970, 1988

• 2) Schepherd GM:Possible contraindication of angiotensin converting enzyme inhibitors in patients with hereditary angioedema. Am J Med 80:446, 1990 (letter)

• 3) Agostoni A, Cicardi M:Contraindication to the use of ACE inhibitors in patients with Clesterase inhibitor deffciency. Am J Med 90:278, 1991 (letter)

• 4) Atkinson D, Sim T, Lee J et at:Hereditary angioedema exacerbated by angiotensin converting enzyme inhibitor. J Allergy Cliln Immunol 91:364, 1993 (abstr)

• 5) Orfan N, Patterson R, Dykewicz MS:Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema. JAMA 264:1287-1289, 1990
  pubmed

• 6) Cicardi M, Conciato L, Agostoni A:Angioedema due to angiotensin-converting enzyme inhibition:an association frequently unrecognized. Ann Ital Med Int 12:8-10, 1997
  pubmed

• 7) Black PN, Simpson IJ:Angio-oedema and ACE inhibitors. Aust N Z J Med 25:746, 1995 (letter)
  pubmed

• 8) Kozel MMA Mekkes JR, Bos JD:Increased frequency and severity of angio-edema relaterd to long-term therapy with angiotensin-conrtverting enzyme inhibitor in two patients. Clin Exp Dermatol 20:60-61, 1995

• 9) Brown NJ, Snowden M, Griffin MR:Recurrent angiotensin-converting enzyme inhibitor-associated angio-edema. JAMA 278:232-233, 1997
  pubmed

• 10) Chin HL, Buchan DA:Severe angioedema after long-term use of an angiotensin converting enzyme inhibitor. . Ann Intern Med 112:312-313, 1990
  pubmed

• 11) Roberts JR, Wuerz RC:Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema. Ann Emerg Med 20:555-558, 1991
  pubmed

• 12) Litman RS, Sher WH, Hausman SA:Life-threatening acute airway obstrucdon due to enalapril induced angioedema. Immumol Allergy Prac 14:196-199, 1992

• 13) Bielory L, Lee SS, Holland CL et al:Long-acting ACE inhibitor-induced angioedema. Allergy Proc 13:85-87, 1992
  pubmed

• 14) Ebo DG, Stevens WJ:Angioedema of ACE inhibitors. Allergy 52:354-355, 1997
  pubmed

• 15) Kolenc KM, Dobbin KR:Angioedema caused by ACE inhibitor mistaken for allergic reaction. J Emerg Nurs 22:228-231, 1997

• 16) Forskund, Tohmo H, Weckstrom G et al:Angio-oedema induced by enalapril. J Intern Med 238:178-181, 1995

• 17) Jain M, Armstrong L, Hall J:Predisposition to and late onset of upper air-way obstruction following angiotensin-convening enzyme inhibitor therapy. Chest 102:871-874, 1992

• 18) Peacock ME, Brennan WA, Strong SL et al:Angioedema as a complication in periodontal surgery. Report of a case. J Peridontol 62:643-645, 1991

• 19) Kharasch ED:Angiotensin-converting enzyme inhibitor-induced angioedema associated with endotracheal intubation. Aesth Anaflg 74:602-604, 1992

• 20) Ogbureke KUE, Cruz C, Johnson JV et al:Perioperative angioedema in a patient on longterm angiotensin-converting enzyme (ACE)-inhibitor therapy. J Oral Maxillofac Surg 54:917-920, 1996

• 21) Tielemans C, Madhoun P, Lenaers M et al:Anaphylactoid reactions during hemodialysis on AN 69 membranes in patients receiving ACE inhibitors. Kidney Internat 38:982-984, 1990

• 22) Verresen L, Waer M, Vanrenterghem Y et al:Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet 336:1360-1362, 1990
  pubmed

• 23) Jadoul M, Struyven J, Stragier A et al:Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet 337:112, 1991 (letter)

• 24) van Es A, Henny FC, Lobatto S:Lancet 337:112-113 (letter)

• 25) Dinarello CA:ACE inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet 337:370, 1991 (letter)

• 26) Alvarez MA, Martin-Malo A, Espinosa M et al:Lancet 337:370 (letter)

• 27) Tielemans C, Vanherweghem JL, Blumberg A etal:Lancet 337:370-371 (letter)

• 28) Caravaca F, Pizarro JL, Garcia MC et al:More about anaphylactoid reactions in patients dialyzed with AN 69 filter and on angiotensin converting enzyme inhibitors treatment. Nephron 60:372-373, 1992 (letter)
  pubmed

• 29) Baron FR, Garcia JM, Camps EM et al:ACE inhibitors and anaphylactoid reactions to high-flux membrane dialysis (AN69):Clinical aspects. Nephron 60:487, 1992 (letter)

• 30) Perez-Garcia R, Galan A, Vinuesa MG et al:Anaphylactoid reactions during hemodialysis on AN69 membranes:Role of Ace inhibitors and back-filtration. Nephron 61:123, 1992 (letter)

• 31) Pegues DA, Beck-Sague CM, Woollen SW et al:Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors. Kidney Internat 42:1232-1237, 1992

• 32) Mazuecos A, Montoyo C, Andres A et al:Absence of anaphylactoid reactions with the combined use of Ace inhibitors and AN 69 hemodialysis membranes. Nephron 59:519, 1991

• 33) Olbricht CJ, Schaumann D, Fischer D:Anaphylactoid reactions, LDL-apheresis with dextran sulphate, and ACE inhibitors. Lancet 340:908-909, 1992 (letter)
  pubmed

• 34) Kroon AA, Mol MJTM, Stalenhoef AFH:ACE inhibitors and LDL-apheresis with dextran sulphate sdsorption. Lancet 340:1476, 1992 (letter)

• 35) Keller C, Grutzmacher P, Bahr F et al:LDL-apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitors. Lancet 341:60-61, 1993 (letter)
  pubmed

• 36) 厚生省薬務局:アンジオテンシン変換酵素 (ACE) 阻害剤服用患者におけるLDLアフェレーシス施行時のショック. 医薬品副作用情報 122:2-5, 1993

• 37) Duminy PC, Burger P, du T:Fetal abnormality associated with the use of captopril during pregnancy. SA Med J 60:805, 1981

• 38) Mehta N, Modi N:ACE inhibitors in pregnancy. Lancet 2:96, 1989

• 39) Cunniff C, Jones KL, Phillipson J et al:Oligohydramnios sequence and renal tubular malformation associated With maternal enalapril use. Am J Obstet Gynecol 162:187-189, 1990
  pubmed

• 40) Barr M, Cohen MM:ACE inhibitor fetopathy and hypocalvaria:The kidney-skull connection. Tetralogy 44:485-495, 1991

• 41) Boutroy MJ, Vert P, De Ligny BH et al:Captopril administration in pregnancy impairs fetal angiotensin converting enzyme activity and neonatal adaptation. Lancet 2:935-936, 1984

• 42) Schubiger G, Flury G, Nussberger J:Enalapril for pregnancy-induced hypertension:acute renal failure in a neonate. Ann Intern Med 108:215-216, 1988

• 43) Kreft-Jais C, Plouin PF, Tchobroutsky C:Angiotensin-converting enzyme inhibitors during Pregnancy:a survey of 22 patients given captopril and nine given enalapril. Br J Obstet Gynecol 95:420-422, 1988

• 44) Pipkin BF, Baker PN, Symonds EM:ACE inhibitors in pregnancy. Lancet 2:96-97, 1989

• 45) Rosa FW, Bosco LA, Graham CF et al:Neonatal anuria with maternal angiotensin-converting enzyme inhibition. Obstet Gynecol 74:371-374, 1989
  pubmed

• 46) Buttar HS:An overview of the influence of ACE inhibitors on fetal-placental circuladon and perinatal development. Moll Cell Biol 176:61-71, 1997

Part4 / 基礎編

P.337 掲載の参考文献

• 1) 金勝慶:レニン-アンジオテンシン系の循環器系臓器障害における役割. 日薬理誌 109:223-233, 1997
  Medical*Online

• 2) Lindpaintner K, Ganten D:The cardiac reninangiotensin system:an appraisal of present experimental and clinical evidence. Circ Res 73:413-423, 1991

• 3) Dzau VJ:Circulating versus local reninangiotensin system in cardiovascular homeostasis. Circulation 77 (suppl I):14-113, 1988

• 4) Sadoshima J, Izumo S:Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 73:413-423, 1993
  pubmed

• 5) Kim S, Ohta K, Hamaguchi A et al:Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 25:1252-1259, 1995
  pubmed

• 6) Kim S, Ohta K, Hamaguchi, A et al:Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-β1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 273:509-515, 1995

• 7) Kim S, Ohta K, Hamaguchi A et al:Effects of an AT1, receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats. Br J Pharmacol 118:549-556, 1996

• 8) Ohta K, Kim S, Iwao H:Role of angiotensinconverting enzyme, adrenergic receptors and blood pressure in cardiac gene expression of spontaneously hypertensive rats during development. Hypertension 28:627-634, 1996
  pubmed

• 9) Mullins JJ, Peters J, Ganten D:Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344:541-544, 1990
  pubmed

• 10) Ohta, K, Kim S, Wanibuchi H et al:Contribution of local renin-angiotensin system to cardiac hypertrophy, phenotypic modulation and remodeling in TGR (mRen2) 27 transgenic rats. Circulation 94:785-791, 1996
  pubmed

• 11) Sadoshima J, Xu Y, Slayter HS et al:Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75:977-984, 1993
  pubmed

• 12) Thienelt CD, Weinberg EO, Bartunek J et al:Load-induced growth responses in isolated adult rat hearts:role of the AT1 receptor. Circulation 95:2677-2683, 1997
  pubmed

• 13) Serneri GGN, Boddi M, Coppo M et al:Evidence for the existence of a functional cardiac renin-angiotensin system in humans. Circulation 94:1886-1893, 1996

• 14) Schelling P, Fischer H, Ganten D:Angiotensin and cell growth:a link to cardiovascular hypertrophy. J Hypertens 9:3-15, 1991
  pubmed

• 15) Gibbons GH, Pratt RE, Dzau VJ:Vascular smooth muscle cell hypertrophy vs. hyperplasia:Autocrine transforming growth factor-β1 expression determines growth response to angiotensin II. J Clin Invest 90:456-461, 1992

• 16) Feener EP, Northrup JM, Aiello LP et al:Angiotensin II induces plasminogen activator inhibitor-1 and-2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 95:1353-1362, 1995
  pubmed

• 17) Kim S, Kawamura M, Wanibuchi H et al:Angiotensin II type I receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery Circulation 92:88-95, 1995

• 18) Kim S, Izumi Y, Hamaguchi A et al:Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat balloon-injured artery. Circulation 97:1731-1731, 1998
  pubmed

• 19) Rakugi H, Jacob HJ, Krieger JE et al:Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation 87:283-290, 1993
  pubmed

• 20) Song K, Shiota N, Takai Set al:Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys Atherosclerosis 138:171-182, 1998

• 21) Kim S, Wanibuchi H, Hamaguchi A et al:Angiotensin blockade improves cardiac and renal complications of type II diabetic rats. Hypertension 30:1054-1061, 1997
  pubmed

• 22) Takemoto M, Egashira K, Usui M et al:Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats J Clin Invest 99:278-287, 1997
  pubmed

• 23) Ichikawa I, Harris RC:Angiotensin actions in the kidney:Renewed insight into the old hormone. Kidney nter 40:583-596, 1991

• 24) Kagami S, Kuhara T, Okada K et al:Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 51:664-671, 1997
  pubmed

• 25) Kim S, Ohta K, Hamaguchi A et al:Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Int 46:1346-1358, 1994
  pubmed

• 26) Kim S, Ohta K, Hamaguchi A et al:Role of angiotensin II in renal injury of deoxycorticosterone-acetate-salt hypertensive rats. Hypertension 24:195-204, 1994
  pubmed

• 27) Pitt B, Segal R, Martinez FA et al:Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE) . Lancet 349:747-752, 1997
  pubmed

P.343 掲載の参考文献

• 1) Griendling KK, Murphy TJ, Alexander RW:Molecular biology of the renin-angiotensin system. Circulation 87:1816-1828, 1993
  pubmed

• 2) Tamura K, Umemura S, Fukamizu A et al:Recent advances in the study of renin and angiotensinogen genes:from molecules to the whole body. Hypertens Res 18:7-18, 1995

• 3) Soubrier F, Alhenc-Gelas F, Hubert C et al:Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA 85:9386-9390, 1988
  pubmed

• 4) 田村功一, 深水昭吉, 村上和雄:レニン-アンジオテンシン系の生化学. 最新内科学大系15-副腎疾患, 水・電解質異常-, 山村雄一, 吉利和監修, 中山書店, 東京, 1993, pp. 253-266

• 5) Wei L, Alhenc-Gelas F, Corvol P et al:The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem 266:9002-9008, 1991
  pubmed

• 6) Hubert C, Houot A-M, Corvol P et al:Structure of the angiotensin I-converting enzyme gene. J Biol Chem 266:15377-15383, 1991

• 7) Howard TE, Shai S-Y, Langford KG et al:Transcription of testicular angiotensin-converting enzyme (ACE) is initiated within the 12th intron of the somatic ACE gene. Mol Cell Biol 10:4294-4302, 1990
  pubmed

• 8) Thekkumkara TJ, Livingston W, Kumar RS et al:Use of alternative polyadenylation sites for tissue-specific transcription of two angiotensinconverting enzyme mRNAs. Nucleic Acids Res 20:683-687, 1992
  pubmed

• 9) Howard T, Balogh R Overbeek P et al:Sperm-specific expression of angiotensin-converting enzyme (ACE) is mediated by a 91-base-pair promoter containing a CRE-like element. Mol Cell Biol 13:18-27, 1993
  pubmed

• 10) 田村功一, 梅村敏:レニン-アンジオテンシン系の遺伝子制御. 医学のあゆみ 169:437-442, 1994
  Medical*Online

• 11) Langford KG, Shai S-Y, Howard TE et al:Transgenic mice demonstrate a testis-specific promoter for angiotensin-converting enzyme. J Biol Chem 266:15559-15562, 1991
  pubmed

• 12) Howard T, Balogh R, Overbeek P et al:Sperm-specific expression of angiotensin-converting enzyme (ACE) is mediated by a 91-base-pair promoter containing a CRE-like element. Mol Cell Biol 13:18-27, 1993
  pubmed

• 13) Zhou Y, Sun Z, Means AR et al:cAMP-response element modulator t is a positive regulator of testis angiotensin converting enzyme transcription. Proc Natl Acad Sci USA 93:12262-12277 , 1996

• 14) Rieder MJ, Carmona R, Krieger JE et al:Suppression of angiotensin-converting enzyme expression and activity by shear stress. Circ Res 80:312-319, 1997
  pubmed

• 15) Fernadez-Alfonso MS, Kreutz R, Zeh K et al:Differential regulation of vascular angiotensin I-converting enzyme in Hypertension. Hypertension 24:280-286, 1994

• 16) Shiota N, Miyazaki M, Okunishi H:Increase of angiotensin convening enzyme expression in the hypertensive aorta. Hypertension 20:168-174, 1992

• 17) Schunkert H, Dzau VJ, Tang SS et al:Increased rat cardiac angiotensin convening enzyme activity and mRNA expression in pressure overload ventricular hypertrophy:effects on coronary resistance, contractility, and relaxation. J Clin Invest 86:1913-1920, 1990

• 18) Iwai N, Shimoike H, Kinoshita M:Cardiac renin-angiotensin system in the hypertrophied heart. Circutation 92:2690-2696, 1995
  pubmed

• 19) Schunkert H, Ingelfinger JR, Hirsch AT et al:Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ Res 72:312-318, 1993
  pubmed

• 20) Tanimoto K, Sugiyama F, Goto Y et al:Angiotensinogen-deficient mice with hypotension. J Biol Chem, 269:31334-31337, 1994
  pubmed

• 21) Umemura S, Kihara M, Sumida Yet al:Endocrinological abnormalities in angiotensinogen gene-knockout mice:studies of homlonal responses to dietary salt loading. J Hypertens 16:285-289, 1998

• 22) Nyui N, Tamura K, Mizuno K et al:Stretch-induced MAP kinase activation in cardiomy-ocytes of angiotensinogen deficient mice. Biochem Biophys Res Commun 235:36-41, 1997

• 23) Nyui N, Tamura K, Mizuno K et al:GP130 is involved in stretch-induced MAP kinase activation in cardiac myocytes. Biochem Biophys Res Commun 245:928-932, 1998
  pubmed

• 24) Sumida Y, Umemura S, Tamura Ket al:Increased cardiac angiotensin II receptors in angiotensinogen-deficient mice. Hypertension 31:45-49, 1998

• 25) Tamura K Umemura S, Sumida Y et al:Effect of genetic deffciency of angiotensinogen on renin-angiotensin system. Hyertension (in press) , 1998

• 26) Rigat B, Hubert C, Alhenc-Gelas Fet al:An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346, 1990

• 27) DanserAHJ, Schalekamp MADH, Bax WA et al:Angiotensin-converting enzyme in the human heart:effect of the deletion/insertion polymorphism. Circulation 92:1387-1388, 1995

• 28) Inoue I, Nakajima T, Williams CS et al:A nucleotide substitution in the promoter of human angiotensinogen is asociated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99:1786-1797, 1997

• 29) Sato N, Katsuya T, Rakugi H et al:Association of variants in critical core promoter element of angiotensinogen gene with increased risk of essential hypertension in Japaneses. Hypertension 30:321-325, 1997
  pubmed

• 30) Ishigami T, Umemura S, Tamura K et al:5:upstream core promoter region of angiotensinogen gene and essential hypertension. Hypertension 30:1325-1330, 1997
  pubmed

• 31) Ishigami T, Iwamoto T, Tamura K et al:Angiotensin I convening enzylne gene polymorphis and essential hypertension in Japan. Am J Hypertens 8:95-97, 1995

• 32) 平林高之, 岡本洋, 北畠顕:ACE遺伝子多型性. 腎と透析 39:87-91, 1995

• 33) Lindpaintner K, Pfeffer MA, KreutZ R et al:A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 332:706-711, 1995
  pubmed

• 34) Watanabe Y, Ishigami T, Kawano Y et al:Angiotensin-converting enzyme gene I/D polymorphism and carotid plaques in Japanese. Hypertension 30:569-573, 1997

• 35) Hibi K Ishigami T, Kimura K et al:Angiotensin-converting enzyme gene polymorphism adds risk for the severity of coronary atherosclerosis in smokers. Hypertension 30:574-579, 1997
  pubmed

• 36) Shiota N, Okunishi H, Fukamizu A et al:Activation of two angiotensin-generating systems in the balloon-injured artery. FEBS lett 323:239-242, 1993
  pubmed

P.353 掲載の参考文献

• 1) Rigat B, Hubert C, Alhenc Gelas F et al:An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346, 1990
  pubmed

• 2) Ueda S, Heeley R P, Lees K R et al:Mistyping of the human angiotensin-converting enzyme gene polymorphism:frequency, causes and possible methods to avoid errors in typing. J Mol Endocrinol 17:27-30, 1996
  pubmed

• 3) Lindpaintner K, Pfeffer M A, Kreutz R et al:A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 332:706-711, 1995
  pubmed

• 4) Odawara M, Matsunuma A, Yamashita K:A pitfall in the association study of ACE gene polymorphism. Diabetes Care 19:543-544, 1996

• 5) Cambien F, Costerousse O, Tiret L et al:Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation 90:669-676, 1994
  pubmed

• 6) Furuya K, Yamaguchi E, Itoh A et al:Deletion polymorphism in the angiotensin I converting enzyme (ACE) gene as a genetic risk factor for sarcoidosis. Thorax 51:777-780, 1996
  pubmed

• 7) Tiret L, Rigat B, Visvikis S et al:Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 51:197-205, 1992
  pubmed

• 8) McKenzie C A, Julier C, Forrester T et al:Segregation and linkage analysis of serum angiotensin I-converting enzyme levels:evidence for two quantitave-trait loci. Am J Hum Genet 57:1426-1435, 1995

• 9) Villard E, Tiret L, Visvikis S et al:Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hun Genet 58:1268-1278, 1996

• 10) Cambien F, Poirier O, Lecerf L et al:Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359:641-644, 1992
  pubmed

• 11) Mattu R K, Needham E W, Galton D J et al:A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study. Circulation 91:270-274, 1995
  pubmed

• 12) Katsuya T, Horiuchi M, Chen Y D et al:Relations between deletion polymorphism of the angiotensin-converting enzyme gene and insulin resistance, glucose intolerance, hyperinsulinemia, and dyslipidemia. Arteriocler Vasc Biol 15:779-782, 1995
  pubmed

• 13) Celermajer D S, Sorensen K E. Barley J et al:Angiotensin-converting enzyme genotype is not associated with endothelial dysfunction in subjects without other coronary risk factors. Atherosclerosis 111:121-126, 1994

• 14) Jeng J-R, Ham H-J, Yueh K-C et al:Plasminogen activotor inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension. Am J Hypertens 11:235-239, 1998

• 15) Lachurie M L, Azizi M, Guyene T T et al:Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 91:2933-2942, 1995
  pubmed

• 16) Ohishi M, Fujii K, Minamino T et al:A potent risk factor for restenosis. Nature Genet 5:324-325, 1993
  pubmed

• 17) Ohishi M, Rakugi H, Ogihara T:Association between a deletion polymorphism of the angiotensin-converting-enzymes gene ang left ventricular hypertrophy. N Engl J. Med 331:1097-1098, 1994

• 18) Katsuya T, Koike G, Yee T W et al:Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 345:1600-1603, 1995
  pubmed

• 19) Samani N J, Thompson J R, O'Toole L et al:A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 94:708-712, 1996

• 20) Jeunemaitre X, Ledru F, Battaglia S et al:Genetic polymorphisms of the renin-angiotensin system and angiographic extent and severity of coronary artery disease:the CORGENE study. Hum Genet 99:66-73, 1997
  pubmed

• 21) Agerholm Larsen B, Nordestgaard B G, Steffe-nsen R et al:ACE gene polymorphism:ischemic heart disease and longevity in 10,150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation 95:2358-2367, 1997

• 22) Hilbert P, Lindpaintner K, Beckmann J S et al:Chromosomal mapping of two genetic loci associated with blood-pressure regulation in hereditary hypertensive rats. Nature 353:521-529, 1991
  pubmed

• 23) Jacob H J, Lindpaintner K, Lincoln S E et al:Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell 67:213-224, 1991
  pubmed

• 24) Kreutz R Hubner N, James M R et al:Dissection of a quantitative trait locus for genetic hypertension on rat chromosome 10. Proc Natl Acad Sci USA 92:8778-8782, 1995
  pubmed

• 25) Krege J H, Kim H S, Moyer J S et al:Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 29:150-157, 1997
  pubmed

• 26) Zee R Y, Lou Y K Griffiths L R et al:Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem Biophys Res Commun 184:9-15, 1992
  pubmed

• 27) Higashimori K Zhao Y, Higald J et al:Association analysis of a polymorphism of the angiotensin converting enzyme gene with essential hypertension in the Japanese population. Biochem Biophys Res Commun 191:399-404, 1993

• 28) Jeunemaitre X, Lifton R P, Hunt S C et al:Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension. Nat Genet 1:72-75, 1992
  pubmed

• 29) O'Donnell C J, Lindpaintner K, Larson M G et al:Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart study. Circulation 97:1766-1772, 1998

• 30) Fornage M F, Amos C I, Kardia S et al:Variation in the region of the angiotensin-converting enzyme gene influences interindividual differences in young white males. Circulation 97:1773-1779, 1998

• 31) Krege J H, John S W, Langenbach L L et al:Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 375:146-148, 1995
  pubmed

• 32) Mondorf U F, Russ A, Wiesemann A et al:Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. Am J Hypertens 11:174-183, 1998 ,
  pubmed

• 33) Schunkert H, Hense H W, Holmer S R et al:Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventdcular hypertrophy. N Engl J Med 330:1634-1638, 1994
  pubmed

• 34) Lindpaintner K, Lee M, Larson M G et al:Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med 334:1023-1028, 1996
  pubmed

• 35) Marian A J, Yu Q T, Workman R et al:Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 342:1085-1086, 1993
  pubmed

• 36) Raynolds M V, Bristow M R, Bush E W et al:Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 342:1073-1075, 1993
  pubmed

• 37) Marre M, Jeunemaitre X, Gallois Y et al:Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes:Genetique de la Nephropathie Diabetique GENEDIAB) study group. J Chin Invest 99:1585-1595, 1997

• 38) Kario K Kanai N, Saito K et al:Ischemic stroke and the gene for angiotensin-converting enzyme in Japanese hypertensives. Circulation 93:1630-1633, 1996
  pubmed

• 39) Catto A, Carter A M, Barrett J H et al:Angiotensin-converting enzyme insertion/deletion polymorphism ang cerebrovascular disease. Stroke 27:435-440, 1996

• 40) Nakata Y, Katsuya T, Rakugi H et al:Polymorphism of angiotensin converting enzyme, angiotensinogen, and apolipoprotein E genes in a Japanese population with cerebrovascular disease. Am J Hypertens 10:1391-1395, 1997

• 41) Staessen J A, Wang J G, Ginocchio G et al:The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 15:1579-1592, 1997

P.362 掲載の参考文献

• 1) Koller B H, Smithies O:Altering genes in animals by gene targeting. Annu Rev lmmunol 10:705-730, 1992
  pubmed

• 2) Bronson S K, Smithies O:Altering mice by homologous recombination using embryonic stem cells. J Biol Chem 269:27155-27158, 1994
  pubmed

• 3) Evans M J, Kaufman M H:Establishment in culture of pluripotential cells from mouse embryos. Nature 292:154-156, 1981
  pubmed

• 4) Smithies O, Gregg R G, Boggs S S et al:Insertion of DNA sequences into the human chromosomal β-globin locus by homologous recombination. Nature 317:230-234, 1985

• 5) Mansour S L, Thomas K R, Capecchi M R:Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells:a general strategy for targeting mutations to non-selectable genes. Nature 336:348-352, 1988
  pubmed

• 6) Hooper M L:Embryonal stem cells:Introducing planned changes into the animal germline, Harwood Academic Publishers, 1992

• 7) Joyner A L (ed.):Gene targeting:Apractical approach, IRL Press, 1993 (野田哲生監訳:ジーンターゲティング, メディカル・サイエンス・インターナショナル, 東京, 1995)

• 8) Smithies O, Maeda N:Gene targeting approaches to complex genetic diseases:atherosclerosis and essential hypertension. Proc Natl Acad Sci USA 92:5266-5272, 1995
  pubmed

• 9) Coffman T M:Gene targeting in physiological investigations:studies of the renin-angiotensin system. Am J Physiol 274:F999-F1005, 1998
  pubmed

• 10) Clark A E Sharp M G F, Mullins J J:Gene targeting and its application to basic hypertension research:Clin Sci 90:435-446, 1996

• 11) Krege J H, John S W M, Langenbach L L et al:Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 375:146-148, 1995

• 12) Esther C R Jr, Howard T E, Marino E Met al:Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 74:953-965, 1996

• 13) Krege J H, Hodgin J B, Hagaman J Ret al:A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25:1111-1115, 1995

• 14) Tian B, Meng Q C, Chen Y-Fet al:Blood pressures and cardiovascular homeostasis in mice having reduced or absent angiotensin-converting enzyme gene function. Hypertension 30:128-133, 1997
  pubmed

• 15) Krege J H, Kim H-S, Moyer J S et al:Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 29:150-157, 1997
  pubmed

• 16) Hilgers K F, Reddi V, Krege J H et al:Aberrant renal vascular morphology and renin expression in mutant mice lacking angiotensin-converting enzyme. Hypertension 29:216-221, 1997
  pubmed

• 17) Kim H-S, Krege J H, Kluckman K D et al:Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 92:2735-2739, 1995
  pubmed

• 18) Nagata M, Tanimoto K, Fukamizu A et al:Nephrogenesis and renovascular development in angiotensinogen-deficient mice. Lab Invest 75:745-753, 1996
  pubmed

• 19) Niimura F, Labosky P A, Kakuchi J et al:Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 96:2947-2954, 1995
  pubmed

• 20) Ito M, Oliverio M I, Mannon P J et al:Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 92:3521-3525, 1995
  pubmed

• 21) Sugaya T, Nishimatsu S, Tanimoto K et al:Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 270:18719-18722, 1995
  pubmed

• 22) Oliverio M I, Madsen K, Best C F et al:Renal growth and development in mice lacking AT 1A receptors for angiotensin II. Am J Physiol 274:F43-F50, 1998
  pubmed

• 23) Chen X, Li W, Yoshida H et al:Targeting deletion of angiotensin type 1B receptor gene in the mouse. Am J Physiol 272:F299-F304, 1997

• 24) Tsuchida S, Matsusaka T, Chen X et al:Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest 101:755-760, 1998
  pubmed

• 25) Oliverio M I, Best C F, Smithies O et al:A severe kidney phenotype in AT 1A receptor-deffcient mice. J Am Soc Nephrol 9 (program and abstr. issue):406A 1997

• 26) Hilgers K F, Norwood V F, Gomez R A:Angiotensin' s role in renal development. Semin Nephrol 17:492-501, 1997
  pubmed

• 27) Hagaman J R, Moyer J S, Bachman E S et al:Angiotensin-converting enzyme and male fertility. Proc Natl Acad Sci USA 195:2552-2557, 1998

• 28) Krege J H, Moyer J S, Langenbach L L et al:Angiotensin-converting enzyme gene and atherosclerosis. Arterioscler Thromb Vasc Biol 17:1245-1250, 1997
  pubmed

• 29) Smithies O:A mouse view of hypertension. Hypertension 30:1318-1324, 1997
  pubmed

• 30) Smithies O, Kim H-S:Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc Natl Acad Sci USA 91:3612-3615, 1994
  pubmed

• 31) Campbell D J, Kladis A, Duncan A-M:Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23:439-449, 1994
  pubmed

• 32) Esther C R Jr, Marino E M, Howard T E et al:The critical role of tissue angiotensin-convening enzyme as revealed by gene targeting in mice. J Clin Invest 99:2375-2385, 1997

• 33) Hagaman J R, Peng L, Hiller S et al:Testis-specific angiotensin converting enzyme is required for male fertility. (Abstract) 8th International Symposium on Spermatology (Montreal), 1998:Hagaman J R, Smithies O. (私信)

Part5 / 資料編

P.367 掲載の参考文献

• 1) 塩之入洋, 成瀬雅彦, 高崎泉:ACE阻害薬の分類と作用機序. 医学のあゆみ 174:753-760, 1995
  Medical*Online

• 2) Shionoiri H:Pharmacoldnetic drug interactions with ACE inhibitors. Clin Pharmacokinetics 25:20-58, 1993
  pubmed